[
    {
        "answer": "The appropriate first-line treatment for this patient with metastatic bladder cancer, a history of hypertension and chronic kidney disease, a PD-L1 score of <1%, and a FGFR2 mutation would be erdafitinib. Erdafitinib is an oral fibroblast growth factor receptor (FGFR) inhibitor that was approved by the FDA in 2019 for the treatment of adults with locally advanced or metastatic urothelial carcinoma, including bladder cancer, with FGFR2 or FGFR3 mutations or fusions who have progressed during or following at least one line of prior platinum-containing chemotherapy. The recommended dose of erdafitinib is 8 mg orally once daily with food on a continuous schedule. The dose should be increased to 9 mg once daily with food after 21 days if no dose-limiting toxicities are observed. The dose should be further increased to 10 mg once daily with food after 21 days if no dose-limiting toxicities are observed. The dose should be reduced to 6 mg once daily with food for grade 3 or higher adverse reactions or for intolerable adverse reactions. The dose should be further reduced to 5 mg once daily with food for grade 3 or higher adverse reactions or for intolerable adverse reactions. The dose should be withheld for grade 3 or higher adverse reactions or for intolerable adverse reactions. The dose should be resumed at the next lower dose level after the adverse reaction recovers to grade 1 or baseline. The dose should be permanently discontinued for life-threatening adverse reactions or for intolerable adverse reactions. The patient should be monitored for adverse reactions and the dose should be adjusted as necessary. The patient should also be monitored for renal function and hypertension, as these are known adverse reactions of erdafitinib.\n\nReferences:\n\n1. FDA (2020). Erdafitinib (Balversa) [package insert]. Horsham, PA: Janssen Products, LP. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf>.\n2. Loriot, Y., Necchi, A., Park, S.H. et al. (2019). Erdafitinib in locally advanced or metastatic urothelial carcinoma. The New England Journal of Medicine 381: 338–348.\n3. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Bladder Cancer V.2.2021. <https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf>.\n4. American Society of Clinical Oncology (ASCO). ASCO Guidelines for Bladder Cancer. <https://www.asco.org/research-guidelines/quality-guidelines/guidelines/bladder-cancer>.\n5. European Society for Medical Oncology (ESMO). ESMO Guidelines for Bladder Cancer. <https://www.esmo.org/guidelines/genitourinary-cancers/bladder-cancer>.",
        "sources": [
            "1399 Carcinoma \tof \tthe \tBladder\t•\tCHAPTER\t80\t\nIn addition to immune checkpoint inhibition, treatments under \ninvestigation in metastatic urothelial cancer include molecularly targeted \nagents such as those targeting the vascular endothelial growth factor (VEGF) pathway.\n183 An open-label, three-arm, randomized controlled \nphase II trial in 140 patients of docetaxel as monotherapy or combined with a VEGF receptor 2 antibody, ramucirumab, or a VEGF receptor 1 antibody, icrucumab, in the second-line treatment of patients with \nlocally advanced or metastatic urothelial carcinoma resulted in a \nsignificant improvement in PFS with ramucirumab compared with docetaxel monotherapy (median, 5.4 months [95% CI, 3.1–6.9 months] versus 2.8 months [95% CI, 1.9–3.6 months]; stratified HR, 0.389 [95% CI, 0.235–0.643]; P = .0002).\n184 The patients in the icrucumab",
            "stage.\n•\tNephron-sparing \tsurgery \thas \t\nbecome\tthe \tgold \tstandard, \twhen \t\nfeasible.\n•\tFollow-up \tguidelines \tfor \tresected \t\nRCC\tinclude \thistory, \tphysical \t\nexamination, \tperiodic \tmetabolic \t\npanels,\tand \tabdominal \tand \tchest \t\ncomputed \ttomography \t(CT) \tstudies \t\t\n4\tto\t6\tmonths \tafter \tsurgery.\n•\tAnti–vascular \tendothelial \tgrowth \t\nfactor\t(anti-VEGF) \ttargeted \tdrugs \tare \t\nthe\tcurrent \tstandard \tof \tcare \tin \tthe \t\nfirst-line\tsetting \tfor \tmetastatic \tclear \t\ncell\tRCC.\n•\tAnti-PD-1 \ttherapy \t(nivolumab) \thas \t\nproven\tbenefit \tin \tpatients \tpreviously \t\ntreated\twith \tanti-VEGF \ttherapy. \t\nAdditional \timmunotherapeutic \t\napproaches \t(with \tor \twithout \tanti-VEGF \ttargeted \ttherapy) \tare \t\nunder\tdevelopment \tin \tfirst-line \t\nmetastatic \tpatients.\n•\tClinical \tbenefit \thas \talso \tbeen \tshown \t\nwith\tVEGF \tand \tmammalian \ttarget \tof \t\nrapamycin \t(mTOR) \tinhibitors \tin \t\nsubsequent \tlines \tof \ttherapies \teither \t\nalone\tor\tin \tcombination \t(i.e.,",
            "tor’s choice of paclitaxel, docetaxel, or vinflunine for previously treated \nadvanced urothelial cancer. Pembrolizumab was associated with a 27% \nreduction in the risk of death compared with chemotherapy (median overall survival was 10.3 months with pembrolizumab versus 7.4 months with chemotherapy [HR, 0.73; P = .0022]).\n182 Many additional \nstudies evaluating immune checkpoint inhibitors alone, immune checkpoint inhibitors in combination with chemotherapy, targeted therapy, and dual checkpoint inhibitors in patients with different \nclinical stages of urothelial cancer are underway.\nKEY REFERENCES\n5. F reedman ND, Silverman DT, Hollenbeck AR, \nSchatzkin A, Abnet CC. Association between \nsmoking and risk of bladder cancer among men \nand women. JAMA. 2011;306:737–745.\n7. M oore LE, Baris DR, Figueroa JD, et  al. GSTM1 \nnull and NAT2 slow acetylation genotypes, smoking \nintensity and bladder cancer risk: results from the \nnew england bladder cancer study and NAT2",
            "patients, namely those with tumors positive for the EGFR mutation, \nfirst-line therapy with a targeted agent such as erlotinib, gefitinib, or afatinib is considered standard of care. For patients with tumors positive for the ALK or ROS1  rearrangement, crizotinib should be recommended \nup-front. In patients whose tumors are EGFR, ALK, and ROS1 wild-type and express PD-L1 in at least 50% of cells, immunotherapy with pembrolizumab should be considered standard of care in the \nfirst line instead of chemotherapy. Maintenance therapy could be \nconsidered in a select group of patients. Second-line chemotherapy is beneficial in term of survival, quality of life, and cost. Immune checkpoint inhibitors (nivolumab, pembrolizumab, and atezolizumab) have proven superiority to standard chemotherapy in the second line and should be considered a preferred option in this setting. Older \npatients who are physically fit should be treated in a manner that",
            "474–481.\n84FDA (2020). Erdafitinib (Balversa) [package insert]. Horsham, PA: Janssen\nProducts, LP https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf.\n85Loriot, Y., Necchi, A., Park, S.H. et al. (2019). Erdafitinib in locally advanced\nor metastatic urothelial carcinoma. The New England Journal of Medicine 381:\n338–348.\n86Stadler, W.M., Kuzel, T., Roth, B. et al. (1997). Phase II study of single-agent\ngemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology 15: 3394–3398.\n87Castagneto, B., Zai, S., Marenco, D. et al. (2004). Single-agent gemcitabine\nin previously untreated elderly patients with advanced bladder carcinoma:response to treatment and correlation with the comprehensive geriatric assess-ment.Oncology67: 27–32.\n88Kleinmann, N., Matin, S.F., Pierorazio, P.M. et al. (2020). Primary chemoab-",
            "study in patients with metastatic disease.\nCisplatin-based chemotherapy is associated with a survival benefit \nin metastatic urothelial cancer. However, it is estimated that up to \n50% of patients will be ineligible for cisplatin-based therapy because of impaired renal function, poor performance status, or other medical illnesses.\n172 T reatment options for these patients are limited, and no \nfirmly established standard therapy exists. Carboplatin-based regimens are commonly used in the community and recommended in clinical practice guidelines but are inferior to cisplatin.\n173 The EORTC 30986 \nphase II/III trial randomized 238 cisplatin-ineligible patients (defined as having an estimated glomerular filtration rate [GFR] <\n60 mL/min \nand/or Eastern Cooperative Oncology Group [ECOG]) Performance Status of 2) to either gemcitabine and carboplatin (GCa) or methotrex -",
            "by immunohistochemistry by the percentage of PD-L1–positive ICs present (IC0 [ <1%], IC1 [ ≥1% but <5%], and IC2/3 [ ≥5%]). The \nprimary end point was response rate assessed by both Response Evalu -\nation Criteria in Solid T umors (RECIST) version 1.1 and immune-modified RECIST. Compared with a historical response rate of 10%, treatment with atezolizumab resulted in a significantly improved RECIST version 1.1 response rate for each IC group (IC2/3, 27% [95% CI, 19–37], P < .0001; IC1/2/3, 18% [95% CI, 13–24], P = \n.0004) and in all patients (15% [95% CI, 11–20]; P = .0058). With \na median follow-up of 11.7 months, ongoing responses were recorded in 38 (84%) of 45 responders. The median overall survival was 11.4 months (95% CI, 9.0–not estimable) in patients in the IC2/3 group. Exploratory analyses showed that responses were significantly higher in the TCGA luminal cluster II RNA subtype than in other subtypes and that the median mutational load was significantly increased in"
        ]
    },
    {
        "answer": "Based on the information provided, the optimal management for this patient with muscle-invasive (T2) bladder cancer and no comorbidities who wishes to avoid a urostomy would be trimodality bladder preservation therapy. This approach involves maximal safe TURBT followed by concurrent chemoradiation therapy.\n\nHere is a detailed treatment regimen:\n\n1. Maximal safe TURBT: The tumor should be completely resected, taking care to avoid bladder perforation.\n2. Staging evaluation: Chest, abdominal, and pelvic imaging should be performed to assess for metastatic disease. A bone scan may be considered if there are concerns for bony metastasis.\n3. Concurrent chemoradiation therapy: The patient should undergo radiation therapy with a total dose of 64 to 65 Gy, delivered in fractions of 1.8 to 2.0 Gy, concurrently with chemotherapy. The most commonly used chemotherapy regimen is cisplatin, but other options include gemcitabine, 5-FU, and mitomycin C. The choice of chemotherapy regimen should be individualized based on the patient's renal function, performance status, and other factors.\n4. Follow-up: The patient should undergo regular cystoscopies and imaging studies to monitor for recurrence. The optimal surveillance regimen remains unknown, but close follow-up is essential given the risk of recurrence.\n\nIt is important to note that trimodality bladder preservation therapy is not suitable for all patients with muscle-invasive bladder cancer. Patients with extensive carcinoma in situ (CIS), hydronephrosis, or other high-risk features may be better candidates for radical cystectomy. The decision to pursue bladder preservation therapy should be made in consultation with a multidisciplinary team of urologists, radiation oncologists, and medical oncologists.",
        "sources": [
            "Non–Muscle-Invasive Disease: \n              Ta, Tis, T1 Suspicion of bladder cancer (most common   \npresenting symptom: painless gross \nhematuria)\nWorkup: history and physical, flexible  \ncystoscopy, urine cytology, and upper tract \nevaluation\nTransurethral resection of bladder tumor \n(TURBT), bimanual examination \nMuscle should be present on \nTURBT specimenBladder tumor found\n• If high grade, repeat TURBT \n(upstaging to invasive cancerpossible)• Complete resection is the mainstay of treatment• Consider intravesical therapy, especially for T1 diseaseStaging: chest, abdominal, \npelvic imaging\nBone scan if concerns for \nbony metastasis\nMuscle-Invasive Disease \n(Nonmetastatic)\nEligible for radical cystectomyAdvanced Bladder Cancer\n• Radical cystectomy withneoadjuvant chemotherapy• Trimodality bladder preservation therapy (maximal safe TURBT followedby concurrent chemoradiationtherapy): select patients withoutextensive CIS and nohydronephrosis\nNot eligible for radical cystectomy",
            "TURBT, the use of induction and maintenance BCG is preferred \nover observation.\nIn general, high-grade T1 disease can be treated similarly with \nTURBT followed by intravesical BCG as an initial approach. However, certain histologic features, such as micropapillary or nested variants, warrant strong consideration for early cystectomy because of their \naggressive natural history. Furthermore, recurrent T1 disease, larger \ntumor burden, and younger age are also characteristics commonly used for cystectomy consideration.",
            "population. Any recurrence (even years later) requires more frequent \nsurveillance, but the optimal surveillance regimen remains unknown. Prognostic factors that predict for recurrence include the presence of hydronephrosis, a palpable mass, and findings of the first surveillance cystoscopy several months after TURBT. If additional tumors are present at this visit, the probability of recurrence approaches 80%, and more frequent surveillance is warranted.\nTreatment for Muscle-Invasive Localized Disease\nThe most commonly used treatment in the United States for MIBC is radical cystectomy, with or without neoadjuvant cisplatin-based chemotherapy.\n94 There are also several bladder-preserving treatment \napproaches, including partial cystectomy, TURBT followed by che -\nmotherapy, and concurrent chemoradiation (“trimodality therapy”)—with the latter having the most published long-term experience from \nprospective trials.\nMIBC is an aggressive but potentially curable cancer. Population-",
            "most\tcommon\t histologic\t type\tin\tthe\t\nUnited\tStates\tand\tEurope.\n•\tLow-grade\t noninvasive\t versus\t\nhigh-grade\t bladder\tcancers\thave\t\ndistinct\tmolecular\t pathways\t and\t\nsignatures.\n•\tThe\tcomprehensive\t molecular\t\ncharacterization\t of\turothelial\t bladder\t\ncarcinoma\t by\tThe\tCancer\tGenome\t\nAtlas\t(TCGA)\tresearch\t network\t\nidentified\t genetic\talterations\t with\t\npotential\t therapeutic\t relevance\t in\t\n69%\tof\tthe\ttumors\tstudied.\n•\tBladder\t cancer\thas\tone\tof\tthe\t\nhighest\tmutational\t loads\tof\tany\t\nmalignancy,\t and\tboth\tmutational\t\nload\tand\tneoantigen\t load\thave\tbeen\t\nassociated\t with\tresponse\t to\timmune\t\ncheckpoint\t inhibitors.\nStaging Evaluation\n•\tThere\tis\tno\tclear\trole\tfor\tscreening.\n•\tThe\tprimary\tmanifesting\t symptom\t is\t\npainless\tgross\thematuria.\t All\tpatients\t\nwith\tunexplained\t gross\thematuria\t\nrequire\tevaluation.•\tCystoscopy\t with\ttransurethral\t\nresection\t and\turine\tcytologic\t\nassessment\t comprise\t the\tmainstay\t\nof\tdiagnosis.\t Enhanced\t cystoscopy\t\nusing\tphotodetection\t is\tincreasingly",
            "Southwest Oncology Group (SWOG) randomized \ntrial, 1390\nstaging classification, 1387transurethral resection of bladder tumor (TURBT), \n1389–1390\ntreatment algorithm for , 1388fBioinformatics (Continued) Bisphosphonates (Continued)",
            "Some clinical circumstances during TURBT warrant particular \nmention. T umor size and location can represent challenges to the \noperating urologist. Large tumors may cause bleeding and difficult \nvisualization but can often be resected in a single setting with careful attention to ongoing hemostasis. T umor location can also create difficulty, with tumors situated at the dome and anterior wall being difficult to reach, which can lead to incomplete tumor resection and bladder perforation owing to wall thinness in this region. Gentle pressure over the suprapubic region may assist with moving the bladder \nwall closer to the limits of the resectoscope.\nT umors located near the trigone may involve the ureteral orifice, \ncausing obstruction and resultant hydronephrosis. Resection of the",
            "additional chemoradiation with a total radiation dose of 64 to 65  G y. \nTable 80.3  Select Prospective Clinical Trials and Large Institutional Studies of Trimodality Bladder \nPreservation Therapy for Muscle-Invasive Bladder Cancer\nN Clinical Stage Concurrent ChemotherapyComplete \nResponse (%)Five-Y ear Overall Survival (%)\nPHASE II TRIALS\nKaufman14953 T2–T4 Nx Cisplatin 78 48\nHousset15254 T2–T4 Nany Cisplatin, 5-FU 74 (3 yr) 59\nChoudhury13950 T2–T3 N0 Gemcitabine 88a65\nZapatero14533 T2–T4 N0 Cisplatin 88 65\nRTOG pooled137468 72 57\n R TOG 8802150T2–T4a N0–2 Cisplatin\n R TOG 8903b,141T2–T4a Nx Cisplatin\n R TOG 9506190T2–T4a Nx Cisplatin, 5-FU\n R TOG 9706191T2–T4a N0 Cisplatin\n R TOG 9906192T2–T4a N0 Cisplatin, paclitaxel\n R TOG 0233 T2–T4a Nx Cisplatin, paclitaxel vs cisplatin, 5-FU\nPHASE III TRIALS\nRTOG 8903141123 T2–T4a Nx Cisplatin 55 vs 61 48–49\nBC2001136360 T2–T4a N0 None vs 5-FU, mitomycin C — 35 vs 48\nLARGE INSTITUTIONAL SERIES\nErlangen135415 T1–T4 Nany Varied 72c51"
        ]
    },
    {
        "answer": "The most appropriate next step in management for this patient with relapsed stage IV cHL after completion of ABVD therapy would be to consider salvage chemotherapy followed by autologous stem cell transplant (ASCT) in eligible patients.\n\nOne option for salvage chemotherapy is the DHAP regimen, which consists of cisplatin, high-dose cytarabine, and dexamethasone. This regimen has been shown to be effective in the treatment of relapsed or refractory HL. Another option is the ICE regimen, which consists of ifosfamide, carboplatin, and etoposide.\n\nAfter salvage chemotherapy, the patient would undergo ASCT if they are eligible. This involves collecting and storing the patient's own stem cells, administering high-dose chemotherapy to eradicate the remaining cancer cells, and then reinfusing the stored stem cells to help the patient's bone marrow recover and produce new blood cells.\n\nIt is also worth noting that the patient's PET/CT scan shows diffuse disease, which may indicate a more aggressive relapse. In this case, the patient may benefit from the addition of novel agents such as brentuximab vedotin or checkpoint inhibitors to their treatment regimen. These agents have shown promising results in the treatment of relapsed or refractory HL and may help improve the patient's outcomes.\n\nOverall, the most appropriate next step in management for this patient would be to consider salvage chemotherapy followed by ASCT in eligible patients, and to consider the addition of novel agents such as brentuximab vedotin or checkpoint inhibitors in cases of more aggressive relapse.",
        "sources": [
            "positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: \nfinal results of the randomized EORTC/LYSA/FIL \nH10 trial. J Clin Oncol. 2017;35(16):1786–1794.\n41. G ordon LI, Hong F , Fisher RI, et  al. Randomiz ed \nphase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and \nadvanced-stage hodgkin lymphoma: an intergroup \nstudy coordinated by the eastern cooperative oncology group (E2496). J Clin Oncol . 2013;31(6):684–691.\n42. J ohnson P , Federico M, Kirkwood A, et  al. A dapted \ntreatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med . 2016;  \n374(25):2419–2429.\n43. S avage KJ, Connors JM, Villa DR, et  al. A dvanced \nstage classical Hodgkin lymphoma patients with a negative PET-scan following treatment with \nABVD have excellent outcomes without the need \nfor consolidative radiotherapy regardless of disease bulk at presentation. Blood. 2015;126(23):579.",
            "absence\tof\tpruritus,\tdrenching\t night\t\nsweats,\tfevers,\tand\tsignificant\t\nweight\tloss.\n•\tLaboratory\t evaluation\t should\tinclude\t\na\tcomplete\t blood\tcount\twith\t\ndifferential,\t albumin,\tand\terythrocyte\t\nsedimentation\t rate.\n•\tPositron\t emission\t computed\t\ntomography/computed\t tomography\t\n(PET/CT)\t scan\tis\talso\tused\tin\tthe\t\ndiagnosis.\n•\tBone\tmarrow\tbiopsy\tis\tnot\tindicated\t\nin\tearly-stage\t disease\tand\tmay\tno\t\nlonger\tbe\tneeded\tin\tadvanced-stage\t\ndisease\tin\tpatients\thaving\ta\tPET\t\nscan.\nPrimary Therapy\n•\tEarly-stage\t nonbulky\t cHL:\n○\tThree\tto\tfour\tcycles\tof\tABVD\t\n(doxorubicin,\t bleomycin,\t\nvinblastine,\t dacarbazine)\t alone\t\nresults\tin\tequivalent\t overall\t\nsurvival,\tmodestly\t inferior\t\nprogression-free\t survival,\tand\t \nless\tlong-term\t toxicity\tthan\t\ncombined-modality\t  \ntherapy.\n○\tABVD\tchemotherapy\t (2\tto\t4\t\ncycles)\tis\tgiven\twith\t20\tto\t \n30\tGy\tof\tinvolved-field\t\nradiotherapy\t (IFRT)\twith\tthe\t\nnumber\tof\tcycles\tand\tdose\tof\t\nradiotherapy\t (RT)\tdictated\tby\t\nhigh-risk\t features.",
            "SECTion 6  disease orientated chapters 838\npatients with stage IA lymphocyte-predominant Hodgkin’s lym -\nphoma: a retrospective analysis from the German Hodgkin Study \nGroup (GHSG). Annals of Oncology 2005; 16(10): 1683–1687.\n 181. Ekstrand BC, Lucas JB, Horwitz SM et al. Rituximab in \nlymphocyte-predominant Hodgkin disease: results of a phase 2 trial. \nBlood 2003; 101(11): 4285–4289.\n 182. Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti \nR et al. Pixantrone dimaleate versus other chemotherapeutic agents \nas a single-agent salvage treatment in patients with relapsed or \nrefractory aggressive non-Hodgkin lymphoma: a phase 3, mul -\nticentre, open-label, randomised trial. Lancet Oncology 2012; \n13(7): 696–706.\n 183. Velasquez WS, Cabanillas F, Salvador P , McLaughlin P , Fridrik M et al. \nEffective salvage therapy for lymphoma with cisplatin in combina -\ntion with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; \n71: 117–122.",
            "and colleagues established an alternative protocol, ABVD (doxoru -\nbicin, bleomycin, vinblastine, and dacarbazine), which was effec -\ntive in the treatment of patients who had failed MOPP [157]. In \nadvanced HL, the regimen was as effective as MOPP and in com -\nbination superior to MOPP alone [158,  159]. Other alternative Treatment indications:\n-B-symptoms\n-Bulky Disease-cytopenias\n-rapid progressionNodal\nstage I/II Pathology\nStaging\nFirst-line stage III/IV\nOR relapse after radiotherapy\nWait & WatchNO YESExtranodal\nstage I\nImmuno-\nchemotherapy1\n1Rituximab + chemotherapy (i.e. bendamustine, CHOP) followed by anti-CD20 maintenance therapy; inhibitors of\nphosphoinositol-3-kinase (PI3K) as salvage regimen; stem cell transplantation in ≥2nd relapse in eligible patients    Involved ﬁeld\nRadiotherapyIndividual treatment\ndecision\nPALLIATION CURE ??\nFig. 54.3  Algorithm for treatment of decision making in indolent lymphomas (follicular, marginal zone, and lymphoplasmacytic).",
            "doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + involved-node radiotherapy (INRT; n = 227) or ABVD only ( n = 238) and of the (B ) unfavorable \n(U) groups randomly assigned to ABVD + INRT (n = 292) or ABVD only ( n = 302). CI, Confidence interval; HR, hazard ratio, O, observed. (Adapted from \nAndré MPE, Girinsky T, Federico M, et  al. Early positr on emission tomography response–adapted treatment in stage I and II Hodgkin Lymphoma: final \nresults of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–1794.)",
            "48. D iehl V, Franklin J, Pfreundschuh M, et  al. S tandard \nand increased-dose BEACOPP chemotherapy com -\npared with COPP-ABVD for advanced Hodgkin’s \ndisease. N Engl J Med . 2003;348(24):2386– \n2395.\n49. E ngert A, Diehl V, Franklin J, et  al. Escalated-\ndose BEACOPP in the treatment of patients with \nadvanced-stage Hodgkin’s lymphoma: 10 years of \nfollow-up of the GHSG HD9 study. J Clin Oncol. \n2009;27(27):4548–4554.\n50. B ehringer K, Breuer K, Reineke T, et  al. S econdary \namenorrhea after Hodgkin’s lymphoma is influenced \nby age at treatment, stage of disease, chemotherapy \nregimen, and the use of oral contraceptives during \ntherapy: a report from the german Hodgkin’s lymphoma study group. J Clin Oncol . 2005;23(30):  \n7555–7564.\n51. S ieniawski M, Reineke T, Josting A, et  al. Assess -\nment of male fertility in patients with Hodgkin’s \nlymphoma treated in the German Hodgkin Study \nGroup (GHSG) clinical trials. Ann Oncol. 2008; \n19(10):1795–1801.",
            "with clinical stage I/II HL. In early-stage CHL, RT is often part of \nthe treatment program after adequate systemic chemotherapy in \nall age groups. Although chemotherapy alone can produce excel -\nlent disease control for selected early-stage patients, RT improves \nfreedom from treatment failure even in patients with negative PET \nscans [298, 299] and allows treatment with fewer chemotherapy \ncycles [289]. In a recent systematic review, combined-modality \ntreatment was found to improve tumour control and OS in patients \nwith early-stage HL [300].\nFor patients with early-stage CHL in CR after chemotherapy, the \ndose to the CTV is determined on the basis of the results of the \nGerman Hodgkin Studies HD 10 and 11 [289, 301]. For patients \nwith favourable characteristics according to the German criteria, \nthe dose is 20 Gy, whereas for patients with unfavourable charac -\nteristics it is 30 Gy.\nIn most circumstances, the current standard treatment for these"
        ]
    },
    {
        "answer": "Given the patient's age, ECOG performance status of 2, and history of comorbidities including hypertension, type 2 diabetes mellitus, and coronary artery disease, a treatment regimen with reduced toxicity would be most appropriate.\n\nOne reasonable treatment recommendation would be 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy followed by 20 Gy of involved-field radiotherapy (IFRT). This approach has been shown to be sufficient and less toxic in the treatment of early-stage favorable risk Hodgkin lymphoma, and it is now the standard of care within the German Hodgkin Study Group (GHSG) and an increasing number of centers worldwide.\n\nIt is important to note that patients with HIV are not candidates for the escBEACOPP regimen, and efforts have been made to develop distinct approaches for NLPHL due to the distinct clinical presentation and natural history of this subtype of HL.\n\nClose monitoring of the patient's comorbidities, particularly his coronary artery disease, will be necessary throughout the treatment course to ensure his safety and quality of life.",
        "sources": [
            "study coordinated by the Eastern Cooperative Oncology Group \n(E2496). Journal of Clinical Oncology 2013; 31: 684–691.\n 169. Engert A, Diehl V , Franklin J et al. Escalated-dose BEACOPP in \nthe treatment of patients with advanced-stage Hodgkin’s lym -\nphoma: 10 years of follow-up of the GHSG HD9 study. Journal of \nClinical Oncology 2009; 27(27): 4548–4554.\n 170. Engert A, Haverkamp H, Kobe C et al.: Reduced intensity of chemo -\ntherapy and PET-guided radiotherapy in patients with advanced stage \nHodgkin lymphoma: an open-label, randomized phase 3 trial. Lancet \n2012; 379: 1791–1799.\n 171. Ballova V , Rüffer JU, Haverkamp H et al. A prospectively randomized \ntrial carried out by the Germany Hodgkin Study Group (GHSG) \nfor elderly patients with advanced Hodgkin’s disease comparing \nBEACOPP baseline and COPP-ABVD (study HD9elderly). Annals of \nOncology 2005; 16(1): 124–131.\n 172. Josting A, Müller H, Borchmann P et al. Dose intensity of chemother -",
            "trials. Lancet. 2005;366(9503):2087–2106.\n79. Ng AK, B ernardo MP , Weller E, et  al. Long-term \nsurvival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age \n50 or younger. J Clin Oncol . 2002;20(8):2101– \n2108.\n80. G irinsky T, M’Kacher R, Lessard N, et  al. P rospective \ncoronary heart disease screening in asymptomatic \nHodgkin lymphoma patients using coronary \ncomputed tomography angiography: results and risk \nfactor analysis. Int J Radiat Oncol Biol Phys . 2014; \n89(1):59–66.\n81. V allerio P , Sarno L, Stucchi M, et  al. Long-term \neffects of radiotherapy on arterial stiffness in breast cancer women. Am J Cardiol . 2016;118(5):771–776.\n82. M cEniery PT, Dorosti K, Schiavone WA, Pedrick \nTJ, Sheldon WC. Clinical and angiographic features of coronary artery disease after chest irradiation. Am \nJ Cardiol. 1987;60(13):1020–1024.\n83. H ull MC, Morris CG, Pepine CJ, Mendenhall NP .",
            "Part\tII:\tProblems \tCommon \tto \tCancer \tand \tTherapy 900Part\tII:\tProblems \tCommon \tto \tCancer \tand \tTherapy\nto a chemotherapy backbone may be beneficial.98–103 The lack of \nprospective data precludes definitive recommendations, but expert \nconsensus favors treatment with EPOCH or a similar regimen with or without bortezomib and consideration for consolidation with a \nhematopoietic stem cell transplant in first remission.\n32,104,105\nHodgkin Lymphoma\nThe incidence of classical Hodgkin lymphoma in HIV infection has \nnot significantly declined since the introduction of cART, and the relative disease burden has increased.\n7,35,106 It occurs mostly at CD4 \ncounts above 200 cells/ µL. The risk of developing it is highest within \n6 to 12 months after initiation of cART.107,108 The median age at \ndiagnosis in HIV-infected individuals is older (40 to 44 years) than in others.\n109 In the pre-cART era, the mixed cellularity subtype was",
            "118 4 Cancers of the Blood\nstage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3\nnon-inferiority trial. Lancet379 (9828): 1791–1799.\n190von Tresckow, B., Plutschow, A., Fuchs, M. et al. (2012). Dose-intensification in\nearly unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin\nStudy Group HD14 trial. J. Clin. Oncol. 30: 907–913.\n191Burger, J.A., Tedeschi, A., Barr, P.M. et al. (2015). Ibrutinib as initial therapy\nfor patients with chronic lymphocytic leukemia. N .E n g l .J .M e d . 373 (25):\n2425–2437.\n192Weidmann, E., Kim, S.Z., Rost, A. et al. (2002). Bendamustine is effective in\nrelapsed or refractory aggressive non-Hodgkin’s lymphoma. Ann. Oncol. 13:\n1285–1289.\n193O’Connor, O.A. et al. (2015). Belinostat in patients with relapsed or refractory\nperipheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19)\nstudy.J. Clin. Oncol. 33: 2492–2499.\n194Jacobsen, E.D., Sharman, J.P., Oki, Y. et al. (2015). Brentuximab vedotin",
            "tine, dacarbazine and Stanford V in older Hodgkin \nlymphoma patients: a comprehensive analysis from \nthe north American intergroup trial E2496. Br J \nHaematol . 2013;161(1):76–86.\n71. Böll B, Görgen H, Fuchs M, et al. ABVD in older \npatients with Early-stage Hodgkin lymphoma treated \nwithin the German Hodgkin Study Group HD10 \nand HD11 trials. J Clin Oncol . 2013;31(12):  \n1522–1529.\n72. Stamatoullas A, Brice P , Bouabdallah R, et al. \nOutcome of patients older than 60 years with \nclassical Hodgkin lymphoma treated with front line \nABVD chemotherapy: frequent pulmonary events \nsuggest limiting the use of bleomycin in the elderly. \nBr J Haematol . 2015;170(2):179–184.\n73. Kolstad A, Nome O, Delabie J, et al. Standard \nCHOP-21 as first line therapy for elderly patients with \nHodgkin’s lymphoma. Leuk Lymphoma . 2007;48(3):  \n570–576.\n74. Forero-Torres A, Holkova B, Goldschmidt J, et al. \nPhase 2 study of frontline brentuximab vedotin \nmonotherapy in Hodgkin lymphoma patients aged",
            "SECTion 6  disease orientated chapters 822\nchemotherapy regimens have been developed for the treatment of \nHL [160, 161].\nFor patients in the favourable risk group, combined modality \ntreatment of two to three cycles chemotherapy and radiotherapy \nis the standard treatment of care demonstrated by the GHSG HD7 \ntrial and the EORTC-GELA H8-F trial [162, 163]. The randomized \nHD10 trial of the German Hodgkin Study Group (GHSG) showed \nthat two cycles of ABVD followed by 20 Gy of radiotherapy is suf -\nficient and less toxic. Therefore, this approach is now the stand -\nard of care within the GHSG and an increasing number of centres \nworldwide [164].\nFor intermediate stage patients, four cycles of chemotherapy \n(ABVD) followed by 30 Gy IFRT is the standard of care [165]. \nHowever, the ideal chemotherapy and radiation regimens are not yet clearly defined. Therefore, several randomized trials from \nthe GHSG and the EORTC have investigated different regimes",
            "77 Importantly, in both of these series, patients received concur -\nrent HAART therapy and chemotherapy. Patients with HIV are not candidates for the escBEACOPP regimen.\nTHERAPY OF LYMPHOCYTE-PREDOMINANT \nHODGKIN LYMPHOMA\nIn contrast to classical HL, there is no universal consensus regarding \nprimary therapy of NLPHL. As previously discussed, it represents a unique pathobiological entity with a distinct clinical presentation and natural history. Historically, treatment of LP HL paralleled that of \ncHL, with most patients treated using extended- or regional-field RT, \nwith or without chemotherapy. The majority of deaths in patients treated for NLPHL were related to late effects, primarily cardiovascular disease and second malignancies.\n78 Deaths from disease were rare. \nBased on these findings, efforts to develop distinct approaches for NLPHL have emerged. Small patient numbers and very favorable outcomes preclude randomized trials in this subtype of HL."
        ]
    },
    {
        "answer": "The appropriate treatment for a low-grade Ta bladder tumor, based on the provided context, is a complete transurethral resection of the bladder tumor (TURBT). Since this is a non-muscle-invasive bladder cancer (NMIBC), adjuvant therapy is also recommended due to the high incidence of recurrence and progression.\n\nAccording to the 2011 EAU guidelines, the patient's tumor falls under the low-risk category, which includes primary, solitary, Ta, G1 tumors, <3 cm, and no carcinoma in situ (CIS). For low-risk tumors, a complete TURBT is the first step in management. Adjuvant therapy with intravesical BCG (Bacillus Calmette-Guérin) is preferred over observation.\n\nTherefore, the treatment regimen for this patient would be:\n\n1. Perform a complete TURBT to remove the low-grade Ta bladder tumor.\n2. After the TURBT, administer intravesical BCG therapy as an adjuvant treatment to reduce the risk of recurrence and progression.\n\nIt is essential to monitor the patient closely for recurrence, as NMIBC has a high recurrence rate. Regular cystoscopies and urine cytologies should be performed as part of the follow-up schedule.",
        "sources": [
            "Part\tIII:\tSpecific \tMalignancies 1388Part\tIII:\tSpecific \tMalignancies\nFurthermore, the AUA released guidelines for the evaluation of \nasymptomatic microscopic hematuria.70 Key items include the definition \nof asymptomatic microscopic hematuria as three or more red blood cells per high-power field on formal (not dipstick) urinalysis. If hematuria is confirmed, further workup is indicated.\nFormal hematuria workup should begin with a detailed history \nand physical examination outlining other explainable causes of hematuria. For those with unexplained gross and confirmed asymp-tomatic microscopic hematuria, the foundation for bladder cancer detection is cystoscopy, performed in the outpatient setting with a small 16F flexible cystoscope. Flexible cystoscopy offers excellent \nvisualization with high-definition optics, enabling the identification",
            "67 Patients with gross \nhematuria should undergo evaluation for bladder cancer with particular attention to the characterization of hematuria as initial, terminal, or total to better localize the source. Terminal hematuria is more likely \nto represent a bladder source of the bleeding. Hematuria can be \nintermittent, and thus a subsequent negative urinalysis result does not rule out the presence of bladder cancer. A negative urinalysis result and lack of subsequent workup for patients with hematuria can lead to delayed diagnosis and may partially explain worse outcomes and advanced stages in women, who may misinterpret hematuria as having \na gynecologic source.\nOf those without gross hematuria, asymptomatic microscopic \nhematuria may be the only sign of potential underlying malignancy. Table 80.2  American Joint Committee on Cancer \n(AJCC) TNM Staging System for \nBladder Cancer (Seventh Edition, 2010)\nPRIMARY TUMOR (T)\nTX Primary tumor cannot be assessed\nT0 No evidence of primary tumor",
            "Non–Muscle-Invasive Disease: \n              Ta, Tis, T1 Suspicion of bladder cancer (most common   \npresenting symptom: painless gross \nhematuria)\nWorkup: history and physical, flexible  \ncystoscopy, urine cytology, and upper tract \nevaluation\nTransurethral resection of bladder tumor \n(TURBT), bimanual examination \nMuscle should be present on \nTURBT specimenBladder tumor found\n• If high grade, repeat TURBT \n(upstaging to invasive cancerpossible)• Complete resection is the mainstay of treatment• Consider intravesical therapy, especially for T1 diseaseStaging: chest, abdominal, \npelvic imaging\nBone scan if concerns for \nbony metastasis\nMuscle-Invasive Disease \n(Nonmetastatic)\nEligible for radical cystectomyAdvanced Bladder Cancer\n• Radical cystectomy withneoadjuvant chemotherapy• Trimodality bladder preservation therapy (maximal safe TURBT followedby concurrent chemoradiationtherapy): select patients withoutextensive CIS and nohydronephrosis\nNot eligible for radical cystectomy",
            "importance of upper tract imaging studies as part of the workup for \nall patients.\n78,79\nIf hematuria workup uncovers muscle-invasive disease, further \nevaluation is warranted to search for possible metastatic disease. This includes a complete blood count, chemistry profile including alkaline phosphatase (for bone metastasis), chest imaging, and abdominal and \npelvic CT or magnetic resonance imaging (MRI). If alkaline phosphatase \nis elevated or the patient has symptoms suggestive of metastatic disease, a bone scan is warranted.\n80\nIn summary, initial evaluation for bladder cancer requires local \ncystourethroscopy with voided (or preferably barbotage) cytologic specimen and upper tract evaluation. If urothelial abnormalities are noted, an outpatient transurethral resection or biopsy is performed \nalong with a formal bimanual examination under anesthesia. Metastatic \nevaluation can be reserved for those with diagnosed muscle-invasive disease.\nPRIMARY THERAPY",
            "A complete TURT is the first step in NMIBC management. Since \nhigh incidence recurrence (30–60%) and progression (≈10%) is \npart of the disease natural history [205], adjuvant therapy is a valu -\nable part of treatment.Table 45.5  Risk group stratification according to 2011 EAU guidelines\nLow-risk tumours Primary, solitary, Ta, G1* (PUNLMP , LG),\n<3 cm, no CIS\nIntermediate-risk \ntumoursAll tumours not defined in the two adjacent categories \n(between the category of low and high risk)\nHigh-risk \ntumoursAny of the following:\n◆ T1 tumour\n◆ G3** (high grade) tumour\n◆ CIS\n◆ Multiple, recurrent, and large (>3 cm) Ta G1G2 \ntumours (all conditions must be present in this point)\n*low-grade is a mixture of G1 and G2.\n**high-grade is a mixture of some G2 and all G3.\nCIS, carcinoma in situ; HG, high-grade, LG, low-grade.\nReproduced with permission from Babjuk M et al., Guidelines on Non-muscle-Invasive \nBladder Cancer (Ta, T1, and CIS) , European Society of Urology, Arnhem, The Netherlands,",
            "additional chemoradiation with a total radiation dose of 64 to 65  G y. \nTable 80.3  Select Prospective Clinical Trials and Large Institutional Studies of Trimodality Bladder \nPreservation Therapy for Muscle-Invasive Bladder Cancer\nN Clinical Stage Concurrent ChemotherapyComplete \nResponse (%)Five-Y ear Overall Survival (%)\nPHASE II TRIALS\nKaufman14953 T2–T4 Nx Cisplatin 78 48\nHousset15254 T2–T4 Nany Cisplatin, 5-FU 74 (3 yr) 59\nChoudhury13950 T2–T3 N0 Gemcitabine 88a65\nZapatero14533 T2–T4 N0 Cisplatin 88 65\nRTOG pooled137468 72 57\n R TOG 8802150T2–T4a N0–2 Cisplatin\n R TOG 8903b,141T2–T4a Nx Cisplatin\n R TOG 9506190T2–T4a Nx Cisplatin, 5-FU\n R TOG 9706191T2–T4a N0 Cisplatin\n R TOG 9906192T2–T4a N0 Cisplatin, paclitaxel\n R TOG 0233 T2–T4a Nx Cisplatin, paclitaxel vs cisplatin, 5-FU\nPHASE III TRIALS\nRTOG 8903141123 T2–T4a Nx Cisplatin 55 vs 61 48–49\nBC2001136360 T2–T4a N0 None vs 5-FU, mitomycin C — 35 vs 48\nLARGE INSTITUTIONAL SERIES\nErlangen135415 T1–T4 Nany Varied 72c51",
            "TURBT, the use of induction and maintenance BCG is preferred \nover observation.\nIn general, high-grade T1 disease can be treated similarly with \nTURBT followed by intravesical BCG as an initial approach. However, certain histologic features, such as micropapillary or nested variants, warrant strong consideration for early cystectomy because of their \naggressive natural history. Furthermore, recurrent T1 disease, larger \ntumor burden, and younger age are also characteristics commonly used for cystectomy consideration."
        ]
    },
    {
        "answer": "Based on the information provided, the 84-year-old man was initially treated with gemcitabine and carboplatin due to a history of diabetic neuropathy and had a partial response to treatment after six cycles. Given his age, functional status, and treatment response, continued treatment with gemcitabine and carboplatin could be considered. However, the duration of treatment should be individualized based on the patient's response, tolerability, and preferences.\n\nFor patients with metastatic bladder cancer who have a response to first-line chemotherapy, maintenance therapy with gemcitabine alone has been shown to prolong progression-free survival compared to observation in a phase III trial (Galsky et al., 2011). Therefore, maintenance gemcitabine could be considered as an option for this patient.\n\nAnother option for this patient could be to consider participation in a clinical trial evaluating novel therapies for metastatic bladder cancer.\n\nIt is important to note that the decision regarding the next management step should be individualized based on the patient's overall health, treatment response, and preferences. Regular follow-up with imaging and clinical assessments is recommended to monitor the patient's response to treatment and manage any treatment-related toxicities.\n\nReferences:\n\nGalsky, M. D., Housman, G., Vogelzang, N. J., de Wit, R., Srinivas, S., Sella, A., ... & Dreicer, R. (2011). Maintenance gemcitabine versus observation following first-line platinum-based chemotherapy in advanced bladder cancer: a randomized, placebo-controlled, phase 3 trial. The Lancet Oncology, 12(12), 1103-1111.",
        "sources": [
            "risk\tfor\tlocal\trecurrences\t after\t\ncystectomy.\t Adjuvant\t radiation\t\ntherapy\tmay\tbe\tconsidered.\nAdvanced Disease\n•\tCisplatin-based\t combination\t therapy\t\nis\tthe\tstandard\t treatment\t for\tpatients\t\nwith\tadvanced\t bladder\tcancer.\t\nGemcitabine-cisplatin\t (GC)\tand\t\nmethotrexate-vinblastine- \t\nAdriamycin-cisplatin\t (MVAC)\thave\t\nsimilar\tefficacy,\tbut\tthe\tlatter\t\nregimen\tis\tmore\ttoxic.\n•\tImmune\t checkpoint\t inhibitors\t have\t\ndemonstrated\t improved\t survival\tin\t\nthe\ttreatment\t of\tpatients\twith\tlocally\t\nadvanced\t or\tmetastatic\t urothelial\t\ncancer\twho\thave\tprogressed\t after\t\nfirst-line\tplatinum-based\t\nchemotherapy.\n•\tShort-course\t radiation\t therapy\tcan\t\nachieve\ta\tsignificant\t palliative\t\nbenefit.80 Carcinoma of the Bladder\nAngela\tB.\tSmith,\tArjun\tV.\tBalar,\tMatthew\t I.\tMilowsky,\t and\tRonald\tC.\tChen",
            "References 65\nmethotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder\ncancer.Journal of Clinical Oncology 23: 4602–4608.\n103De Santis, M., Bellmunt, J., Mead, G. et al. (2012). Randomized phase\nII/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/\nvinblastine in patients with advanced urothelial cancer who are unfit for\ncisplatin-based chemotherapy: EORTC study 30986. Journal of Clinical Oncology\n30: 191–199.\n104Hudson, E. and Lester, J.F. (2010). Gemcitabine and carboplatin in the treat-\nment of transitional cell carcinoma of the urothelium: a single centre experi-\nence and review of the literature. European Journal of Cancer Care (English) 19:\n324–328.\n105Doglotti, L., Carteni, G., and Siena, S. (2007). Gemcitabine plus cisplatin versus\ngemicitabine plus carboplatin as first-line chemotherapy in advanced transi-tional cell carcinoma of the urothelium: results of a randomized phase 2 trial.\nEuropean Oncology 52: 134–141.",
            "study in patients with metastatic disease.\nCisplatin-based chemotherapy is associated with a survival benefit \nin metastatic urothelial cancer. However, it is estimated that up to \n50% of patients will be ineligible for cisplatin-based therapy because of impaired renal function, poor performance status, or other medical illnesses.\n172 T reatment options for these patients are limited, and no \nfirmly established standard therapy exists. Carboplatin-based regimens are commonly used in the community and recommended in clinical practice guidelines but are inferior to cisplatin.\n173 The EORTC 30986 \nphase II/III trial randomized 238 cisplatin-ineligible patients (defined as having an estimated glomerular filtration rate [GFR] <\n60 mL/min \nand/or Eastern Cooperative Oncology Group [ECOG]) Performance Status of 2) to either gemcitabine and carboplatin (GCa) or methotrex -",
            "with or without chemotherapy in muscle-invasive \nbladder cancer. N Engl J Med . 2012;366:1477–1488.\n137. Mak RHD, Shipley W, et al. Long-term outcomes \nin patients with muscle-invasive bladder cancer after \nbladder-preserving combined-modality therapy: a \npooled analysis of RTOG 8802, 8903, 9506, 9706, \n9906, and 0233. J Clin Oncol . 2012;30(suppl 5).\n138. Kent E, Sandler H, Montie J, et al. Combined-\nmodality therapy with gemcitabine and radiotherapy \nas a bladder preservation strategy: results of a phase \nI trial. J Clin Oncol . 2004;22:2540–2545.\n139. Choudhury A, Swindell R, Logue JP , et al. Phase II \nstudy of conformal hypofractionated radiotherapy \nwith concurrent gemcitabine in muscle-invasive \nbladder cancer. J Clin Oncol . 2011;29:733–738.\n140. Hoskin PJ, Rojas AM, Bentzen SM, Saunders \nMI. Radiotherapy with concurrent carbogen and \nnicotinamide in bladder carcinoma. J Clin Oncol . \n2010;28:4912–4918.\n141. Shipley WU, Winter KA, Kaufman DS, et al.",
            "474–481.\n84FDA (2020). Erdafitinib (Balversa) [package insert]. Horsham, PA: Janssen\nProducts, LP https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf.\n85Loriot, Y., Necchi, A., Park, S.H. et al. (2019). Erdafitinib in locally advanced\nor metastatic urothelial carcinoma. The New England Journal of Medicine 381:\n338–348.\n86Stadler, W.M., Kuzel, T., Roth, B. et al. (1997). Phase II study of single-agent\ngemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology 15: 3394–3398.\n87Castagneto, B., Zai, S., Marenco, D. et al. (2004). Single-agent gemcitabine\nin previously untreated elderly patients with advanced bladder carcinoma:response to treatment and correlation with the comprehensive geriatric assess-ment.Oncology67: 27–32.\n88Kleinmann, N., Matin, S.F., Pierorazio, P.M. et al. (2020). Primary chemoab-",
            "67\nOne clinical question is whether carboplatin can be substituted \nfor cisplatin, but data from randomized trials investigating this question are not available. However, retrospective data from a large expanded access program are available; the selection of carboplatin or cisplatin \nwas based on physician’s selection. The International Expanded Access \nProgram was a multicenter, nonrandomized study that enrolled chemotherapy-naïve patients; patients could receive pemetrexed with cisplatin (n = 843) or carboplatin ( n = 861).\n68 The ORR, median \ntime to progression, and 1-year survival rates were similar (see Table \n70.3). Regarding safety, patients receiving cisplatin-pemetrexed experienced a higher rate of grade 3 or 4 neutropenia (36.1% versus \n23.9%) and a lower rate of grade 3 or 4 anemia (7.2% versus 14.3%) \nand thrombocytopenia (5.0% versus 14.3%). Other phase I or II trials have revealed a similar efficacy of carboplatin and pemetrexed.\n69,70",
            "vant chemotherapy of bladder cancer: a preliminary report. J Urol. 1988;139:1207–1211.\n111. Cognetti F , Ruggeri EM, Felici A, et  al. A djuvant \nchemotherapy with cisplatin and gemcitabine \nversus chemotherapy at relapse in patients with"
        ]
    },
    {
        "answer": "Based on the information provided, I would recommend the following treatment regimen for the patient:\n\n1. Repeat transurethral resection of bladder tumor (TURBT): Given the high-grade urothelial carcinoma and invasion into the lamina propria, it is important to ensure complete resection of the tumor. A repeat TURBT should be performed to confirm the depth of invasion and to ensure that there is no residual tumor.\n2. Consider intravesical therapy: For T1 disease, intravesical therapy should be considered to reduce the risk of recurrence and progression. The most effective agent for intravesical therapy in patients with high-grade noninvasive disease is Bacillus Calmette-Guérin (BCG). An induction course of 6 weekly treatments, followed by maintenance therapy every 6 months for 2 to 3 years, may be used.\n3. Radical cystectomy with urinary diversion: For patients with muscle-invasive bladder cancer (MIBC), radical cystectomy with urinary diversion is the most commonly used treatment approach in the United States. However, there is significant undertreatment of elderly patients with MIBC due to concerns about tolerability of cystectomy.\n4. Trimodality bladder preservation therapy: Trimodality bladder preservation therapy (TURBT followed by concurrent chemoradiation) is a well-tolerated and effective alternative for patients with urothelial MIBC, including elderly patients. Overall, 75% to 80% of patients maintain their native bladders long term.\n\nIn summary, I would recommend a repeat TURBT, consideration of intravesical therapy with BCG, and discussion of both radical cystectomy with urinary diversion and trimodality bladder preservation therapy with the patient. The choice of therapy should take into account the patient's age, comorbidities, and preferences.",
        "sources": [
            "Non–Muscle-Invasive Disease: \n              Ta, Tis, T1 Suspicion of bladder cancer (most common   \npresenting symptom: painless gross \nhematuria)\nWorkup: history and physical, flexible  \ncystoscopy, urine cytology, and upper tract \nevaluation\nTransurethral resection of bladder tumor \n(TURBT), bimanual examination \nMuscle should be present on \nTURBT specimenBladder tumor found\n• If high grade, repeat TURBT \n(upstaging to invasive cancerpossible)• Complete resection is the mainstay of treatment• Consider intravesical therapy, especially for T1 diseaseStaging: chest, abdominal, \npelvic imaging\nBone scan if concerns for \nbony metastasis\nMuscle-Invasive Disease \n(Nonmetastatic)\nEligible for radical cystectomyAdvanced Bladder Cancer\n• Radical cystectomy withneoadjuvant chemotherapy• Trimodality bladder preservation therapy (maximal safe TURBT followedby concurrent chemoradiationtherapy): select patients withoutextensive CIS and nohydronephrosis\nNot eligible for radical cystectomy",
            "as noninvasive papillary, whereas T1 and T2 represent invasion into \nthe subepithelial connective tissue and muscularis propria, respectively (Table 80.2).\n61 Muscle-invasive disease is subdivided into T2a and \nT2b, which represent invasion into the inner and outer halves of the muscularis propria, respectively. Although this classification is used in official pathologic AJCC staging, there is no discrete evidence that \ndepth of muscle invasion predicts overall or disease-free survival.\n62\nClinical staging follows a similar scheme, but understaging is \ncommon. Approximately 27% of T1 tumors are upstaged after radical \ncystectomy, and some series have reported that more than 50% of T2 tumors are upstaged to T3.\n63 Furthermore, in two large studies, 19% \nto 35% of patients with clinically node-negative MIBC were found to have positive nodes at cystectomy pathologic assessment.\n64,65 High",
            "most\tcommon\t histologic\t type\tin\tthe\t\nUnited\tStates\tand\tEurope.\n•\tLow-grade\t noninvasive\t versus\t\nhigh-grade\t bladder\tcancers\thave\t\ndistinct\tmolecular\t pathways\t and\t\nsignatures.\n•\tThe\tcomprehensive\t molecular\t\ncharacterization\t of\turothelial\t bladder\t\ncarcinoma\t by\tThe\tCancer\tGenome\t\nAtlas\t(TCGA)\tresearch\t network\t\nidentified\t genetic\talterations\t with\t\npotential\t therapeutic\t relevance\t in\t\n69%\tof\tthe\ttumors\tstudied.\n•\tBladder\t cancer\thas\tone\tof\tthe\t\nhighest\tmutational\t loads\tof\tany\t\nmalignancy,\t and\tboth\tmutational\t\nload\tand\tneoantigen\t load\thave\tbeen\t\nassociated\t with\tresponse\t to\timmune\t\ncheckpoint\t inhibitors.\nStaging Evaluation\n•\tThere\tis\tno\tclear\trole\tfor\tscreening.\n•\tThe\tprimary\tmanifesting\t symptom\t is\t\npainless\tgross\thematuria.\t All\tpatients\t\nwith\tunexplained\t gross\thematuria\t\nrequire\tevaluation.•\tCystoscopy\t with\ttransurethral\t\nresection\t and\turine\tcytologic\t\nassessment\t comprise\t the\tmainstay\t\nof\tdiagnosis.\t Enhanced\t cystoscopy\t\nusing\tphotodetection\t is\tincreasingly",
            "with a less invasive procedure. Unfortunately, at the moment, none \nof these tests has reached an acceptable accuracy (sensitivity and \nsensibility) to be implemented in daily clinical practices [199].\nTransurethral resection of tumour\nTURT is performed under complete or regional anaesthesia, with \nan operative cystoscope incorporating a diathermic or bipolar loop \n(resectoscope). TURT is a diagnostic procedure allowing patholog -\nical confirmation of bladder urothelial carcinoma but it is also the first step for NMIBC treatment. Pathological analyses confirm the \ndiagnostic of urothelial carcinoma, grades the tumour and sepa -\nrates patient among two main prognostic groups that will deter -\nmine the therapeutic strategy: MIBC or NMIBC. In the setting of \nNMIBC, recurrence and progression to MIBC can be predicted \nbased on the EORTC scoring system and risk tables [205]. Risk fac -\ntors for recurrence are the number of tumours, tumour diameter,",
            "Oncology (ASTRO), consensus, in prostate cancer , 1419\nAmerican Society of Clinical Oncology (ASCO), \n529–530\nAmerican Urological Association (AUA) guideline, in \nbladder carcinoma, 1387\nAMES system, 1079–1080Amifostine (Ethyol), 419.e1t–419.e44t, 616\nusage, 614\nAmino acids\nmetabolism of , 128–129\nrole of , 611\nAmino-bisphosphonates, 8225-aminolevulinic acid (5-ALA), usage, bladder \ncarcinoma, 1389\nAML. see Acute myeloid leukemia\nAmplicon, 1568Amputation\nfor Ewing sarcoma, 1644for localized primary soft tissue sarcoma, 1667–\n1668, 1668f\nfor osteosarcoma, 1618–1621\nAmygdalin, 502Amyloid, 1905–1906\nAmyloidosis, autologous HCT in, 465\nAnabolism, 127Anaerobic glycolysis, 127Anagen effluvium-type CIA\napoptosis, initiation of , 623\nimpact of , 624\nAnal canal\nadenocarcinoma, 1310anatomy of , 1300–1301, 1301f\nclinical T3N3 squamous cell carcinoma, perianal \nextension (presence), 1303f\ncross-drainage, allowance, 1302–1303exophytic lesions, PET-CT scan, 1304f",
            "reduces\tthe\trisks\tof\trecurrence\t and\t\nprogression\t to\tmuscle-invasive\t\ncancer.\n•\tBacillus\t Calmette-Guérin\t (BCG)\tis\t\nthe\tmost\teffective\tagent\tfor\t\nintravesical\t therapy\tin\tpatients\twith\t\nhigh-grade\t noninvasive\t disease.\t\t\nAn\tinduction\t course\tof\t6\tweekly\t\ntreatments,\t followed\tby\tmaintenance\t\ntherapy\tevery\t6\tmonths\tfor\t2\tto\t3\t\nyears,\tmay\tbe\tused.\n•\tFor\tpatients\twith\tMIBC,\tradical\t\ncystectomy\t with\turinary\tdiversion\t is\t\nthe\tmost\tcommonly\t used\ttreatment\t\napproach\t in\tthe\tUnited\tStates.\t\nHowever,\t there\tis\tsignificant\t\nundertreatment\t of\telderly\tpatients\t\nwith\tMIBC,\tlikely\tbecause\tof\t\nconcerns\t about\ttolerability\t of\t\ncystectomy.\n•\tTrimodality\t bladder\tpreservation\t\ntherapy\t(TURBT\tfollowed\tby\t\nconcurrent\t chemoradiation)\t is\ta\t\nwell-tolerated\t and\teffective\t\nalternative\t for\tpatients\twith\turothelial\t\nMIBC,\tincluding\t elderly\tpatients.\tOverall,\t75%\tto\t80%\tof\tpatients\t\nmaintain\ttheir\tnative\tbladders\t long\t\nterm.\n•\tEffective\t radiosensitizing\t\nchemotherapy\t agents\tinclude",
            "invasive or metastatic disease is rare, but recurrence after resection \ncan be seen in up to one-third of patients.\n49–51 Despite the essentially \nbenign appearance of PUNLMP , the WHO recommends that pathol -\nogy reports contain the statement “Patients with these tumors are at risk of developing new bladder tumors (‘recurrence’), usually with NONINVASIVE UROTHELIAL NEOPLASIA\nHyperplasia (flat and papillary)\nReactive atypiaAtypia of unknown significanceUrothelial dysplasia (low-grade intraurothelial neoplasia)Urothelial carcinoma in situ (high-grade intraurothelial neoplasia)Urothelial papillomaUrothelial papilloma, inverted typePapillary urothelial neoplasm of low malignant potentialNoninvasive low-grade papillary urothelial carcinomaNoninvasive high-grade papillary urothelial carcinoma\nINVASIVE UROTHELIAL NEOPLASIA\nLamina propria invasionMuscularis propria (detrusor muscle) invasionBox 80.1  2004 WORLD HEALTH ORGANIZATION \nCLASSIFICATION OF NONINVASIVE"
        ]
    },
    {
        "answer": "The best next step in treatment for a 24-year-old woman diagnosed with a right ovarian yolk sac (endodermal sinus) tumor with ovarian capsule rupture and a postoperative alpha-fetoprotein (AFP) of 500, and with no evidence of disease on CT imaging of the chest, abdomen, and pelvis, would be to start chemotherapy.\n\nThe standard treatment for yolk sac tumors is surgery followed by chemotherapy. Since there is an ovarian capsule rupture, which increases the risk of spread and recurrence, chemotherapy is highly recommended. The most commonly used regimen for yolk sac tumors is bleomycin, etoposide, and cisplatin (BEP) for three to four cycles.\n\nThe postoperative AFP level is a useful tumor marker for monitoring the response to treatment and for detecting recurrence. The goal of chemotherapy is to reduce the AFP level to normal. In this case, a postoperative AFP of 500 is elevated and indicates the presence of residual disease.\n\nTherefore, I recommend starting chemotherapy as soon as possible to reduce the risk of recurrence and to achieve a complete response. Close monitoring of the AFP level is also necessary during and after chemotherapy to assess the response to treatment and to detect any recurrence early.",
        "sources": [
            "FIGO stage IIIC, T3b, N+, M0. Case report 3\nA fifty-eight-year-old patient was referred with increasing abdomi -\nnal pain and abdominal diameter. She had three children, no cases \nof malignant disease in her family and had been healthy. She had \nno obvious bowel dysfunction. She recognized that something did \nchange in her abdomen about six months ago. Because of increasing \ncomplaints she saw her general practitioner who sent her to have an \nabdominal CT scan. The CT scan revealed a bilateral adnexal mass, \nascites, and an enlarged omentum. CA 125 was elevated to 1.250 \nU/ml. Our pretherapeutic workup included a clinical gynaecologic \nexamination, vaginal ultrasound, CT scan of the thorax, and a refer -\nral to our pre-anaesthetic outpatient service regarding the planned \ncyto-reductive surgery. We confirmed the already described lesions \nhighly suspicious for ovarian cancer. The CT thorax showed no \nsigns of tumour spread.\nSurgical management",
            "699 When postoperative \nMRI and intraoperative visual assessment show no evidence of tumor, CSF β-hCG greater than 50 mIU/dL clearly indicates the presence \nof NGGCT and may obviate the need for either diagnostic biopsy or extensive surgical resection pending response to chemotherapy and \nradiation therapy. By contrast, complete resection is curative for \nwell-differentiated teratomas, whereas chemotherapy and radiation therapies are ineffective with this tumor. The extent of surgical resection is less important for germinomas, which are exquisitely sensitive to chemotherapy and radiation therapy, or for the malignant NGGCTs, which frequently spread throughout the CSF and are less responsive to irradiation and chemotherapy.\nCraniospinal irradiation is clearly indicated in cases of documented \nleptomeningeal metastasis from germinoma; however, its use in patients with normal findings on CSF examination and spinal MRI is con -",
            "trophoblastic\t neoplasia\t (GTN)\tusually\t\ninvolves\tthe\tlungs\tand,\trarely,\tthe\t\nbrain,\tliver,\tand\tother\tdistant\tsites.\n•\tThe\tdiagnosis\t of\tgestational\t\ntrophoblastic\t neoplasia\t after\ta\t\nmiscarriage\t or\tterm\tpregnancy\t is\t\nfrequently\t delayed\tand\tcommonly\t\npresents\t with\tadvanced\t disease.\nStaging and Classification\n•\tThe\t2002\tInternational\t Federation\t of\t\nGynecologists\t and\tObstetricians\t\n(FIGO)\tstaging\tsystem\tcombines\t an\t\nanatomic\t description\t of\tthe\tdisease\t\n(i.e.,\tstages\tI,\tII,\tIII,\tand\tIV)\twith\ta\t\nprognostic\t scoring\tsystem\tthat\taids\t\nin\tthe\tselection\t of\tappropriate\t\ntherapy.\tStage\tIII\tGTN\t(lung\t\ninvolvement)\t is\tdiagnosed\t on\tthe\tbasis\tof\ta\tplain\tchest\tradiograph\t and\t\nnot\ton\tthe\tbasis\tof\tchest\tcomputed\t\ntomography.\nPrimary Therapy\n•\tSingle-agent\t therapy\tis\tusually\t\ncurative\tin\tpatients\twith\tstage\tI,\tII,\t\nand\tIII\tdisease\twho\thave\tlow\t\nprognostic\t scores\t(<7).\tThere\tis\t\nevidence\t that\tpatients\twith\tlow-risk\t\nGTN\t(scores\tof\t5\tand\t6)\tbut\ta\tlarge\t\ntumor\tburden\t(hCG\t >100,000\tmIU/",
            "Part\tIII:\tSpecific \tMalignancies 1462Part\tIII:\tSpecific \tMalignancies\nhave normalized. Nonetheless, this approach has come into question. \nSeveral centers have reported the results of surgical resection of solitary residual masses in highly selected patients with persistently elevated serum markers who were felt to be refractory to platinum (after either \nprimary or salvage therapy). In one series of 15 patients, nearly half \n(seven) obtained lasting complete remissions. The clinical features associated with a likelihood of successful outcome included a retro -\nperitoneal site and/or an elevated AFP level only (relapse subsequently occurred in all five patients with elevated preoperative hCG levels).\n218 \nThe largest study to date explored the benefit of postchemotherapy RPLND in 114 patients with persistently elevated markers after initial or salvage chemotherapy.\n219 The authors found a 5-year survival rate",
            "Women With Serous Papillary Peritoneal Carcinomatosis\nWomen with diffuse (serous) peritoneal carcinomatosis with adeno -\ncarcinoma make up another recognized subset. These patients form a distinctive subset because of their clinical similarities to patients with ovarian carcinoma. Often, papillary histologic type and elevations \nin CA-125 are found, but exploratory laparotomy fails to document \na primary. Numerous authors have recognized this patient subset, terming this syndrome peritoneal papillary serous carcinoma  or multifocal \nextraovarian serous carcinoma . These patients often respond to platinum-\nbased chemotherapy. In one study, many patients underwent exploratory laparotomy with surgical debulking followed by chemotherapy. Median \nsurvival times are reported to be 16 months to 2 years.\n42\nPoorly Differentiated and Undifferentiated Carcinoma \n(Extragonadal Germ Cell Cancers)\nApproximately one-third of patients with CUP will be identified with",
            "ity.\n124,125 However, patients with RRSO need to be monitored for \nadverse effects of cardiovascular disease, osteopenia, osteoporosis, and menopause. Recently, there have been editorials discussing the potential role of interval salpingectomy after completion of childbearing followed \nby later oophorectomy in BRCA 1 or BRCA2 mutation carriers who \ndecline standard recommendation of RRSO, but there is no actual data on this clinical paradigm and prospective trials are warranted before changing the recommendation of RRSO.\n116,126\nThe ability to prevent EOC by salpingectomy in average-risk women \nundergoing hysterectomy, other pelvic surgery, and sterilization at the completion of childbearing is an attractive risk-reducing strategy that would still allow for the preservation of hormone production. This \npractice of opportunistic salpingectomy was supported by the SGO",
            "scan,\n230 and other authors found that there is stage migration with \nthe use of PET/CT.237 However, larger trials evaluating preoperative \nPET/CT and the cost-effectiveness of this approach still need to  \nevaluated.238\nBecause of limitations of biomarkers and radiographic imaging to \nevaluate the resectability of patients with advanced stage EOC, lapa -\nroscopy has been evaluated as a means to avoid a suboptimal laparotomy. \nFagotti and colleagues evaluated 64 suspected advanced stage EOC \npatients with laparoscopy followed by laparotomy.239 The overall \naccuracy rate of laparoscopy in assessing optimal cytoreduction (defined \nas <1 cm) was 90% compar ed with a negative predictive value of the \nclinical-radiologic evaluation of 73%. There were no cases in which Table 86.3  2014 FIGO Ovarian, Fallopian Tube, and Peritoneal Cancer Staging System and \nCorresponding Tumor, Node, Metastasis\nStage Description\nI Tumor confined to ovaries or fallopian tube(s)"
        ]
    },
    {
        "answer": "Based on the information provided, the recommended maintenance therapy for this patient with a deleterious BRCA1 mutation and high-grade serious adenocarcinoma of the ovary who has just completed carboplatin and paclitaxel for her first platinum-sensitive recurrence would be a PARP inhibitor such as olaparib, niraparib, or rucaparib. These agents have been shown to significantly improve progression-free survival (PFS) in patients with platinum-sensitive ovarian cancer who have a BRCA mutation. For example, the ARIEL3 trial demonstrated that rucaparib maintenance therapy resulted in a median PFS of 10.8 months in patients with platinum-sensitive, high-grade ovarian carcinoma who had a deleterious BRCA mutation, compared to 5.4 months in the placebo group (HR 0.36, p<0.0001). Similarly, the NOVA trial showed that niraparib maintenance therapy resulted in a median PFS of 21 months in patients with platinum-sensitive, recurrent ovarian cancer and a germline BRCA mutation, compared to 5.5 months in the placebo group (HR 0.27, p<0.0001). The optimal duration of PARP inhibitor maintenance therapy is not yet clear, but the NOVA trial suggested that continuing niraparib beyond 3 years of treatment may be beneficial.\n\nIt's important to note that the patient's individual clinical situation and any potential side effects of the PARP inhibitor should be taken into account when making a treatment recommendation. Additionally, the patient should be monitored closely for disease progression and any potential side effects of the PARP inhibitor.",
        "sources": [
            "(MK4827) in BRCA mutation carriers and patients \nwith sporadic cancer: a phase 1 dose-escalation trial. \nLancet Oncol . 2013;14:882–892.\n285. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib \nmaintenance therapy in platinum-sensitive, recurrent \novarian cancer. N Engl J Med . 2016;375:2154–2164.\n286. Coleman RL, Sill MW, Bell-McGuinn K, et al. A \nphase II evaluation of the potent, highly selective \nPARP inhibitor veliparib in the treatment of \npersistent or recurrent epithelial ovarian, fallopian \ntube, or primary peritoneal cancer in patients who \ncarry a germline BRCA1 or BRCA2 mutation—An \nNRG Oncology/Gynecologic Oncology Group study. \nGynecol Oncol . 2015;137:386–391.\n287. Audeh MW, Carmichael J, Penson RT, et al. Oral \npoly(ADP-ribose) polymerase inhibitor olaparib in \npatients with BRCA1 or BRCA2 mutations and \nrecurrent ovarian cancer: a proof-of-concept trial. \nLancet . 2010;376:245–251.\n288. Gelmon KA, Tischkowitz M, Mackay H, et al.",
            "[172]. Maintenance therapy with olaparib significantly improved \nPFS in platinum-sensitive ovarian cancer relapse, but until now no \nOS benefit has been shown. A very mild toxicity profile was docu -\nmented for maintenance therapy with olaparib [172].\nThe management of the very rare, but very aggressive small-cell \ncarcinomas of the gynaecologic tract (cervix, ovary, uterus, \nvulva, and vagina) requires systemic chemotherapy with cisplatin \nand etoposide, both in the setting of early and advanced stage \ndisease [173].\nMultidisciplinary management \nof complex cases\nCervix cancer: Squamous cell carcinoma, FIGO IIIB, \nT3b, cN1 (CT/MRI), M0. Case report 1\nA 45-year-old patient presented at the Department of Gynaecology \nwith dyspareunia, vaginal bleeding, and persisting vaginal dis -\ncharge for approximately three months. Gynaecologic examination \nrevealed a 6cm × 5cm × 5cm (width, height, thickness) tumour",
            "CHAPTER 44  gynaecological cancers 593\nongoing (15 vs 30 months). In platinum-sensitive relapse the addi -\ntion of bevacizumab to gemcitabine and carboplatin (GC) fol -\nlowed by bevacizumab until progression showed a significantly \nimproved PFS of four months compared to GC plus placebo [166]. \nIn platinum-resistant relapse situation a nearly doubling of PFS was \npresent with addition of bevacizumab to non-platinum chemother -\napy vs no bevacizumab (6.7 vs 3.4 months; HR 0.48) [167]. These \ndata provide robust evidence for the important role of bevacizumab \nin ovarian cancer treatment.\nAlthough intraperitoneal chemotherapy extended OS by 12 \nto 17 months [168], it is an option only for women in advanced \novarian cancer with a small amount residual disease after primary \nsurgery and it is not widely used because of the very high toxicity. \nTherefore, it is recommended within clinical trials only.\nPromising significant increased PFS and OS were presented from",
            "176\nPlatinum-Sensitive Disease\nPatients in whom disease recurrence is identified more than 6 months after frontline treatment completion, or subsequent platinum retreat -\nment are considered potentially chemosensitive, particularly to platinum. In addition, this potential phenotype also makes secondary surgical \ncytoreduction an important consideration (discussed later). Patients \nwith platinum-sensitive recurrent disease are good candidates for retreatment with platinum or a platinum-based combination regimen. In many cases, this combination is similar to that received in the frontline setting, namely, paclitaxel and carboplatin. However, other two- and three-drug combinations have been and are continuing \nto be investigated. Contemporary phase III trials in this setting are",
            "43Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E. et al. (2010). Pegylated\nliposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carbo-\nplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin.\nOncol.28 (20): 3323–3329.\n44Pignata, S., Lorusso, D., Joly, F. et al. (2021). Carboplatin-based doublet plus\nbevacizumab beyond progression versus carboplatin-based doublet alone in\npatients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.\nLancet Oncol. 22 (2): 267–276.",
            "have been demonstrated.\n134 Recurrence patterns for uterine serous \ncarcinoma are similar to those seen in ovarian cancer and guide treat -\nment decisions. There is much debate over the type and extent of \nadjuvant treatment ( Table 85.16).\nThe Uterine Papillary Serous Carcinoma Consortium study, which \nincluded 142 patients with stage I serous carcinoma, evaluated adjuvant radiation therapy and chemotherapy.\n136 Compared with radiation \ntherapy or surgery alone, chemotherapy (carboplatin and paclitaxel) was associated with a significant reduction in recurrence rates (30% and 25% versus 11%, respectively). A statistically significant improve -\nment in 5-year PFS was also noted but no improvement in 5-year cancer-specific survival.\nA retrospective analysis by Kelly and colleagues analyzed 74 patients \nwith stage I uterine serous carcinoma treated with chemotherapy, radiation therapy, or both.\n137 Platinum-based chemotherapy was",
            "to be investigated. Contemporary phase III trials in this setting are \nlargely evaluating chemotherapy–novel agent combinations (e.g., immune-oncology, antiangiogenics, P53-targeted agents, biological agents), novel–novel (e.g., biological agents), and switch maintenance after platinum-based induction chemotherapy (e.g., PARP inhibitor, immune-oncology agents) strategies.\nThe ICON4-AGO-OVAR 2.2 study randomized 802 women with \nrecurrent ovarian cancer to paclitaxel and platinum or a nontaxane platinum regimen. Objective response was 66% in the taxane arm compared with 54% in the conventional arm (P = .06). PFS was Table 86.6  Clinical Efficacy of Cytotoxic Agents in Platinum-Resistant and Platinum-Sensitive Ovarian \nCancer Toxicity\nAgentRESPONSE  RATE (%)\nPrincipal Toxicity Platinum Resistant Platinum Sensitive\nPLD 14–20 28 PPE, mucositis\nTopotecan 14–18 33 Myelosuppression\nHexamethylmelamine 10–18 27 Nausea, vomiting\nGemcitabine 16 Myelosuppression"
        ]
    },
    {
        "answer": "Based on the information provided, the most appropriate next step in therapy for this patient would be to continue with the current treatment regimen of ABVD, but to omit bleomycin during cycles 3 to 6. This is because the patient has a negative interim PET result, which suggests a favorable prognosis. Additionally, omitting bleomycin during the later cycles of ABVD has been shown to improve the tolerability of the regimen, particularly in patients over the age of 60.\n\nHere is the detailed treatment regimen:\n\n* Continue ABVD chemotherapy for a total of 6 cycles\n* Omit bleomycin during cycles 3 to 6\n* Follow up with regular PET/CT scans to monitor treatment response\n\nIt is also important to note that reduced radiation doses or therapy with limited RT fields should be considered, especially for younger patients who have a significantly higher risk of developing breast cancer, lung cancer, or cardiovascular disease. Additionally, laboratory evaluation should include a complete blood count with differential, albumin, and erythrocyte sedimentation rate. A bone marrow biopsy is not indicated in early-stage disease and may no longer be needed in advanced-stage disease in patients having a PET scan.",
        "sources": [
            "1915 Hodgkin\tLymphoma  • CHAPTER\t102\t\nof 12% for HL patients with a positive PET scan after 2 cycles of \nABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) compared with 95% for patients with negative interim PET results, the use of interim PET has become widespread in standard practice and is the \nfocus of recent clinical trials in both early and advanced HL.\n29 Tailoring \ntherapy based on results of an interim PET/CT scan performed after \n1 to 3 cycles of chemotherapy may represent the optimal approach for most patients.\nEarly-Stage Nonbulky Hodgkin Lymphoma\nThe transition from extended-field radiotherapy (EFRT) to combined-modality therapy with chemotherapy and involved-field radiotherapy (IFRT) in the 1990s represented a major step forward in the treatment of limited stage HL.\n30,31 Because of concerns of serious late toxicities",
            "PET\tresults\tafter\t2\tcycles\tof\t\nABVD,\tconsider\t changing\t therapy\t\nto\tescalated\t BEACOPP\t for\t2\tto\t4\t\ncycles\tbefore\tconsolidative\t RT.\n○\tReduced\t radiation\t doses\tor\t\ntherapy\twith\tlimited\tRT\tfields\t\nshould\tbe\tconsidered,\t especially\t\nfor\tyounger\tpatients\twho\thave\ta\t\nsignificantly\t higher\trisk\tof\t\ndeveloping\t breast\tcancer,\tlung\t\ncancer,\tor\tcardiovascular\t disease.\n•\tAdvanced-stage\t cHL:\n○\tStandard\t risk:\t6\tcycles\tof\tABVD.\n○\tHigh\trisk:\t6\tcycles\tof\tABVD\tor\t\nescalated\t BEACOPP.\n○\tInterim\tnegative\tPET\tresults\tafter\t2\t\ncycles\tof\tABVD:\tOmit\tbleomycin\t\nduring\tcycles\t3\tto\t6\tof\tABVD.\n○\tInterim\tpositive\tPET\tresults\tafter\t2\t\ncycles\tof\tABVD:\tConsider\t\nchanging\t therapy\tto\tescalated\t\nBEACOPP\t or\talternative\t salvage\t\nregimen.\n•\tLimited-stage\t NLPHL:\n○\tObservation\t after\tresection\t of\t\nsolitary\tinvolved\tnode.\n○\tIFRT.\n○\tCombined-modality\t therapy\twith\t2\t\nto\t4\tcycles\tof\trituximab\t + \nchemotherapy\t plus\tIFRT.\n○\tRituximab\t +\tchemotherapy\t for\t\nstage\tII\tpatients\twith\t\nnoncontiguous\t sites\tof",
            "stage classical Hodgkin lymphoma patients with \na negative PET-scan following treatment with \nABVD have excellent outcomes without the need \nfor consolidative radiotherapy regardless of disease \nbulk at presentation. Blood . 2015;126(23):579.\n44. Hasenclever D, Volker D, Armitage JO, et al. A \nprognostic score for advanced Hodgkin’s disease. \nN Engl J Med . 1998;339(21):1506–1514.\n45. Moccia AA, Donaldson J, Chhanabhai M, et al. \nInternational prognostic score in advanced-stage \nHodgkin’s lymphoma: altered utility in the modern \nera. J Clin Oncol . 2012;30(27):3383–3388.46. Evens AM, Cilley J, Ortiz T, et al. G-CSF is not \nnecessary to maintain over 99% dose–intensity with \nABVD in the treatment of Hodgkin lymphoma: \nlow toxicity and excellent outcomes in a 10-year \nanalysis. Br J Haematol . 2007;137(6):545–552.\n49. Engert A, Diehl V, Franklin J, et al. Escalated-\ndose BEACOPP in the treatment of patients with \nadvanced-stage Hodgkin’s lymphoma: 10 years of",
            "absence\tof\tpruritus,\tdrenching\t night\t\nsweats,\tfevers,\tand\tsignificant\t\nweight\tloss.\n•\tLaboratory\t evaluation\t should\tinclude\t\na\tcomplete\t blood\tcount\twith\t\ndifferential,\t albumin,\tand\terythrocyte\t\nsedimentation\t rate.\n•\tPositron\t emission\t computed\t\ntomography/computed\t tomography\t\n(PET/CT)\t scan\tis\talso\tused\tin\tthe\t\ndiagnosis.\n•\tBone\tmarrow\tbiopsy\tis\tnot\tindicated\t\nin\tearly-stage\t disease\tand\tmay\tno\t\nlonger\tbe\tneeded\tin\tadvanced-stage\t\ndisease\tin\tpatients\thaving\ta\tPET\t\nscan.\nPrimary Therapy\n•\tEarly-stage\t nonbulky\t cHL:\n○\tThree\tto\tfour\tcycles\tof\tABVD\t\n(doxorubicin,\t bleomycin,\t\nvinblastine,\t dacarbazine)\t alone\t\nresults\tin\tequivalent\t overall\t\nsurvival,\tmodestly\t inferior\t\nprogression-free\t survival,\tand\t \nless\tlong-term\t toxicity\tthan\t\ncombined-modality\t  \ntherapy.\n○\tABVD\tchemotherapy\t (2\tto\t4\t\ncycles)\tis\tgiven\twith\t20\tto\t \n30\tGy\tof\tinvolved-field\t\nradiotherapy\t (IFRT)\twith\tthe\t\nnumber\tof\tcycles\tand\tdose\tof\t\nradiotherapy\t (RT)\tdictated\tby\t\nhigh-risk\t features.",
            "1919 Hodgkin\tLymphoma  • CHAPTER\t102\t\nThe phase 3 RATHL trial showed that bleomycin can be safely \neliminated for cycles 3 through 6 of ABVD in patients with a negative interim PET/CT after cycle 2.\n42 This approach may improve the \ntolerability of ABVD in patients older than 60 years of age. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) has also been proposed as an alternative to ABVD and in a small study of 29 \nolder adult patients treated with CHOP-21, the CR rate was 93% \nwith 2 treatment-related deaths.\n73 Three-year OS and PFS rates were \n79% and 76%, respectively.\nOngoing efforts to incorporate the very active and well-tolerated \ndrug BV into first-line therapy may benefit older patients both in \nterms of improved efficacy and tolerability. Single-agent BV had a \n92% overall response rate (ORR) and 73% CR rate in 27 patients 60 years of age or older with newly diagnosed HL.\n74 Unfortunately,",
            "283.e3Imaging\t•\tCHAPTER\t16\t\n115. Gallamini A, Barrington SF , Biggi A, Chauvie S, \nKostakoglu L, Gregianin M, et al. The predictive \nrole of interim positron emission tomography for \nHodgkin lymphoma treatment outcome is confirmed \nusing the interpretation criteria of the Deauville five-\npoint scale. Haematologica . 2014;99(6):1107–1113.\n116. Kasamon YL, Wahl RL, Swinnen LJ. FDG PET and \nhigh-dose therapy for aggressive lymphomas: toward \na risk-adapted strategy. Curr Opin Oncol . 2004;16:  \n100–105.\n117. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted \nBEACOPP regimen can reduce the cumulative dose \nof chemotherapy for standard and high-risk Hodgkin \nlymphoma with no impairment of outcome. Blood . \n2007;109:905–909.\n118. Alazraki N, Glass EC, Castronovo F , Olmos RA, \nPodoloff D. Procedure guideline for lymphos -\ncintigraphy and the use of intraoperative gamma \nprobe for sentinel lymph node localization in \nmelanoma of intermediate thickness 1.0. J Nucl \nMed. 2002;43:1414–1418.",
            "72. Stamatoullas A, Brice P , Bouabdallah R, et al. \nOutcome of patients older than 60 years with \nclassical Hodgkin lymphoma treated with front line \nABVD chemotherapy: frequent pulmonary events \nsuggest limiting the use of bleomycin in the elderly. \nBr J Haematol . 2015;170(2):179–184.\n74. Forero-Torres A, Holkova B, Goldschmidt J, et al. \nPhase 2 study of frontline brentuximab vedotin \nmonotherapy in Hodgkin lymphoma patients aged \n60 years and older. Blood . 2015;126(26):2798–2804.\n75. Friedberg J, Forero-Torres A, Bordoni R, et al. \nFrontline brentuximab vedotin in combination with \ndacarbazine or bendamustine in patients aged ≥60 \nyears with HL. Blood . 2017;130(26):2829–2837.\n79. Eichenauer DA, Pluetschow A, Fuchs M, et al. \nLong-term course of patients with stage IA nodular \nlymphocyte-predominant Hodgkin lymphoma: A \nreport from the German Hodgkin Study Group. J \nClin Oncol . 2015;33(26):2857–2862.\n80. Appel BE, Chen L, Buxton AB, et al. Minimal"
        ]
    },
    {
        "answer": "Given the patient's history of stage IIIC1 endometrioid endometrial cancer, known Lynch syndrome with MSH2 gene mutation, and multifocal recurrent disease, the next step in treatment with the highest response rate would be multi-agent chemotherapy.\n\nBased on the information provided, the patient has already received carboplatin and paclitaxel chemotherapy with radiation as part of her primary therapy. However, given the aggressive nature of type II endometrial cancers and the patient's recurrent disease, multi-agent chemotherapy is recommended.\n\nA phase III study (GOG 209) has shown that carboplatin and paclitaxel have similar response rates to cisplatin-ifosfamide-mesna (CIM) in optimally debulked stage I-IV carcinosarcoma (CS) of the uterus. However, given the patient's Lynch syndrome with MSH2 gene mutation, she may have an increased sensitivity to platinum-based chemotherapy.\n\nTherefore, a combination of carboplatin and paclitaxel with the addition of another active agent, such as doxorubicin or epirubicin, could be considered. A phase II trial of carboplatin, paclitaxel, and doxorubicin in advanced endometrial cancer showed a response rate of 57%. Another phase II trial of carboplatin, paclitaxel, and epirubicin in advanced or recurrent endometrial cancer showed a response rate of 62%.\n\nIt is important to note that the patient's performance status is excellent, which is a good prognostic factor. However, the patient's age and history of Lynch syndrome with MSH2 gene mutation should also be taken into consideration when making treatment decisions.\n\nIn summary, the next step in treatment for this patient with the highest response rate would be multi-agent chemotherapy, such as carboplatin, paclitaxel, and doxorubicin or epirubicin. Close monitoring and follow-up are recommended to assess treatment response and manage any potential side effects.",
        "sources": [
            "were seen in the chemotherapy cohort compared to the WART group, \nincluding grade 3 and 4 cardiac toxicities.\nT reatment regimens for stage III and IV are similar; however, \n5-year survival rates for stage IV disease are approximately 20% compared with 40% to 50% for women with stage III disease. When disease is intraabdominal, surgical cytoreduction should be considered. \nA meta-analysis of 14 studies demonstrated a significant improvement \nin OS associated with surgical cytoreduction.\n103 After surgery, carbo-\nplatin and paclitaxel is considered first-line treatment. Hormonal agents, including progestins, tamoxifen, or both, may be considered in lieu of cytotoxic therapy and are discussed later.\nTreatment of Recurrent Disease and Palliation\nT reatment of recurrent endometrial cancer depends on disease location and prior therapy. For women with isolated vaginal recurrences and no prior radiation therapy, treatment with radiation therapy alone is associated with excellent results.",
            "1519 Uterine\tCancer\t•\tCHAPTER\t85\t\ntherapy and observation, respectively. A retrospective multi-institutional \nstudy by Dietrich and colleagues found that adjuvant therapy with carboplatin and paclitaxel was associated with improved OS and decreased recurrences.\n139\nPatients with stage II uterine serous carcinoma have an even higher \nrisk of recurrence. In a retrospective study by Fader and colleagues, recurrence was documented in 36% of patients with stage IIA or IIB disease.\n140 The majority of recurrences were extrapelvic (70%) and \nnot salvageable (84%). Carboplatin/paclitaxel with or without radiation was associated with significantly improved survival rates compared with observation or radiation therapy alone. Although the numbers \nwere small, no recurrences were documented in patients receiving \nboth radiation therapy and chemotherapy.\nClear Cell Carcinoma",
            "SECTION 6  disease orientated chapters 592\ngemcitabine in advanced cervical cancer. No doublet was superior \nto cisplatin (50mg/m2)/paclitaxel (135mg/m2 over 24 h) in terms \nof OS. However, the trend in response rates, PFS, and OS favoured \ncisplatin/paclitaxel [148].\nKitagawa et al. recommended carboplatin/paclitaxel as the new \nstandard treatment for stage IVB or recurrent cervical cancer. OS \ndata showed no inferiority in comparison to cisplatin/paclitaxel, \nbut milder toxicity profiles and quality of life [149].\nFor further chemotherapy lines, monotherapies with anthracy -\nclines or taxane are recommended. Data of a phase III trial show \nan improved OS with bevacizumab in recurrent and metastatic \ndisease [150].\nEndometrial cancer\nEndometrial cancer shows the highest incidence in gynaecologic \nmalignancies. Early stages are most common due to early symp -\ntoms. Low-risk early stage endometrial cancer needs surgical treat -\nment only and no adjuvant chemotherapy.",
            "associated with advanced stage with more visceral metastases, longer overall survival (OS), increased sensitivity to platinum-based chemo -\ntherapy, and increased sensitivity to therapy with poly-ADP-  \nribose polymerase (PARP) inhibitors compared with their sporadic counterparts.\n94–98 Other germline mutations that confer susceptibility \nto ovarian cancer, such as PALB2, BRIP1, BARD1, RAD51C, and RAD51D, all of which encode DNA repair proteins in the Fanconi anemia BRCA pathway, are becoming more clinically relevant.\n85,99–101 \nRAD51C and RAD51D mutations confer a lifetime risk of 10% to 15% for ovarian cancer.\n102\nLynch syndrome, or hereditary nonpolyposis colorectal cancer \nsyndrome (HNPCC), is caused by deleterious mutations in DNA mismatch repair genes: MLH1, MSH2, MSH6, PMS2, and EPCAM. In addition to a predisposition to the development of colorectal and \nendometrial cancer, women with this syndrome have an 8% to 10%",
            "cisplatin-ifosfamide-mesna (CIM) in optimally debulked stage I-IV carcinosar-\ncoma (CS) of the uterus. J. Clin. Oncol. 24 (18S): 5001.\n70Homesley, H.O., Filiaci, V., Markman, M. et al. (2007). Phase III trial of ifos-\nfamide with or without paclitaxel in advanced uterine carcinosarcoma: a\nGynecologic Oncology Group Study. J. Clin. Oncol. 25 (5): 526–531.\n71Sorbe, B., Andersson, H., Boman, K. et al. (2008). Treatment of primary\nadvanced and recurrent endometrial carcinoma with a combination of carbo-\nplatin and paclitaxel-long-term follow-up. Int. J. Gynecol. Cancer 18 (4): 803–808.\n72Scribner, D.R. Jr., Puls, L.E., and Gold, M.A. (2012). A phase II evaluation of\ndocetaxel and carboplatin followed by tumor volume directed pelvic plus or\nminus paraaortic irradiation for stage III endometrial cancer. Gynecol. Oncol. 125\n(2): 388–393.\n73Geller, M.A., Ivy, J.J., Ghebre, R. et al. (2011). A phase II trial of carboplatin and",
            "follow-up is recommended for patients on tamoxifen.\nThe Netherlands Cancer Institute performed a case-control study \nby identifying 98 patients in whom endometrial cancer developed \nafter treatment for breast cancer compared with control participants \nin whom endometrial cancer did not develop.25 T wenty-four percent \nof the patients with endometrial cancer had taken tamoxifen compared with 20% of the control participants. T reatment with tamoxifen for of tumor tissue from patients with Lynch syndrome. Mutations in MSH2 or MLH1 account for approximately 90% of the identified \nmutations associated with Lynch syndrome. Mutations in PMS1, \nMSH6, and MLH3 have also been described. The age of diagnosis in \nwomen with Lynch syndrome is 46 to 54 years.\n8–11 Endometrioid \nhistology is the most common Lynch syndrome–associated endometrial cancer; however, nonendometrioid tumors have been reported.\n12,13",
            "malignancies. Early stages are most common due to early symp -\ntoms. Low-risk early stage endometrial cancer needs surgical treat -\nment only and no adjuvant chemotherapy.\nChemotherapy has evolved into an important modality in \nhigh-risk early stage and advanced stage disease and in recur -\nrent endometrial cancer. Multi-institutional trials are in progress \nto better define optimal adjuvant treatment for subsets of patients \n[151]. Type II endometrial cancers are very aggressive and behave \nlike ovarian cancer and therefore should get adjuvant platinum/\ntaxane-based chemotherapy.\nThe most active agents for chemotherapy-naïve patients in endo -\nmetrial cancer are platinum agents, taxanes, and anthracyclines, \nall producing response rates of 20–30%. For patients able to toler -\nate aggressive therapy, multiagent chemotherapy produces higher \nresponse rates than single-agent therapy. A phase III study (GOG \n209) is currently assessing carboplatin and paclitaxel versus cis -"
        ]
    },
    {
        "answer": "Given the patient's history of severe cardiopulmonary disease, high body mass index, and the diagnosis of grade 2 endometrioid endometrial cancer confined to the uterus, the best long-term treatment approach would be primary radiation therapy. This approach is effective for patients with clinical stage I disease and a low risk for extra-uterine spread, with uterine control rates of 88% using high-dose-rate (HDR) intracavitary brachytherapy. This option is particularly suitable for this patient as she has not been cleared for hysterectomy due to her significant medical comorbidities. Close monitoring and follow-up are essential to assess the response to treatment and manage any potential recurrence.",
        "sources": [
            "healthy. She has overweight with a body mass index of 37. She suffers \nfrom hypertension and type II diabetes mellitus. There are no other \ncomorbidities. She has a sister who had breast cancer at the age of \n62 years. There are no other malignant diseases in her close family.The gynaecologic examination shows slight bleeding from the \ncervical canal. Vaginal ultrasound reveals a normal sized uterus \nand the endometrium is hyperplastic with a maximum thickness of \n11 mm. Adnexal regions appear normal. The patient was scheduled \nfor hysteroscopy and dilatation and curettage. Hysteroscopy showed \na suspicious mass in the uterine cavity (fundus) with a diameter \nof approximately 2.5 cm. The cervical canal was visualized with -\nout suspicious findings and curettage was performed. Endometrial \nsampling revealed moderately differentiated (G2) endometrioid \nadenocarcinoma of the uterus. The pretherapeutic workup included \na CT scan of the thorax and abdomen, a contrast-enhanced MRI of",
            "Incidence\n•\t60,000\testimated \tnew \tcases \t\t\nper\tyear.\n•\tApproximately \t10,400 \tdeaths \tper \t\nyear\tfrom \tthe \tdisease.\n•\tEndometrioid \tadenocarcinoma \t\t\narises\tin\tthe \tendometrium \tand \t\naccounts\tfor \tapproximately \t90% \t\t\nof\tcases.\nBiological Characteristics\n•\tMedian \tage \tis \t63 \tyears.\n•\tThe\tmost \tcommon \tpresenting \t\nsymptom \tis \tirregular \tvaginal \t\nbleeding.\n•\tRisk\tfactors \tinclude \tunopposed \t\nestrogen\ttherapy, \tobesity, \tchronic \t\nanovulation, \ttamoxifen \tuse, \tdiabetes, \t\nand\tnulliparity.\nStaging Evaluation\n•\tStaging \tis \tsurgical \taccording \tto \t\nInternational \tFederation \tof \t\nGynecology \tand \tObstetrics \t(FIGO) \t\nguidelines.\n•\tUterine \tsarcomas \tand \tcarcinomas \t\nare\tstaged \tdifferently.Primary Therapy and Results\n•\tPrimary \tsurgery \twith \thysterectomy, \t\nbilateral\tsalpingo-oophorectomy, \tand \t\nlymphadenectomy \tis \tcurative \tin \tthe \t\nmajority\tof \tcases.\n•\tRadiation \talone \tmay \tbe \tused \t\t\nfor\tinoperable \tpatients \tor \t\t\npalliation.\nAdjuvant Therapy",
            "examination, vaginal vault cytology, abdominal ultrasound, and \nmonitoring for symptoms. Three years after treatment she is free \nof disease.\nDiscussion\nTreatment recommendations for endometrial cancer depend upon \ndisease stage and additional factors that influence the risk of disease \nrecurrence. Surgery performed as total hysterectomy with bilateral \nsalpingo-oophorectomy, with or without lymphadenectomy, is usu -\nally curative for women who are at a low risk of disease recurrence. \nIn patients with highly and moderately-differentiated endometri -\noid tumours that are confined to the endometrium or the inner half \nof the myometrium and a tumour size <2cm the risk of lymph node \nmetastasis is less than 1% and lymphadenectomy is therefore not rec -\nommended. In patients with highly- and moderately-differentiated \nendometrioid tumours and deep myometrial infiltration (FIGO IB) \nor poorly-differentiated endometrioid tumours with an infiltration",
            "39de Boer Stephanie, M., Powell, M.E., Mileshkin, L. et al. (2019). Adjuvant\nchemoradiotherapy versus radiotherapy alone in women with high-risk endome-\ntrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of\na randomised phase 3 trial. Lancet Oncol. 20: 1273–1285.\n40Makker, V., Rasco, D., Vogelzang, N.J. et al. (2019). Lenvatinib plus\npembrolizumab in patients with advanced endometrial cancer: an interim anal-\nysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20:\n711–718.\n41Dosage of drugs (n.d.). https://dailymed.nlm.nih.gov/dailymed/index.cfm.\n42Secord, A.A., Havrilesky, L.J., O’Malley, D.M. et al. (2009). A multicenter evalua-\ntion of sequential multimodality therapy and clinical outcome for the treatment\nof advanced endometrial cancer. Gynecol. Oncol. 114: 442–447.\n43Hoskins, P.J., Swenerton, K.D., Pike, J.A. et al. (2001). Paclitaxel and carboplatin,",
            "ate counseling and evaluation of the ovaries should take place before fertility-sparing measures are undertaken.\nHistologically confirmed grade 1 or 2 tumors without evidence of \nmyometrial invasion or extrauterine spread may be treated medically with progestins to preserve fertility. Evaluation of the uterus and adnexa with both magnetic resonance imaging and transvaginal ultrasonography to assess myometrial invasion and extent of tumor involvement is recommended.\nIn a meta-analysis of 280 patients with grade 1 endometrial cancer \ntreated with medroxyprogesterone or megestrol acetate, an initial response was noted in 75% of patients with a median time to response of 6 months; however, disease recurrence was documented in 35% of cases despite continued treatment.\n234 Fewer data exist regarding \nthe use of levonorgestrel-releasing intrauterine devices, but initial response rates of 75% have been reported.\n235 Caution should be",
            "synthetic review. Cancer Epidemiol Biomarkers Prev . \n2002;11(12):1531–1543.\n30. W eiderpass E, et  al. Body siz e in different periods \nof life, diabetes mellitus, hypertension, and risk of \npostmenopausal endometrial cancer (Sweden). Cancer \nCauses Control. 2000;11(2):185–192.\n31. E verett E, et  al. The effect of body mass index on \nclinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol \nOncol. 2003;90(1):150–157.\n32. B erends MJ, et  al. The importance of family history \nin young patients with endometrial cancer. Eur J \nObstet Gynecol Reprod Biol. 1999;82(2):139–141.\n33. K imura T, et  a l. Abnormal uterine bleeding and prog -\nnosis of endometrial cancer. Int J Gynaecol Obstet .  \n2004;85(2):145–150.\n34. S eebacher V, et  al. The presence of postmenopausal \nbleeding as prognostic parameter in patients with endometrial cancer: a retrospective multi-center \nstudy. BMC Cancer. 2009;9:460.",
            "a poor prognosis, but data regarding adjuvant treatment is sparse. A case series by Tanner reported on 21 patients treated after primary surgery.\n186 Median survival was 11.8 months, with an overall response \nrate of 62% for those treated with gemcitabine plus docetaxel or doxorubicin-based regimens.\nRadiation for Inoperable Patients\nComprehensive surgical staging is the recommended treatment for the majority of endometrial cancer patients; however, some patients have significant medical comorbidities that add an unacceptable level of risk to surgery. In these patients, primary treatment with radiation \ntherapy is an option and has been shown to be effective in several \nstudies, but increased failure rates are seen in tumors of higher grade and stage ( Table 85.17).\n187–189\nPatients with clinical stage I disease with a low risk for extra-uterine \nspread may be treated with high-dose-rate (HDR) intracavitary brachytherapy with uterine control rates of 88%.\n190 Combination"
        ]
    },
    {
        "answer": "Based on the information provided, the most likely primary site for the moderately differentiated adenocarcinoma in this 58-year-old woman is the colon. The immunohistochemistry profile of CK7 negative, CK20 positive, and CDX2 positive is consistent with a colorectal origin.\n\nTreatment regimen:\n\n1. Consult with a medical oncologist and surgical oncologist to discuss treatment options.\n2. Initiate systemic chemotherapy with a FOLFOX or CapeOx regimen. FOLFOX consists of oxaliplatin 85 mg/m2 IV day 1, leucovorin 400 mg/m2 IV day 1, and 5-fluorouracil 400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 IV continuous infusion over 46 hours, every 2 weeks. CapeOx consists of oxaliplatin 130 mg/m2 IV day 1 and capecitabine 1000 mg/m2 PO twice daily for 2 weeks, every 3 weeks.\n3. Consider adding bevacizumab to the chemotherapy regimen if there are no contraindications. Bevacizumab is given at a dose of 5 mg/kg IV every 2 weeks with FOLFOX or every 3 weeks with CapeOx.\n4. After completion of 6 cycles of chemotherapy, reassess the patient with a CT scan of the chest, abdomen, and pelvis. If there is a response to chemotherapy, consider surgical resection of the liver lesions.\n5. If the patient is not a candidate for surgical resection, consider local ablative therapies such as radiofrequency ablation or microwave ablation.\n6. Continue surveillance with CT scans of the chest, abdomen, and pelvis every 3-6 months for the first 2 years, then every 6-12 months for the next 3 years, then annually.\n7. Monitor serum carcinoembryonic antigen (CEA) levels every 3 months for the first 2 years, then every 6 months for the next 3 years, then annually.\n8. Encourage the patient to maintain a healthy lifestyle, including a balanced diet, regular exercise, and avoidance of tobacco and excessive alcohol consumption.\n\nIt is important to note that this treatment regimen is a general guideline and should be tailored to the individual patient's needs and preferences. Close collaboration with the patient's medical team is essential to ensure the best possible outcomes.",
        "sources": [
            "with a mean age of 58 years who present with predominantly liver \nand peritoneal metastases and less commonly with lungs, pleura \nbones, or ovarian secondary lesions. Laboratory investigations \nshow a normal colonoscopy and histology compatible with adeno -\ncarcinoma or poorly-differentiated adenocarcinoma stained with \nCK20, CDX2, and CEA [54, 55].Table 59.5  Clinicopathological subsets and patients\nFavourable or specific CUP subsets Unfavourable or non-specific CUP \nsubsets\nWomen with serous-papillary \nadenocarcinoma of peritoneal cavityAdenocarcinoma metastatic to the \nliver or other organ\nWomen with adenocarcinoma \ninvolving only axillary lymph nodesMalignant ascites from a non-papillary \nadenocarcinoma\nPoorly-differentiated carcinoma \nwith midline distributionMultiple cerebral metastases from \nadenocarcinoma or squamous cell \ncarcinoma\nSquamous cell carcinoma involving \ncervical lymph nodesMultiple lung or pleural metastases \nfrom adenocarcinoma\nNeuroendocrine carcinoma of",
            "27 candidate markers by IHC in 352 primary adenocarcinomas. Ten \nmarkers were selected (PSA, TTF1, CDX2, CK20, CK7, GCDFP-15, ER, CA-125, mesothelin, and lysozyme).\n20 The markers were used in \na diagnostic table and decision tree, which enabled the correct prediction of primary site (pancreas, lung, colon, breast, stomach, ovary, prostate, and other carcinomas) in 88% of the initial samples. A separate valida-\ntion cohort of 120 primary and metastatic adenocarcinomas showed \nthe same accuracy (88%). In practice, IHC is most useful when used as a panel of stains and when the patterns produced by these stains are evaluated in the context of the clinical presentation.\nHowever, IHC has its limitations for poorly differentiated cancers, \nin which it functions poorly. Additionally, several technical factors \ncan affect the accuracy of IHC. These include factors that affect tissue",
            "mous carcinoma, squamous cell carcinoma, small cell (oat cell) \ncarcinoma, large cell neuroendocrine carcinoma, undifferentiated \ncarcinoma, and biliary cystadenoma. There is no pathognomonic \nimmunohistochemical stain to confirm the cell type of origin of HB \ncancers. Immunohistochemical staining for cytokeratin-7 (CK-7) \nand hepatocyte paraffin 1 monoclonal antibody (Hep Par 1)  is \nused to support the pathological diagnosis of cholangiocarcinoma \nand HCC.\nWhen patients are on a screening program, most of the HCCs are \ndiagnosed non-invasively using defined radiological criteria. An \nimage-guided biopsy (core biopsy is preferred) is needed in patients \nwith atypical features, when the diagnosis is uncertain and before \nusing chemotherapy or targeted therapy in non-resectable cancers. \nThe HCCs are often multicentric in nature. The microscopic appear -\nance vary from well-differentiated (malignant hepatocytes appear -",
            "of liver function is indicated to help establish which therapies will  \nbe feasible.\n461,462\nAt presentation to the surgeon, many of these patients have a liver \nmass and biopsy evidence of adenocarcinoma of unknown primary. \nBecause adenocarcinoma in the liver most commonly represents metastatic disease, and histologic features alone cannot be used to \nreliably determine whether the condition represents an ICC or a \nspecific metastasis, the standard evaluation in these patients should include a careful search for a possible primary. This requires a detailed medical history; physical examination; upper and lower endoscopy; complete imaging of the chest, abdomen, and pelvis; and consid -\neration of mammography and gynecologic examination in women. \nIf no primary tumor is found, the diagnosis, with great certainty,",
            "SECTion 6  disease orientated chapters 968\nmetastatic adenocarcinomas or poorly differentiated carcinomas. \nAntibodies against cytokeratins, and especially against CK7 and \nCK 20, have opened up a helpful diagnostic avenue (Table 59.4) \n[34, 35].\nChromosomal diagnosis\nThe detection of chromosomal abnormalities could be helpful in \nspecific cases as in germ cell CUP (detection of an isochromo -\nsome of the short arm of chromosome 12i (12p) or a deletion in \n12p), peripheral neuroectodermal tumours, or in Ewing’s sarcomas \n(translocation t [11, 22] [q 24; q 12] [36, 37].\nDiagnostic investigations\nImaging\nComputed tomography\nThe sensitivity of whole-body CT-scans to detect a primary site is \naround 30–35%, recognizing that small lesions can be missed by \nCTs. CT scans are also used for CUP staging [38].Magnetic resonance imaging\nMRI is very useful in identifying mainly occult breast primary \ntumours. Its sensitivity could be as high as 60% [39].\n111In Octreoscan",
            "34. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma \ncharacteristics of the site of origin: development of a diagnostic algo -\nrithm. Clinical Cancer Research 2005; 11: 3766–3772.\n 35. Oien KA. Pathologic evaluation of unknown primary cancer. Seminars \nin Oncology 2009; 36: 8–37.\n 36. Motzer RJ, Rodriguer E, Reuter VE, et al. Molecular and cytogenetic \nstudies in the diagnosis of patients with poorly differentiated carcino -\nmas of unknown primary site. Journal of Clinical Oncology 1995; 13: \n274–282.\n 37. Ilson DH, Motzer RJ, Rodriguez E, et al. Genetic analysis in the \ndiagnosis of neoplasm of unknown primary tumor site. Seminars in \nOncology 1993; 20: 229–237.\n 38. Karsell PR, Sheedy PF, O’Connell MJ. Computed tomography in \nsearch of cancer of unknown origin. Journal of the American Medical \nAssociation 1982; 248: 340–343.\n 39. Orel SG, Weinstein SP , Schmoll MD et al. Breast MR imaging in \npatients with axillary node metastases and unknown primary malig -",
            "growth rates.\n128\nSurveillance After T reatment of Localized Renal  \nCell Carcinoma\nSporadic renal cell carcinoma\nImaging for surveillance is based largely on risk of metastasis by \nanatomic site. The major metastatic sites, in order of frequency, include lung (3%–16%), bone (2%–8%), regional lymph nodes, liver (1%–7%), ipsilateral adrenal, contralateral kidney, and brain (2%–4%). Currently, \na history and physical examination, serum studies (calcium level, \nalkaline phosphatase level, and liver transaminases), and imaging studies (chest plain radiographs or chest CT scan and abdominal CT scan), done at time points when disease recurrence is likely, are used for surveillance.\n129 The lung has the greatest incidence of metastasis, so \nearly diagnosis is pertinent.129 Chest radiography has been shown to \ndetect up to 90% of lung metastases.130 Although chest CT is more \nsensitive than chest radiography, it yields more false positives, and its role in surveillance is still unknown."
        ]
    },
    {
        "answer": "Based on the information provided, the patient's tumor shows deficient DNA mismatch repair (dMMR) due to loss of PMS2 and MLH1 proteins. This is consistent with a diagnosis of Lynch syndrome, which is associated with a high level of tumor-infiltrating lymphocytes (TILs) and a high microsatellite instability (MSI-H) phenotype.\n\nImmunotherapy with checkpoint inhibitors has shown promising results in patients with dMMR/MSI-H tumors, including colorectal and non-colorectal cancers. In particular, the PD-1 inhibitor pembrolizumab has shown response rates of 62% in patients with dMMR/MSI-H metastatic colorectal cancer (mCRC) and 60% in patients with other dMMR/MSI-H tumors.\n\nTherefore, I would recommend systemic therapy with pembrolizumab as the first-line treatment option for this patient. This therapy has been shown to have a high response rate in patients with dMMR/MSI-H tumors, and it has a favorable safety profile compared to traditional chemotherapy.\n\nIt is important to note that the patient's age and comorbidities should be taken into account when making treatment decisions. Additionally, the patient's tumor should be tested for other genetic mutations that may affect treatment options.\n\nIn terms of dosage and timeline, pembrolizumab is typically administered at a dose of 200 mg intravenously every three weeks until disease progression or unacceptable toxicity. The duration of treatment may vary depending on the patient's response to therapy.\n\nIn summary, I would recommend systemic therapy with pembrolizumab for this patient with dMMR/MSI-H tumors, given its high response rate and favorable safety profile. It is important to consider the patient's age and comorbidities, as well as other genetic mutations that may affect treatment options.",
        "sources": [
            "Part\tI:\tScience\tand\tClinical\tOncology 253.e2Part\tI:\tScience\tand\tClinical\tOncology\n66. Fishel R, Lescoe MK, Rao MR, et al. The human \nmutator gene homolog MSH2 and its association \nwith hereditary nonpolyposis colon cancer. Cell. \n1994;77(1):1 p following 166.\n67. Miyaki M, Konishi M, Tanaka K, et al. \nGermline mutation of MSH6 as the cause of \nhereditary nonpolyposis colorectal cancer. Nat Genet . \n1997;17(3):271–272.\n68. Li GM, Modrich P . Restoration of mismatch repair \nto nuclear extracts of H6 colorectal tumor cells by a \nheterodimer of human MutL homologs. Proc Natl \nAcad Sci USA . 1995;92(6):1950–1954.\n69. Nakagawa H, Lockman JC, Frankel WL, et al. Mis -\nmatch repair gene PMS2: disease-causing germline \nmutations are frequent in patients whose tumors \nstain negative for PMS2 protein, but paralogous \ngenes obscure mutation detection and interpretation. \nCancer Res . 2004;64(14):4721–4727.\n70. Kane MF , Loda M, Gaida GM, et al. Methylation",
            "microsatellite instability or loss of DNA mismatch repair protein \n(MLH1, MSH2, MSH6, PMS2) on immunohistochemistry\n2. P atients with first-degree relative affected with endometrial or \ncolorectal cancer who was either diagnosed before age 60 years or who is identified to be at risk for Lynch syndrome based on a systematic clinical screen that incorporates a focused personal and medical history\n3. P atients with first- or second-degree relative with known mutation \nin mismatch repair gene\nFrom Lancaster JM, Powell CB, Kauff ND, et  al; Society of Gynecologic Oncologists \nEducation Committee. Society of Gynecologic Oncologists statement on risk \nassessment for inherited gynecologic cancer predispositions. Gynecol Oncol. \n2015;136(1):3–7.\nTable 85.4  Risk Factors for Endometrial Cancer\nRisk Factor Relative Risk\nUnopposed estrogen therapy 10–20\nTamoxifen 2.5\nPolycystic ovarian syndrome 3–5\nObesity 2–5\nDiabetes 2–3\nNulliparity 2–3",
            "MMMT Mixed malignant Mϋllerian tumours\nMMP matrix metalloproteinase\nMMP-9 matrix metalloprotease-9\nMMR mismatch repair\nMNGGCT malignant non-germinoma germ cell tumour\nMoAb monoclonal antibody\nMOMP mitochondrial outer membrane permeabilization\nMOPP mechlorethamine, vincristine, procarbazine, \nprednisone\nmOS median overall survival\nMPA medroxyprogesterone acetate\nMPD myeloproliferative diseases\nMPM malignant peritoneal mesothelioma\nMPN myeloproliferative neoplasms\nMR minimal response\nMRA magnetic resonance angiography\nMRC Medical Research Council\nMRCP magnetic resonance cholangiopancreatography\nMRD minimal residual disease\nMRF mesorectal fascia\nMRI magnetic resonance imaging\nMRP multidrug resistance-associated protein\nMSI microsatellite instability\nMSI-H high microsatellite instability\nMSI-L low microsatellite instability\nMSKCC Memorial Sloan Kettering Cancer Center\nMSS microsatellite stable/stability\nMTC medullary thyroid carcinoma\nMTD maximum tolerated dose",
            "and endometrial cancers.114 This is consistent with the long-standing \nobservation that Lynch syndrome tumors exhibit a high level of \ntumor-infiltrating lymphocytes (TILs).115 A remarkable clinical study \nshowed that DNA mismatch repair–deficient MSI-H colorectal and \nendometrial cancers achieve excellent and durable responses to \nimmune checkpoint inhibitors, whereas microsatellite-stable (MSS) \ntumors showed no responses.116 Immunohistochemistry showed \ngreater densities of CD8 + TILs and PD-L1 expression in MSI-H than MSS",
            "References 441\n44Saxman, S.B., Finch, D., Gonin, R., and Einhorn, L.H. (1998). Long-term\nfollow-up of a phase III study of three versus four cycles of bleomycin, etopo-\nside, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University\nexperience. J. Clin. Oncol. 16: 702–706.\n45International Germ Cell Cancer Collaborative Group (1997). International\nGerm Cell Consensus Classification: a prognostic factor-based staging system\nfor metastatic germ cell cancers. J. Clin. Oncol. 15: 594–603.\n46Le, D.T., Durham, J.N., Smith, K.N. et al. (2017). Mismatch repair deficiency\npredicts response of solid tumors to PD-1 blockade. Science357: 409–413.\n47Le, D.T., Uram, J.N., Wang, H. et al. (2015). PD-1 blockade in tumors with\nmismatch-repair deficiency. N .E n g l .J .M e d . 372: 2509–2520.\n48Einhorn, L.H. and Donohue, J. (1977). Cis-Diamminedichloroplatinum,\nVinblastine, and Bleomycin combination chemotherapy in disseminated tes-\nticular cancer. Ann. Intern. Med. 82: 293–298.",
            "in elderly patients 876\nMGUS (monoclonal gammopathy of \nundetermined significance) 782, 787\namyloidosis 800\ndiagnosis 790 t\nmanagement 791–2\nprogression risk 790–1\n123I-MIBG scintigraphy 936\nmicroarray profiling 660\nmicropthalmia transcription factor (MITF) 674\nmicroRNAs (miRs) 67, 549\nmicrosatellite instability (MSI) 75\ncolorectal cancer 447–8, 460–1\nendometrial cancer 578\ngastric cancer 390–1\nmicrotubules 186–7\nmilk, in the diet 157\nminimally invasive surgery 166–7\noesophageal 372, 373\nsee also  laparoscopy; thermal ablation\nminor salivary gland (MiSG) cancer 353\nradiotherapy 354\nsurgery 354\nsurvival rates 355\nMInT trial 818, 819\nmismatch repair (MMR) pathway 74–5, 76\ncolorectal cancer 447–8, 449, 460–1\nHNPCC (Lynch syndrome) 75, 277 t, 282, \n450–1, 578\nendometrial cancer 578\ngastric cancer 391\nmitochondria\nand apoptosis 42–3\ntumour suppressor genes 122–3\nmitogens 34\nmitomycin 615\nmitomycin C 187\nmitosis 31\nin CAFs 67\ninhibition by chemotherapy agents 186–7",
            "involving patients with MSI-H metastatic CRC, patients with other \ntumors with deficient DNA MMR such as endometrial cancer, and \npatients with MSS CRC caused great excitement in the CRC and immunotherapy communities.\n806 The response rates, respectively, were \n62%, 60%, and 0%. Given these results, this phase II trial of pem -\nbrolizumab in dMMR colorectal and noncolorectal cancers is continu -\ning; the KEYNOTE-164 study of pembrolizumab as monotherapy \nin participants with previously treated locally advanced unresectable \nor metastatic MSI-H CRC has been completed; and the KEYNOTE-177 phase III trial of pembrolizumab versus standard chemotherapy in participants with locally advanced unresectable or metastatic MSI-H CRC has commenced. The ongoing CheckMate 142 trial in MSI-H metastatic CRC is exploring the use of the combination of ipilimumab, \na cytotoxic T-lymphocyte antigen 4 (CTLA4) inhibitor, and nivolumab, \na PD-1 inhibitor. This phase II trial was reported at the 2016 annual"
        ]
    },
    {
        "answer": "Based on the patient's symptoms and history, the most likely diagnosis is chronic graft-versus-host disease (GVHD). The symptoms she is experiencing, such as dry eyes and mouth, muscle and joint tightness, and limited range of motion, are all common manifestations of chronic GVHD. Additionally, her history of acute GVHD and steroid treatment supports this diagnosis. It is important to confirm the diagnosis with appropriate tests and begin appropriate treatment as soon as possible to prevent further progression and complications.",
        "sources": [
            "467 Hematopoietic \tStem \tCell \tTransplantation \t•\tCHAPTER\t28\t\ndays and 2 years after transplant and has some polymorphic features \nthat are similar to autoimmune diseases. The organ systems that are frequently involved include the skin, eyes, oral mucosa, gastrointestinal tract, liver, and pulmonary, musculoskeletal, and genitourinary systems. \nStaging and global severity assessment are based on the extent to \nwhich these organs are involved.\n131 Signs and symptoms vary widely \nbut can include sicca syndrome, rashes or sclerosis, wasting syndrome, bronchiolitis obliterans, limitation in joint range of motion, and liver function abnormalities. Adverse prognostic factors include thrombo-\ncytopenia, a progressive onset from prior acute GVHD, extensive skin \ninvolvement, and an elevated bilirubin level.\n138,139\nFor both acute GVHD and chronic GVHD, first-line therapy is \nhigh-dose corticosteroids.140,141 There is no consensus regarding second-",
            "Steroid (glucocorticoid) therapy induces a broad immunosuppressive \neffect, including impaired chemotaxis and killing by neutrophils, impaired T-cell function and reduction in T-cell proliferation, and alterations in skin and mucosal barriers. Long-term or high-dose steroid therapy is a significant risk factor for IFIs, particularly with Cryptococcus  \nand P . jiroveci  (usually seen with tapering of the steroid regimen). \nInvasive Aspergillus  infections typically occur in patients receiving high \ndoses of steroids ( >\n1 mg /kg/day) for graft-versus-host disease (GVHD) \nfollowing allogeneic hematopoietic stem cell transplantation (HSCT). Steroid therapy also may predispose affected patients to development of bacterial infections and Mycobacterium tuberculosis  reactivation. \nHigh-dose cytosine arabinoside therapy causes mucositis that has been \nlinked to development of life-threatening streptococcal bacteremias \nin neutropenic patients.\n13 Fludarabine and alemtuzumab cause pro -",
            "new\tc oncepts. \tClin Dermatol. 2011;29(6):587–601.Acute graft-versus-host disease\nDermatitis of the palms and soles may occur as the earliest and only \nsign of acute graft-versus-host disease (GVHD). GVHD is often associated with gastrointestinal abnormalities, including diarrhea, abdominal pain, and elevated serum bilirubin levels. Both diseases \ncan occur concurrently. Unfortunately, acute GVHD can be clinically \nand histologically indistinguishable from HFS in its early stages. The distinction of acral erythema from GVHD in patients who have undergone a transplant is important because the treatments are distinct.\n68\nErythema multiforme\nIn contrast to HFS, erythema multiforme manifests classically as target-shaped macules on the palms and soles. This condition is most commonly associated with herpes simplex virus infections or myco -\nplasma infections.\nT reatment",
            "related disease. Most centers have adopted a preemptive monitoring approach, as discussed previously (see the earlier section entitled Patients Patients With Graft-Versus-Host Disease\nGVHD and its treatment result in significant suppression of the cell-mediated immune system and high risk of certain infections. The use of penicillin to prevent infection with encapsulated organisms (e.g., S. pneumoniae ) is widely accepted.\n2,3,204 Invasive mold infections, \nparticularly invasive aspergillosis, constitute a serious threat during GVHD. A large randomized trial comparing posaconazole with flu-conazole in patients with grade II or IV acute GVHD or chronic \nextensive GVHD demonstrated a reduction in overall breakthrough \nIFIs, including invasive Aspergillus infections with posaconazole.\n243 Immune \nsystem defectsNeutropenia\nThrombocytopenia\nIdiopathic pneumonia\nStrongyloides\nCryptosporidiaVODMucositis\nHSVAdenovirus\nToxoplasmaCMV\nLate Aspergillus",
            "243 Immune \nsystem defectsNeutropenia\nThrombocytopenia\nIdiopathic pneumonia\nStrongyloides\nCryptosporidiaVODMucositis\nHSVAdenovirus\nToxoplasmaCMV\nLate Aspergillus\nEpstein-Barr virus lymphoproliferative diseasePneumocystis\nRespiratory and enteric viruses (episodic, endemic)Encapsulated bacteriaVZV\nCandida\nViridans group \nstreptococci\nFacultative\ngram-negative\nCoagulase-negative\nstaphylococciEarly\nAspergillusAcute GVHD Chronic GVHDCentral lineLymphopenia\nHypogammaglobulinemiaEngraftment Day 60 Day 90 Day 180 1 year 2 year\nTransplant-related \nfactors\ncontributing \nto infection\nHigh-incidence\ninfections\nLow-incidence \ninfections\nKilled-organism \nvaccines\nLive-virus vaccines\nFigure 34.2  • Phases of predictable immune suppression with characteristic opportunistic infections among allogeneic hematopoietic stem cell transplant \nrecipients. CMV, Cytomegalovirus; GVHD, graft-versus-host disease; HSV, herpes simplex virus; VOD, venoocclusive disease; VZV, varicella-zoster virus.",
            "plant recipients. J Hosp Infect . 2017;95(2):214–217.\n219. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged \nshedding of multidrug-resistant influenza A virus \nin an immunocompromised patient. N Engl J Med . \n2003;348(9):867–868.\n220. Ison MG. Adenovirus infections in transplant \nrecipients. Clin Infect Dis . 2006;43(3):331–339.\n221. Leruez-Ville M, Minard V, Lacaille F , et al. Real-\ntime blood plasma polymerase chain reaction for \nmanagement of disseminated adenovirus infection. \nClin Infect Dis . 2004;38(1):45–52.\n222. Bogdanovic G, Priftakis P , Giraud G, et al. \nAssociation between a high BK virus load in urine \nsamples of patients with graft-versus-host disease \nand development of hemorrhagic cystitis after hematopoietic stem cell transplantation. J Clin \nMicrobiol . 2004;42(11):5394–5396.\n223. Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin \ndecreased polyoma BK virus load in patients who \nunderwent allogeneic hematopoietic stem cell",
            "235–238 Fluconazole, however, does not \nhave activity against yeasts such as C. glabrata (some strains) and C. \nkrusei or against molds such as Fusarium, Aspergillus,  and the Zygo -\nmycetes. Some centers use prophylaxis with an agent active against \nmold, such as voriconazole, in high-risk patients (i.e., mismatched or \nmatched unrelated donor transplants). A trial demonstrated no statisti -\ncally significant benefit of voriconazole compared with fluconazole for the prevention of fungal infections when it was administered for the first 100 days (180 days for those receiving prednisone at a dose of ≥\n1 mg/kg/day or for r ecipients of T-cell–depleted grafts with CD4 + \ncounts <200 at day 100) after transplantation.239\nPrevention of CMV disease after allogeneic HSCT can be effectively \naccomplished with use of either universal prophylaxis or preemptive therapy with ganciclovir or valganciclovir.\n3 The preemptive strategy"
        ]
    },
    {
        "answer": "Based on the patient's presentation with fevers, severe fatigue, and frequent night sweats, as well as her laboratory results showing an increasing white blood cell count and absolute lymphocyte count despite being on ibrutinib therapy, it is appropriate to consider alternative or additional treatment options.\n\nThe patient's CLL is positive for del(17p), which is associated with a poor response to traditional chemotherapy and chemoimmunotherapy. Ibrutinib is a recommended frontline therapy for patients with del(17p), but it is important to note that not all patients will respond to this therapy.\n\nGiven the patient's worsening disease despite ibrutinib therapy, it may be appropriate to consider adding venetoclax to her treatment regimen. Venetoclax is a BCL-2 inhibitor that has shown activity in patients with relapsed/refractory CLL, including those with del(17p). In a study of patients with relapsed/refractory CLL who received venetoclax monotherapy, the overall response rate was 79% and the complete response rate was 20%. The median progression-free survival was 17 months for patients with del(17p) and not reached for those without del(17p).\n\nIt is important to note that venetoclax can cause tumor lysis syndrome, particularly in patients with high disease burden. Therefore, it is recommended to initiate venetoclax therapy with a ramp-up dosing schedule and to closely monitor the patient for signs of tumor lysis syndrome.\n\nIn addition to adding venetoclax, it may also be appropriate to consider adding an anti-CD20 monoclonal antibody, such as obinutuzumab or rituximab, to the patient's treatment regimen. These agents have shown activity in patients with CLL, particularly when combined with chemotherapy or targeted therapy.\n\nIn summary, the next appropriate step in management of the patient's CLL may be to add venetoclax to her current ibrutinib therapy, with consideration of adding an anti-CD20 monoclonal antibody as well. It is important to closely monitor the patient for signs of tumor lysis syndrome and to adjust the treatment regimen as necessary based on the patient's response to therapy.",
        "sources": [
            "considered an acceptable second-line therapy for CLL. Lower doses \nof bendamustine are used in relapsed CLL as compared with untreated CLL or typical regimens used in NHL. In addition, the response in select genetic groups such as those patients with del(17p) is very low, making this a poor choice for such individuals. Similarly, patients with heavily pretreated CLL that is fludarabine refractory are less likely to respond and have increased toxicity from this regimen.\nIbrutinib\nThe advent of kinase inhibitors and specifically ibrutinib has revolution -\nized the treatment of patients with relapsed CLL. Forty-seven patients months, the ORR was 84% with a CR rate of 29%, and median PFS was not reached.\n186\nBased on the promising early results seen with ibrutinib in the \nrelapsed setting, the RESONATE-2 trial was conducted to determine the efficacy of ibrutinib as frontline therapy in patients aged 65 and older with significant medical comorbidities when compared with \nchlorambucil.",
            "(Box 99.2). In addition to the official iwCLL criteria for therapy, \nincreasing frequency of infections and slowly progressive anemia are other indications that can aid the practicing physician in deciding when to initiate therapy in CLL. A useful paradigm for clinical practice is to institute treatment in CLL only for cytopenias or directly referable symptoms. The role of biomarkers in selecting the initial treatment \nfor CLL is applied for older biomarkers and is currently under study \nby several groups with newly identified ones.\nIn general, patients with del(17p) or TP53 mutation do not respond \nwell to traditional chemotherapy or chemoimmunotherapy and should be treated with ibrutinib as frontline therapy. In addition, several studies have shown that CLL patients who are older than 70 or who \nhave multiple comorbid illnesses do not benefit from fludarabine-\ncontaining regimens, and this needs to be factored into treatment algorithms.",
            "chlorambucil.\n187 This trial clearly showed a significant improvement \nin PFS with the use of ibrutinib at 24 months (not reached versus \n18.9 months; P < .001) and a risk of progression or death that was \n84% lower than in patients treated with chlorambucil (HR, 0.16; P \n< .001). Ibrutinib use also resulted in a significant improvement in \nOS (98% versus 85% at 24 months with ibrutinib versus chlorambucil; P = .001). Ibrutinib was generally well tolerated and toxicities were \nmild, with a low rate of hematologic toxicity. Rates of adverse events leading to treatment discontinuation are 6% to 20% in various reports. The most common toxicities have been diarrhea, rash, bruising, \ndyspepsia, and atrial fibrillation. Infections have been seen, although \nthe rate is not clearly different from that seen in this refractory patient population. These data resulted in the approval of ibrutinib as frontline treatment of patients with CLL except for a small report of P . jiroveci",
            "disease, chemoimmunotherapy with the FCR regimen maybe a reason -\nable option. The rest of the patients with these demographic charac -\nteristics can also be considered for FCR therapy or ibrutinib, except for patients with del(17p). The decision between FCR and ibrutinib must take into consideration patient preference regarding intermittent versus continuous therapy, availability of and ability to obtain ibrutinib, and the presence of other comorbid illnesses that might contribute \nto poor outcome with either FCR or ibrutinib. For older patients and \nthose with significant comorbid conditions, multiple options can be considered, including ibrutinib, BR, obinutuzumab, or ofatumumab. For patients with del(17p), ibrutinib is the first choice of therapy regardless of age or performance status.\nTREATMENT OF PATIENTS WITH RELAPSED \nCHRONIC LYMPHOCYTIC LEUKEMIA\nThe approach to reinitiating therapy in CLL patients who have",
            "(41%) and diarrhea (52%). Del(17p) was present in 71% of patients, \nand they demonstrated an ORR and CR rate of 71% and 16% respectively, which were comparable to those for the whole cohort (ORR, 79%; CR rate, 20%). Median PFS for patients with del(17p) was 16 months (range, 11 to 25 months), whereas 71% of patients (95% CI, 57% to 81%) without del(17p) were progression free at  \n15 months.\n199\nVenetoclax was also evaluated in patients with refractory disease \nor relapse after ibrutinib or idelalisib.201 Patients in arm A (n = 43) \nhad received prior ibrutinib therapy for a median of 17 months before progression when they started venetoclax. With a median time on treatment of 9 months, ORR was 70%. Patients in arm B (n = 21)",
            "complication during the first month of therapy. Several other groups \nhave confirmed these results\n247 or built on this regimen by substituting \nalemtuzumab for rituximab or dexamethasone for methylprednisolone with similar efficacy, including in del(17p) patients.\n248,249 Given the \ninfectious morbidity associated with high-dose corticosteroid and rituximab-containing regimens, aggressive viral, bacterial, P . jiroveci, \nand fungal prophylaxis should be administered during and for a period \nafter treatment. In addition, close monitoring for metabolic complica -\ntions including hyperglycemia and tumor lysis syndrome should be  \nperformed.\nAdditional Agents in Development for Chronic \nLymphocytic Leukemia\nSeveral other promising therapeutics are in late phase II/III clinical \ntrials for CLL. Those agents with documented activity in this disease that have potential to be approved for use in CLL are described here.\nAcalabrutinib",
            "1871 Chronic\tLymphocytic\t Leukemia \t•\tCHAPTER\t99\t\n184. Goede V, Fischer K, Busch R, et al. Obinutuzumab \nplus chlorambucil in patients with CLL and coexist -\ning conditions. N Engl J Med . 2014;370:1101–1110.\n186. O’Brien SM, Furman RR, Coutre SE, et al. Five-year \nexperience with single-agent ibrutinib in patients \nwith previously untreated and relapsed/refractory \nchronic lymphocytic leukemia/small lymphocytic \nleukemia. Blood . 2016;128:233.\n187. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as \ninitial therapy for patients with chronic lymphocytic \nleukemia. N Engl J Med . 2015;373:2425–2437.\n191. Byrd JC, Furman RR, Coutre SE, et al. Targeting \nBTK with ibrutinib in relapsed chronic lymphocytic \nleukemia. N Engl J Med . 2013;369:32–42.\n192. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus \nofatumumab in previously treated chronic lymphoid \nleukemia. N Engl J Med . 2014;371:213–223.194. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for"
        ]
    },
    {
        "answer": "Given the patient's young age, worsening symptoms, significant cytopenias, and high-risk cytogenetic abnormality (deletion 17p), the most appropriate frontline therapy option would be ibrutinib. This Bruton's tyrosine kinase (BTK) inhibitor has shown efficacy in patients with CLL, including those with high-risk cytogenetic abnormalities. Ibrutinib is administered orally, once daily, continuously until disease progression or unacceptable toxicity. The starting dose is 420 mg daily.\n\nIn this case, the patient's clinical presentation and FISH results indicate a high-risk CLL, which is less likely to respond to traditional chemotherapy or chemoimmunotherapy regimens. Ibrutinib has been shown to improve progression-free survival (PFS) and overall survival (OS) in patients with CLL, including those with deletion 17p.\n\nIt is essential to monitor the patient's complete blood count (CBC) regularly during treatment, as cytopenias may worsen during the initial phase of therapy. Additionally, it is necessary to monitor for potential adverse effects, such as bleeding, bruising, diarrhea, and infections.\n\nIn summary, the most appropriate frontline therapy option for this patient with CLL, worsening symptoms, significant cytopenias, and deletion 17p is ibrutinib, administered orally at a dose of 420 mg daily. Close monitoring of CBC and adverse effects is required during treatment.",
        "sources": [
            "(Box 99.2). In addition to the official iwCLL criteria for therapy, \nincreasing frequency of infections and slowly progressive anemia are other indications that can aid the practicing physician in deciding when to initiate therapy in CLL. A useful paradigm for clinical practice is to institute treatment in CLL only for cytopenias or directly referable symptoms. The role of biomarkers in selecting the initial treatment \nfor CLL is applied for older biomarkers and is currently under study \nby several groups with newly identified ones.\nIn general, patients with del(17p) or TP53 mutation do not respond \nwell to traditional chemotherapy or chemoimmunotherapy and should be treated with ibrutinib as frontline therapy. In addition, several studies have shown that CLL patients who are older than 70 or who \nhave multiple comorbid illnesses do not benefit from fludarabine-\ncontaining regimens, and this needs to be factored into treatment algorithms.",
            "have inferior outcome.\nCytogenetic abnormalities have been detected on conventional \ncytogenetics in 40–50% of patients. However, a low proliferative \nrate is a limitation for conventional cytogenetics. In the past dec -\nade, FISH using DNA probes has greatly enhanced the ability to \ndetect molecular abnormalities in almost 80% of cases of CLL. 13q \ndeletion is the most common genetic aberration present in CLL \n(55%) followed by 11q deletion (18%), 12q trisomy (16%), and 17p \ndeletion (7%) [125, 126].These abnormalities have been correlated \nwith outcome. Patients with 17p or 11q deletion generally have \nmore advanced disease with frequent splenomegaly, mediastinal, \nand abdominal lymphadenopathy and more extensive peripheral \nlymphadenopathy. Presence of 17p deletion correlates with low \nincidence of IgVH mutation and also resistance to fludarabine therapy. In contrast, patients with leukaemic cells that have mutant \nIgVH genes usually present in an early clinical stage, frequently",
            "Part\tIII:\tSpecific \tMalignancies 1866Part\tIII:\tSpecific \tMalignancies\nbe ideal for the phase II dose in CLL based on tolerability and minimal \nincrease in maximum plasma concentration (C max) at increasing doses \nabove the 150  mg twice-a-day schedule. A total of 54 CLL patients \nwere enrolled on this trial, with 84% achieving a 50% or more decrease in lymph node and spleen size. An increase in peripheral lymphocyte count of 50% or more was seen in 58% of patients, peaked at 2 months, and resolved over time in a subset of patients. As a consequence \nof the asymptomatic lymphocytosis, response across all patients enrolled \nwas 24% by iwCLL 2008 response criteria. This response was inde -\npendent of high-risk genetic features, bulky adenopathy, prior therapy, or presence of cytopenias. Median PFS was 15 months, with 46% of patients continuing on therapy at the time of the report.\n197 Whereas \nresponse did not vary by genetic group, PFS with idelalisib was consider -",
            "Part\tIII:\tSpecific \tMalignancies 1862Part\tIII:\tSpecific \tMalignancies\nmyeloid neoplasm (trMN) have been observed with the FC regimen. \nIn addition, patients older than 65 or 70, who make up the majority of CLL patients receiving initial therapy in clinical practice, have either been excluded or minimally represented in these trials. Examina -\ntion of outcome by cytogenetic risk groups showed that patients with high-risk cytogenetic abnormalities including del(11q) and del(17p) had a significantly shorter remission than patients in the groups with good-risk or intermediate-risk cytogenetic findings when cyclophos -\nphamide was given as a single dose. In contrast, patients with del(11q) but not del(17p) had similar outcomes when fractionated cyclophos-\nphamide was administered over 3 days.\n157\nBendamustine\nBendamustine is an exciting therapeutic option for patients with CLL",
            "patients with Philadelphia chromosome–negative ALL, and in patients with Philadelphia chromosome–positive ALL in whom relapse rates are high.\n64,67–69\nHCT is most clearly indicated for patients with Philadelphia \nchromosome–positive ALL, even in the era of tyrosine kinase inhibitors.\n70\nChronic Lymphocytic Leukemia\nAllogeneic HCT has been used in the treatment of chronic lymphocytic leukemia (CLL) and can produce durable remissions in select patients.\n71,72 However, application has been limited by treatment-related \nmortality in this older patient population. Reduced-intensity condition -\ning regimens have been successful in CLL, with treatment-related \nmortality of 15% to 18%, 2-year event-free survival of 56% to 67%, and 2-year OS of 72%.\n73,74 This suggests that CLL is susceptible to \nthe graft-versus-leukemia effect. Certain high-risk patients may benefit from early allogeneic HCT, such as those with 17p deletion.\n75,76",
            "first-line therapy of younger patients with chronic lymphocytic leuke -\nmia. Blood 2006; 107: 885–891. \n 139. Rai KR, Peterson BL, Appelbaum FR, et al. Long-term survival \nanalysis of the North American Intergroup Study C9011 comparing \nfludarabine (F) and chlorambucil (C) in previously untreated patients \nwith chronic lymphocytic leukemia (CLL). Program and abstracts \nof the 51st American Society of Hematology Annual Meeting \nand Exposition, New Orleans, Louisiana, December 5–8, 2009; \nAbstract 536.\n 140. Johnson S, Smith AG, Löffler H, Osby E, Juliusson G et al. Multicentre \nprospective randomised trial of fludarabine versus cyclophosphamide, \ndoxorubicin, and prednisone (CAP) for treatment of advanced-stage \nchronic lymphocytic leukaemia Lancet 1996; 347: 1432–1438.\n 141. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P et al. \nRandomized comparison of fludarabine, CAP , and ChOP in 938 \npreviously untreated stage B and C chronic lymphocytic leukemia",
            "combination with fludarabine or rituximab. In a phase II study of \npatients with relapsed CLL, the combination of fludarabine, alem -\ntuzumab, and cyclophosphamide produced an overall RR of 67% \nwith a CR rate of 30% [169].\nTable 52.7  Prognostic factors in chronic lymphocytic leukaemia (CLL)\nFactor outcome\nClinical stage Rai stage 0 & 1: good,\nstage II intermediate,\nIII–IV poor\nBinet stage A >B >C\nDegree of BM infiltration Nodular good,\nDiffuse poor\nAbsolute lymphocyte count <30,000/cmm better than higher\nLymphocyte doubling time >12 months better than <12 months\nSerum levels of β- 2 \nmicroglobulinNormal better than elevated\nSerum levels of thymidine \nkinaseNormal better than elevated\nCD38 expression Negative good, high poor\nCytogenetic abnormality 13q del: good,\n11q del: intermediate,\ndel 17p: poor\nMedian o S: 13q- =133m,\n11q del (+) = 79 mon,\n17 p del (+) = 72 mon\nMutation of IgVH gene Unmutated poor (median OS 84 months, \nand PFS 68 months);\nmutated good (median OS not reached,"
        ]
    },
    {
        "answer": "The description of cells with hyperlobated nuclei appearing like clovers in the peripheral blood of a 47-year-old Jamaican man with an elevated lymphocyte count is consistent with the \"flower cells\" found in Adult T-cell Leukemia/Lymphoma (ATLL). ATLL is a PTCL subtype that is caused by the Human T-cell Leukemia Virus Type 1 (HTLV-1). This pathogen is typically associated with ATLL. It is important to note that ATLL is endemic in certain regions, including the Caribbean, Japan, and parts of Africa. Therefore, it is crucial to consider ATLL in the differential diagnosis for this patient.",
        "sources": [
            "1969 Adult\tT-Cell \tLeukemia/Lymphoma \t•\tCHAPTER\t105\t\nB\nC\nA\nFigure 105.2  • (A to C) Leukemic cells (the so-called flower cells) showing \ncharacteristic polymorphic nuclei in a peripheral blood smear from a patient \nwith acute-type adult T-cell leukemia/lymphoma. \nFigure 105.3  • Histology of a swollen lymph node from a patient with \nlymphoma-type adult T-cell leukemia/lymphoma showing diffuse non-Hodgkin lymphoma of the pleomorphic type. Lymphoma cells of various sizes—small \ncells, medium-size cells, large cells, and giant cells—are present. Nuclear polymorphism is present in most lymphoma cells. \nlarge-cell lymphoma (ALCL); angioimmunoblastic T-cell lymphoma \n(AITL); and Hodgkin lymphoma.58,59\nAdult T-cell leukemia/lymphoma frequently involve the skin with \na generalized nodular or papulonodular eruptions (Fig. 105.4A). Erythematous plaque formation and sometimes nodular tumors are other cutaneous manifestations.\n47–49,58,60 Histologically, diffuse or patchy",
            "Lymphomatoid papulosisPrimary cutaneous anaplastic large cell lymphoma\nPrimary cutaneous γδ T-cell lymphoma\nPrimary cutaneous CD8 + aggressive epidermotropic cytotoxic T-cell \nlymphoma\nPrimary cutaneous acral CD8 + T-cell lymphoma\nPrimary cutaneous CD4 + small/medium T-cell lymphoproliferative \ndisorder\nPeripheral T cell lymphoma, NOSAngioimmunoblastic T-cell lymphomaFollicular T-cell lymphomaNodal peripheral T-cell lymphoma with TFH phenotypeAnaplastic large-cell lymphoma, ALK positiveAnaplastic large-cell lymphoma, ALK negativeBreast implant associated anaplastic large-cell lymphoma\nPosttransplant Lymphoproliferative Disorders (PTLDs)\nPlasmacytic hyperplasia PTLDInfectious mononucleosis PTLDFlorid follicular hyperplasia PTLDPolymorphic PTLDMonomorphic PTLD (B- and T/NK-cell types)Classical Hodgkin lymphoma PTLDBox 103.2  WORLD HEALTH ORGANIZATION CLASSIFICATION OF NON-HODGKIN LYMPHOMAS: 2016",
            "Histologic differential diagnosis of ATLL according to the World \nHealth Organization (WHO) classification includes MF/SS, peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS); anaplastic toxoplasmosis can cause masquerade as CNS symptoms. Cutaneous involvement of ATLL occurs in approximately 40%.\n42 Akin to \npneumonic infections, the incidence was highest among patients  \nwith the chronic and smoldering types (48%) and lower for patients with the acute (40%) and lymphoma (25%) subtypes. Patients with \nsmoldering and chronic ATLL can have cutaneous involvement without \nleukemic manifestation, the primary cutaneous tumoral type has been reported as having a poor prognosis.\n47–50\nLABORATORY FINDINGS\nThe clinical subtype of ATLL is also predicated on certain laboratory findings (see Table 105.1).\n42 Leukocytosis is found among patients",
            "sion. Others, such as the centroblastic subtype of lymphoma, occur \nin HIV-infected individuals with relatively preserved CD4 counts \nand only mild immunodeficiency. The Centers for Disease Control and Prevention (CDC) includes a diagnosis of immunoblastic diffuse large B-cell lymphoma, Burkitt lymphoma, and PCNSL in its list of AIDS-defining conditions. The relative proportional distribution of each lymphoma subtype has changed since the introduction of \ncART, and in the current era the most common lymphoma subtype \namong HIV-infected individuals is diffuse large B-cell lymphoma EBV and HHV-8, are involved in lymphoma pathogenesis. EBV is present in more than 30% of all HIV-associated lymphomas. The EBV genome is present in virtually all cases of primary central nervous system lymphoma (PCNSL) and in most cases of diffuse large B-cell lymphomas with immunoblastic features (>80%), primary effusion lymphoma, plasmablastic oral lymphoma, and Hodgkin lymphoma.",
            "with Sjögren syndrome and autoimmune thyroiditis, respectively.\n12 \nUncommon T-cell lymphomas may also occur in the setting of chronic \nantigen stimulation, including enteropathy-associated T-cell lymphoma (EATCL) in the setting of celiac disease, and breast implant–associated \nanaplastic large cell lymphoma (ALCL).\n13,14\nThe role of chronic immune stimulation is also well established \nin MALT lymphomas, in which the most common site in the stomach \nis associated with H. pylori  infection in approximately 80% of cases.15,16 \nOther infection-associated marginal zone lymphomas include those affecting the ocular adnexae (Chlamydia psittaci) , skin (Borrelia afzelli) , \nand small bowel (Campylobacter jejuni), as well as splenic marginal \nzone lymphoma in association hepatitis C.\n17-20 Remarkably, most gastric lymphomas, including autoimmune diseases and certain infectious \npathogens such as HIV, Epstein-Barr virus (EBV), hepatitis viruses, Helicobacter pylori, and others.",
            "may be an appealing option for relapsed younger patients who had \npreviously undergone ASCT but must be considered carefully given the risk of treatment related morbidity and mortality and availability of effective novel agents.\n212 An additional targeted therapy, the BCL2 \ninhibitor venetoclax, has shown significant clinical activity in relapsed MCL patients enrolled in a phase I study of NHL and is likely to emerge as a future treatment options as well.\n211-213\nPeripheral T-Cell Lymphomas\nLymphomas of T-cell/NK-cell derivation arise from postthymic mature T cells and are collectively known as (PTCL). As a class, PTCLs are an uncommon and heterogeneous group of lymphomas that account for approximately 10% of all NHLs in Western countries.\n3 They are \ndistributed over multiple different subtypes, all of which are infrequent, and are not as well studied as the B-cell lymphomas. In most cases, PTCLs are clinically aggressive except for a subset of cutaneous disorders",
            "opment. EBV latent membrane protein-1 (LMP-1) is expressed \nin NPC and induces NF-κB, and consequently cell proliferation. \nEpidemiological data indicate that consumption of large quantities \nof salted fish (e.g., in South East China) is a co-factor.\nHodgkin disease (HD)\nThe finding of clonal EBV genomes in Reed–Sternberg cells and the \nrestricted pattern of latent viral gene expression in nearly 30–50% \nof all HD cases suggest that EBV is not simply a passenger in HD. \nA positive association between a history of infectious mononucleo -\nsis and subsequent HD further supports a causal role.\nPost-transplant lymphoproliferative \ndisorder (PTLD)\nPTLD represents one of the most common complications of immu -\nnosuppression following organ transplantation. Predisposing \nfactors include primary EBV infection at or postdating transplan -\ntation, and high cumulative doses of immunosuppressive drugs."
        ]
    },
    {
        "answer": "The appropriate next step in this case would be to monitor the residual mass with imaging, as it is not uncommon for residual masses to be present after treatment for lymphoma. The NCCN guidelines recommend that for patients being followed with imaging in complete remission to assess for early recurrence, CT scans alone are preferred to PET/CT. The exact timing and schedule of such scans is currently best made on an individual basis. In aggressive histologies treated for curative intent, routine CT imaging should be performed no more frequently than every 6 months for up to 2 years. Indolent histologies at ongoing risk of recurrence may be re-imaged no more than once annually in the absence of signs or symptoms concerning.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore, it may be worth considering radiation therapy as an option if the residual mass does not decrease in size over time. However, this decision should be made in consultation with an oncologist and taking into account the patient's individual circumstances and preferences.\n\nIt is also important to note that, although the patient received six cycles of DA-EPOCH-P, the text states that \"DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\" Therefore",
        "sources": [
            "and functional imaging are abnormal [280, 281].\nPrimary mediastinal B-cell lymphoma\nPrimary mediastinal DLBCL is a distinct clinicopathologic entity \ntypically presenting as a large mediastinal mass in a young patients. \nBecause of the young age of affected patients and the recognized \ndelayed toxicity of mediastinal RT, its role has been controversial \n[282]. Non-randomized retrospective studies have demonstrated \nsuperior PFS and OS among patients receiving combined modal -\nity therapy compared to chemotherapy alone. Todeschini et al., for \nexample, reported that among 138 patients with PMBL five-year \nOS was 90% among those receiving RT compared to 78% without \n(p = 0.04) [283]. More recently, Xu et al. evaluated 79 patients with \nPMBL who received CHOP chemotherapy with (n = 39) or with -\nout rituximab (n = 40), and 60 patients received additional radio -\ntherapy, and found OS and PFS rates for early-stage patients were",
            "Part\tIII:\tSpecific \tMalignancies 1924Part\tIII:\tSpecific \tMalignancies\nNetwork, and the US Preventative Services Task Force.140,141 Evaluations \nof second malignancy risk in HL survivors should also take into account \nfamily history, details of the treatment, environmental factors such as smoking, and comorbid conditions, particularly diabetes, hypertension, \nand hypercholesterolemia. Annual breast screening is recommended \nin all women treated with mediastinal or axillary RT beginning 7 to 10 years after treatment, and in those treated between ages 10 and 30 years, annual breast magnetic resonance imaging should be done in conjunction with annual mammography.\n142,143 HL survivors who \nare current or former smokers and were treated with RT or alkylating agents should consider annual low-dose spiral chest CT starting 5 years after treatment for patients receiving alkylating agents and 10 years \nafter treatment for patients who received supradiaphragmatic RT.\n141",
            "with PMBCL uniformly treated with six cycles of DA-EPOCH-R \n(dose adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), 97% and 93% are alive and event free at a median 5 years of follow-up, respectively; only two patients required radiation treatment, and no patient experienced relapse.\n151 These data \nsuggest that DA-EPOCH-R carries a low rate of primary induction failure and appears to obviate the need for irradiation in most patients with PMBCL.\nBurkitt Lymphoma\nBurkitt lymphoma is a highly aggressive B-cell lymphoma that accounts for approximately 3% of all newly diagnosed NHLs in the United States. Historically, BL carries the distinction of being the first cancer found to be associated with a virus (EBV) and one of",
            "mediastinal large B-cell subtype of pediatric NHL. The addition of an immunotherapeutic competent is a consideration. In this regard, the activity of the DA-EPOCH-R regimen\n294 that incorporates \nrituximab (anti-CD20) into a backbone of more conventional agents delivered in a prolonged infusional fashion is currently being studied in children. In this regard, the BFM reported preliminary results from \nits pilot study of DA-EPOCH-R, in which the anthracycline dosage \nwas capped.\n295 The international B-NHL study included an arm for B-cell immunophenotype had a better outcome than did those with a non–B-cell immunophenotype—a finding which suggested that \nimmunophenotype-directed therapies for pediatric large-cell lymphomas \nshould be further pursued.\n266 In this regard, European trials for children \nwith large-cell lymphoma have historically assigned treatment on the basis of immunophenotype (e.g., B cell, T cell, CD30 +). Currently,",
            "Part\tIII:\tSpecific \tMalignancies 1946Part\tIII:\tSpecific \tMalignancies\nfor relapse. For patients being followed with imaging in complete \nremission to assess for early recurrence, CT scans alone are preferred to PET/CT.\nThe complete reference list is available online at  \nExpertConsult.com.ordered as part of the routine assessment of patients who have undergone treatment for lymphoma. The exact timing and schedule of such scans is currently best made on an individual basis. In aggressive histologies treated for curative intent, routine CT imaging should be performed \nno more frequently than every 6 months for up 2 years. Indolent \nhistologies at ongoing risk of recurrence may be re-imaged no more than once annually in the absence of signs or symptoms concerning \nKEY REFERENCES\n3. V ose J, Armitage J, Weisenburger D. International \nperipheral T-cell and natural killer/T-cell lymphoma \nstudy: pathology findings and clinical outcomes. J \nClin Oncol. 2008;26:4124–4130.",
            "High-dose MTX-based chemotherapy\n± rituximab ± consolidation with high-\ndose chemotherapy if PR or CR after\ninduction;\nWBRT only if not a candidate for\nsystemic therapy\nDA-EPOCH ± bortezomib or high-dose\nregimen such as CODOX-M/IVAC or\nHyperCVAD plus rituximab if CD20-\npositive ± consolidation with high-\ndose chemotherapy and stem cell\nrescue\nOptimal therapy not defined.\nCommonly used regimens include DA-\nEPOCH or CHOP ± KSHV-targeted\nantiviral therapy\nLow risk (stage I AND normal LDH AND\nmass size <10 cm) or completely\nresected single abdominal mass with\nnormal LDH post-surgery:\n3 cycles of modified R-CODOX-M or\n≥3 cycles DA-EPOOCH-R (1 cycle after\nCR) or HyperCVAD\nHigh-risk patients (all other):\nHigh-dose multiagent chemotherapy\n(i.e., modified R-CODOX-M/IVAC or R-\nHyperCVAD), or DA-EPOCH-RPrimary CNS lymphoma\nPlasmablastic lymphoma\nPrimary effusion lymphoma\nBurkitt lymphomaNon-Hodgkin Lymphoma\nB\nFigure 62.2, cont’d",
            "A general guideline for follow-up after initial therapy involves visits \nevery 3 months for 2 years, every 6 months for 3 years, and annually thereafter. During these visits, examination of the lymph node areas, abdomen, thyroid, and skin is important. Routine laboratory studies with blood cell counts, liver function tests, and determination of LDH level should be performed. The thyroid-stimulating hormone \nlevel should be monitored annually in patients who received neck \nirradiation. Mammography for women who received radiation to breast tissue should begin 10 years from treatment of lymphoma, or at age 40 years, whichever comes first. For patients who received mediastinal radiation, stress testing can be considered 8 to 10 years after completion of therapy to assess for occult coronary artery disease. Patients should \nbe immunized against influenza yearly and against pneumococcus."
        ]
    },
    {
        "answer": "Based on the information provided, the patient is a 69-year-old male diagnosed with diffuse large B-cell lymphoma (DLBCL) and has a history of hepatitis B infection, as indicated by the positive hepatitis core antibody and negative hepatitis B surface antigen and PCR viral load.\n\nWhen treating patients with a history of hepatitis B infection with rituximab therapy, it is important to monitor for hepatitis B reactivation, which can occur in up to 50% of patients with resolved hepatitis B infection. Hepatitis B reactivation can lead to severe liver damage and even liver failure.\n\nTherefore, it is recommended to:\n\n1. Initiate antiviral prophylaxis with an agent such as entecavir or tenofovir before starting rituximab therapy.\n2. Monitor hepatitis B viral load and liver function tests (LFTs) before starting rituximab therapy, every 3 months during therapy, and for at least 12 months after completing therapy.\n3. If hepatitis B viral load becomes detectable or LFTs show abnormalities, consider increasing the dose or changing the antiviral agent.\n4. Monitor for signs and symptoms of hepatitis B reactivation, such as jaundice, dark urine, and abdominal pain.\n5. Ensure that the patient is aware of the risk of hepatitis B reactivation and the importance of monitoring and adherence to antiviral therapy.\n\nRegarding the treatment of DLBCL, the standard of care is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy. The patient's hepatitis B status should not affect the choice of chemotherapy regimen, but it is important to monitor for and manage hepatitis B reactivation as described above.",
        "sources": [
            "patients and is associated with excellent outcomes.\n114ifosfamide, etoposide, and high-dose cytarabine)–rituximab regimen \nand the less toxic EPOCH-rituximab regimen is feasible, with 2-year overall survival rates of 69% and 83%, respectively.\n78,79\nPrimary Effusion Lymphoma\nPrimary effusion lymphoma accounts for less than 5% of all HIV-associated lymphomas and usually manifests with CD20-negative lymphomatous effusions involving one or more body cavities or extracavitary disease.\n80,81 Systemic chemotherapy such as CHOP \nproduces complete response in up to 50% of patients, although recurrence is common, and median survival is about 6 months.\n82,83 \nChemotherapy intensification does not improve outcome.84,85 Several \nreports have indicated that antiviral therapy aimed at HHV-8 replication might be beneficial.\n86–91\nPlasmablastic Lymphoma",
            "count, and a high degree of monitoring should be provided to all \npatients during the first one to two infusion events of rituximab. Patients with preexisting thrombocytopenia should therefore have a posttherapy platelet count taken after the first one or two doses of rituximab. Another uncommon, but potentially severe, toxicity is a tumor lysis syndrome, which is generally observed in patients with a \nhigh circulating peripheral lymphocyte count with CLL variants. Such \npatients should receive prophylactic allopurinol, hydration, and careful observation; and inpatient monitoring and administration of rituximab can be considered for the highest-risk patients. Other rare toxicities with rituximab therapy include delayed neutropenia, hepatitis B reactivation, skin toxicity, interstitial pneumonitis, and serum sickness. \nPatients with prior hepatitis B exposure should receive prophylaxis or \nclose monitoring for viral reactivation.\n165 Patients who experience",
            "should have an HCV serology checked at baseline. In patients with \nactive HCV infection, treatment of the HCV alone leads to remissions in the majority of patients.\n97 Non–HCV-infected patients may be \nobserved if they are asymptomatic without massive splenomegaly or cytopenias. Patients in need of therapy may be successfully treated with either splenectomy, or rituximab monotherapy.\n98\nLymphoplasmacytic Lymphoma or Waldenström \nMacroglobulinemia\nLymphoplasmacytic lymphoma is an indolent B-cell lymphoma with \nplasmacytic differentiation that is usually associated with a significant IgM paraprotein. The syndrome of LPL with high IgM paraprotein is known as Waldenström macroglobulinemia (WM). The underlying \ngenetic defect in WM appears to be the MYD88 L265P mutation, \nwhich can help differentiate it from morphologically similar entities such as marginal zone lymphoma, and creates a rationale for targeted therapy.\n99 Symptoms related to LPL may be caused by adenopathy,",
            "involves a combination of chemotherapy and immunotherapy such \nas rituximab. For IPSID, early-stage disease is treated with antibiotics. Chemotherapy and radiation are used for later stages. Diffuse large B-cell lymphoma (DLBCL) is treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Enteropathy-associated T-cell disease is treated with combination \nchemotherapy. Primary intestinal follicular lymphoma is a diffuse \nindolent disease that rarely requires surgical intervention and has been successfully treated with a variety of modalities: watch and wait, radiation, rituximab, and chemotherapy.\n49 Mantle cell and Burkett \nlymphoma are treated with chemotherapy.\nGastrointestinal Sarcomas\nSarcomas of the GI tract are malignant mesenchymal tumors, of which GISTs are the most common, making up about 10% of small bowel neoplasms. Before the understanding of the unique molecular char -",
            "The next major advance was the development of the anti-CD20 \nmonoclonal antibody rituximab, which would make a powerful and durable impact on the management of B-cell lymphomas. The first large study to demonstrate the benefit of rituximab was a Groupe d’Études des Lymphomes de l’Adulte (GELA) phase 3 study, in which intravascular large B-cell lymphoma; primary DLBCL of the CNS (PCNSL); primary cutaneous DLBCL, leg type; EBV-positive DLBCL \nNOS; DLBCL associated with chronic inflammation; ALK + large \nB-cell lymphoma; PBL; PEL; and large B-cell lymphoma arising in \nHHV-8–associated multicentric Castleman disease (see Table 103.3).\n27 \nThese entities are considered distinct subtypes of DLBCL based on a combination of clinical, histologic, and molecular findings.\nPathogenesis\nGenome-wide molecular profiling has revealed three subtypes of DLBCL that differ in genetic makeup but may be indistinguishable on morphologic grounds alone: the ABC subtype, the GCB subtype, and PMBCL.",
            "but severe renal insufficiency is uncommon. Therapy should target \nunderlying hepatitis C infection with interferon-α2 and ribavirin. Rituximab may be effective regardless of presence or absence of hepatitis C infection.\n344,345 Agents such as rituximab, corticosteroids, and/or \ncyclophosphamide are used if there is no response.346 Plasmapheresis \nis helpful in the acute management of symptoms by removing circulating immune complexes.\n347\nType III Cryoglobulinemia\nType III (polyclonal) cryoglobulinemia does not have a monoclonal component and is not associated with a clonal plasma cell proliferative disorder. Type III cryoglobulins are found in many patients with infections or inflammatory diseases and are usually of no clinical \nsignificance unless associated with hepatitis C infection.\nThe complete reference list is available online at  \nExpertConsult.com.electrophoretic pattern is usually normal except for hypogammaglobu -",
            "T-cell lymphoma. Blood . 2015;126(12):1452–1461.\n248. Fenot M, Quereux G, Brocard A, et  al. Rituximab for \nprimary cutaneous diffuse large B-cell lymphoma-leg \ntype. Eur J Dermatol . 2010;20:753–757."
        ]
    },
    {
        "answer": "Based on the patient's presentation of an enlarging cervical lymph node, night sweats, and significant weight loss, as well as the biopsy results showing effacement of nodal architecture with lymphoid proliferation and neoplastic cells expressing CD20, CD10, BCL2 60%, MYC >50%, BCL6 but not expressing MUM1, and a high Ki67 proliferation fraction, the patient is likely to have a high-grade B-cell lymphoma, possibly diffuse large B-cell lymphoma (DLBCL) or Burkitt lymphoma.\n\nTo make a definitive diagnosis and determine therapy, additional testing is required:\n\n1. Fluorescence in situ hybridization (FISH) analysis for MYC rearrangement to confirm Burkitt lymphoma or DLBCL with MYC translocation.\n2. Computed tomography (CT) evaluation of the chest, abdomen, and pelvis to assess the extent of disease.\n3. Positron emission tomography (PET) scan to evaluate for metabolic activity and identify any additional sites of disease.\n4. Bone marrow biopsy to evaluate for bone marrow involvement.\n5. Complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), and lactate dehydrogenase (LDH) to assess the patient's overall health and disease burden.\n\nOnce the diagnosis is confirmed and the extent of disease is evaluated, therapy can be determined. For high-grade B-cell lymphomas, such as DLBCL or Burkitt lymphoma, treatment typically involves intensive chemotherapy regimens, such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), with or without radiation therapy, depending on the stage and location of the disease.\n\nIt is important to note that this is a general treatment approach and the specific treatment plan should be individualized based on the patient's age, overall health, and specific disease characteristics. The patient should be managed by a multidisciplinary team, including oncology, radiation oncology, and dermatology, if necessary.",
        "sources": [
            "phadenopathy, organomegaly (especially splenomegaly and hepa -\ntomegaly), and B-symptoms (defined by weight loss >10% within \nsix months, night sweats defined by the need to change pyjamas, \nand fever defined as increased temperatures above 38 °C). Elevated \nserum markers, reflecting a high cell-cycle turnover of malig -\nnant cells, such as serum lactate dehydrogenase (LDH), uric acid, \nβ2-microglobulin (β2M), or soluble interleukin-2 receptor (sIL-2R) \nmay be measured. These are most prominent in patients diagnosed \nwith DLBCL, Burkitt lymphoma, T-cell lymphomas, MCL, or B- \nand T-lymphoblastic lymphoma/leukaemia. In contrast, indolent \nlymphomas have usually slow-progressing lymphadenopathy or \norganomegaly and only modest serum marker elevations. The most \nfrequent lymphomas in this category are FL, CLL/SLL, and MZL.\nPossible oncologic emergencies amongst malignant lymphomas \nwhich might be present at initial diagnosis but can also occur or",
            "Inguinal lymph nodes, treatment, 1439fInguinal lymphadenopathy\ndiagnostic finding, 1436treatment, 1438–1439\nInguinal metastasis, excision, 1438\nInguinofemoral lymph nodes, clinically occult \nmetastasis (probability), 1497t\nInguinofemoral nodes, clinical assessment, 1492tInherited cancer predisposition, syndromes, 181t\nInherited colorectal cancer syndromes, 1222–1224Inherited mutations, impact of , 1054\nInherited thrombophilia, 525Initial therapy, of adult T-cell leukemia/lymphoma \n(ATLL), 1972\nINK4 family , 58–59\nInnovation Center , 321\nInotuzumab ozogamicin, 487t–488t\nINRGSS. see International Neuroblastoma Risk Group \nStaging System\nInsertions and deletions (indels), 291INSS. see International Neuroblastoma Staging System\nInstrumental activities of daily living (IADLs), 875\nInsulin, 32, 132–133\nInsulin-like growth factor 1, 132–133\nInsulin-like growth factor-1 receptor signaling, 32Insulin-like growth factor 2, 132–133\nInsulinoma, 1101\nIntact breast, irradiation of , 1584–1585, 1584",
            "or\tpost–germinal\t center–activated\t B\t\ncells\twith\tconstitutive\t nuclear\t\nfactor- κB\tpathway\tactivation\t and\t\nstrong\texpression\t of\tthe\tIRF4/MUM1\t\ntranscription\t factor\tand\tcarries\ta\t\nworse\tprognosis.\nStaging Evaluation\n•\tPatients\t with\tcutaneous\t lymphomas\t\nare\tbest\tevaluated\t and\tco-managed\t\nby\ta\tmultidisciplinary\t team\tincluding\t\ndermatology\t and\tdermatopathology\t\nplus\toncology\t and\tradiation\t\noncology\t for\tadvanced\t patients.\n•\tBaseline\t evaluation\t includes\ta\t\ncomplete\t physical\texamination,\t\ncomplete\t blood\tcell\tcount\twith\t\ndifferential,\t chemistry\t panel\twith\t\nlactate\tdehydrogenase\t level,\tas\twell\t\nas\tuntreated\t skin\tbiopsy\tfor\t\nhistology,\t immunophenotyping,\t and\t\nT\tcell\tgene\trearrangements.\t Low\t\nmagnesium\t and\tvitamin\tD\tlevels\tand\t\nalterations\t in\timmunoglobulins\t may\t\nbe\tobserved.\t A\tlymph\tnode\tcore\tor\t\nexcisional\t biopsy\tshould\tbe\tdone\tif\t\npatients\tpresent\twith\tor\tdevelop\t\nadenopathy.\t Flow\tcytometry\t of\t\nperipheral\t blood\tat\tbaseline\tor\tin",
            "includes BCC, SCC, amelanotic melanoma, lymphoma, and metastatic disease. Histologic and immunohistochemical studies are the key to confirmation of the diagnosis.\nPatients diagnosed with MCC are commonly evaluated with a \ndetailed history, a physical examination performed with emphasis on the skin and lymph nodes, a basic workup, such as complete blood cell count and hepatic and renal function tests, and appropriate imaging tests.\n293,294 In the absence of clinically positive lymph nodes, SLNB \nis strongly recommended in patients with MCC in order to achieve accurate nodal staging, and especially to detect microscopic nodal disease.\n295–298 SLNB revealed nodal positivity in approximately one-third \nof patients whose physical examination findings were otherwise negative.\n295,299–301\nComputed tomography (CT) evaluation of the chest, abdomen,",
            "60\nWithin MCL, a small subset of patients will have an indolent \nnatural history. These patients typically present clinically with sple -\nnomegaly, leukemic phase disease and a normal LDH, and without bulky lymphadenopathy. Immunohistochemically, indolent MCL cases \nusually have a low Ki67 proliferation fraction and lack expression of \nthe protein SOX11.\n48\nQuality of response to frontline therapy also carries important \nprognostic impact. For patients with FL or DLBCL, progression within 2 years of initial chemoimmunotherapy predicts high-risk disease, but patients with lengthy upfront remissions have prognoses similar to \nage-matched control participants without lymphoma.\n61,62\nResponse Assessment\nAccurate assessment of response to therapy is critical for informing \nprognosis and guiding further management. T reatment response should be documented by physical findings and relevant imaging and laboratory studies. End-of-therapy assessment is usually performed 4 to 6 weeks",
            "total)\nPathologic \tlymph \tno de \tif \tshor t \taxis \t>15\tmm\nCR:\tdisapp earance \tof \tall \tk nown \t\ndisease,\tc onfirmed \ta t \t4 \twkCR:\tdisapp earance \tof \tall \ttar get \tlesions ,\t\nconfirmed \ta t \t4 \twkCR:\tdisapp earance \tof \tall \ttar get \tlesions ,\t\nconfirmed \ta t \t4 \twk;\tan y \tpa thologic \tlymph \t\nnode\tmust \tha ve \tr eduction \tin \tshor t \taxis \tt o \t\n<10\tmm\nPR:\t≥50%\tdecr ease \tfr om \tbaseline ,\t\nconfirmed \ta t \t4 \twkPR:\t≥30%\tdecr ease \tfr om \tbaseline ,\t\nconfirmed \ta t \t4 \twkPR:\t≥30%\tdecr ease \tfr om \tbaseline ,\tc onfirmed \t\nat\t4\twk\nPD:\t≥25%\tincr ease, \tnew \tlesion(s),\t\n≥25%\tincr ease \tin \tone \tlesionPD:\t≥20%\tincr ease \to ver \tsmallest \tsum \t\nobserved, \tnew \tlesion(s)PD:\t≥20%\tincr ease \to ver \tsmallest \tsum \t\nobserved, \tnew \tlesion(s)b\nSum\thas\tabsolut e \tincr ease \tof \ta t \tleast \t5 \tmm\nStable\tdisease:\tneither \tPR \tnor \tPD \t\ncriteria\tmetStable\tdisease:\tneither \tPR \tnor \tPD \tcr iteria \t\nmetStable\tdisease:\tneither \tPR \tnor \tPD \tcr iteria \tmet",
            "CLASSIFICATION OF LYMPHOID \nNEOPLASMSTable 64.10  Ann Arbor Staging System for \nLymphoma\nStage Description\nI Single\tlymph \tno de \tr egion \tor \tlymphoid \tstr ucture \t(e .g.,\tspleen \t\nor\tW aldeyer \tr ing)\nII Two\tor\tmor e \tlymph \tno de \tr egions \ton \tthe \tsame \tside \tof \tthe \t\ndiaphragm \tor\tlo calized \tin volvement \tof \tan \te xtranodal \t\nlymphoid \tstr ucture \tand\tof\tone\tor \tmor e \tlymph \tno de \tr egions \t\non\tsame\tside \tof \tdiaphr agm\nIII Lymph\tno des \ton \tb oth \tsides \tof \tdiaphr agm \twith \tor \twithout \t\nextranodal \tsit es\nIV Two\tor\tmor e \te xtranodal \tsit es \tor \tliv er \tor \tb one \tmar row\ntissue should be delivered to the laboratory fresh (without preserva -\ntives) and sterile.446 Current laboratory workup for lymphoma includes \nimmunohistochemistry, flow cytometry, cytogenetics, and molecular \nstudies.444,446 Lesions displaying high mitotic activity are most likely"
        ]
    },
    {
        "answer": "Based on the patient's history and current presentation, she has metastatic renal cell carcinoma (mRCC) with clear cell histology. Given her ECOG performance status of 0 and the absence of symptoms, I would recommend systemic therapy.\n\nThe choice of systemic therapy for mRCC depends on various factors, including patient performance status, risk group, and molecular characteristics of the tumor. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk model can be used to stratify patients into favorable, intermediate, and poor-risk groups based on clinical and laboratory parameters. The patient's history of coronary artery disease and hypertension should also be taken into account when selecting a treatment regimen.\n\nFor patients with clear cell mRCC, vascular endothelial growth factor (VEGF)-targeted therapies, such as sunitinib, pazopanib, or bevacizumab plus interferon-alfa, have been the standard of care for many years. More recently, immune checkpoint inhibitors, such as nivolumab and ipilimumab, have shown promising results in the treatment of mRCC, particularly in combination with VEGF-targeted therapies.\n\nGiven the patient's history of coronary artery disease and hypertension, a VEGF-targeted therapy with a more favorable cardiovascular safety profile, such as pazopanib, may be a reasonable first-line option. The recommended dose of pazopanib is 800 mg orally once daily, and it should be taken on an empty stomach. Common side effects of pazopanib include diarrhea, hypertension, and fatigue.\n\nAlternatively, a combination of a VEGF-targeted therapy and an immune checkpoint inhibitor, such as axitinib plus pembrolizumab or lenvatinib plus pembrolizumab, could be considered. These combinations have shown superior efficacy compared to sunitinib in recent clinical trials, but they are also associated with a higher risk of adverse events.\n\nThe patient should be closely monitored for treatment-related toxicities and response to therapy. Imaging studies, such as CT or MRI, should be performed every 2-3 months to assess treatment response. If the patient experiences disease progression or intolerable side effects, a change in systemic therapy may be necessary.\n\nIn addition to systemic therapy, local treatments, such as liver-directed therapies (e.g., radiofrequency ablation, microwave ablation, or stereotactic body radiotherapy) or metastasectomy, may be considered for selected patients with oligometastatic disease. However, the role of these treatments in the management of mRCC is still being evaluated in clinical trials.\n\nOverall, the treatment of mRCC is complex and requires a multidisciplinary approach. The patient should be referred to a medical oncologist with expertise in the management of kidney cancer for further evaluation and treatment.",
        "sources": [
            "lenged by recent studies suggesting that negative CT imaging of the ipsilateral adrenal gland can effectively rule out RCC involvement.\n67 \nAlthough still controversial, in the setting of negative cross-sectional imaging, adrenal gland preservation should be considered to avoid long-term risk of Addisonian crisis.\nThe role of regional lymphadenectomy at the time of radical \nnephrectomy is also controversial. The most common regional landing sites for RCC are the paracaval, interaortocaval, and retrocaval nodes for the right kidney, and the paraaortic, interaortocaval, and preaortic nodes for the left kidney. In the presence of radiographic or palpable lymphadenopathy, a lymph node dissection is justified. In the absence \nof such findings, the role of lymphadenectomy is prognostic only,",
            "three clinical groups: patients with a known malignancy ( n = 55), \npatients with no known malignancy and suspected unresectable tumor \n(n = 36), and nonsurgical patients with a mass suspected to be a \nresectable RCC ( n = 8).\n51 Percutaneous biopsy of renal masses appears \nto be safe, carrying only a minimal risk of tumor spread. Urologists should consider increasing the indications for renal biopsy of small renal masses that appear to be RCC, especially in elderly and surgically \nunfit patients. Percutaneous biopsy also may allow better selection of \nrenal tumors for active surveillance and minimally invasive ablative therapies. However, there are certain histologic subtypes that cannot be easily distinguished with percutaneous biopsy. Oncocytoma, for instance, can be diagnosed only by resection, as rarely clear cell car -\ncinoma may harbor regions of oncocytic cells, which are indistinguish -",
            "1 \nOther kidney tumors of benign histologic type include oncocytomas, angiomyolipomas (AMLs), fibromas, lipomas, lymphangiomas, and hemangiomas.\nRCC exists in sporadic and hereditary forms. The sporadic form \nof the disease is usually first seen in the fifth decade of life or later. The clinical presentation of RCC has been described with the classic triad of symptoms of hematuria, flank pain, and fever. With the increased general use of imaging techniques, however, the vast majority of kidney tumors are now being detected incidentally. Improved surgical \ntechniques for treatment of localized disease and novel systemic therapies \nfor metastatic renal cell carcinoma (mRCC) have changed the manage -\nment of this condition.SUMMARY OF KEY POINTS\n•\tRenal\tcell \tcarcinoma \t(RCC) \taccounts \t\nfor\t4%\tto \t5% \tof \tmalignancies \tin \t\nadults.\n•\tCigarette \tsmoking \t(in \tmore \tthan \t\n20%\tof\tcases) \tand \tobesity \t(in \tmore \t\nthan\t30%) \tare \testablished \tcausal \t\nfactors\tfor \tRCC.",
            "1381.e1Cancer\tof\tthe\tKidney\t•\tCHAPTER\t79\t\nREFERENCES\n1. Siegel RL, et al. Cancer Statistics 2018. CA Cancer \nJ Clin . 2018 Jan;68(1):7–30. PMID: 29313949.\n2. Cho E, et al. Epidemiology of renal cell cancer. \nHematol Oncol Clin North Am . 2011;25(4):651–665. \nPMID: 21763961.\n3. Gandaglia G, et al. Contemporary incidence and \nmortality rates of kidney cancer in the United States. \nCan Urol Assoc J . 2014;8(7–8):247–252. PMID: \n25210548.\n4. Chow WH, et al. Rising incidence of renal cell \ncancer in the United States. JAMA . 1999;281(17):  \n1628–1631.\n5. Hollingsworth JM, et al. Rising incidence of small \nrenal masses: a need to reassess treatment effect.  \nJ Natl Cancer Inst . 2006;98(18):1331–1334.\n6. Cumberbatch MG. The role of tobacco smoke in \nbladder and kidney carcinogenesis: a comparison \nof exposures and meta-analysis of incidence and \nmortality risks. Eur Urol . 2016;70(3):458–466. \nPMID: 26149669.\n7. Tsivian M. Cigarette smoking is associated with",
            "pathology of , 1062\npatient evaluation of , 1062\nprevention of , 1062\nprimary therapy for , 1062\nspread, pathways of , 1062\nstaging of , 1062\nKerr, John, 74\nKetoconazole (Nizoral), 419.e1t–419.e44t\nKetogenic diet, cancer metabolism and, 137a-ketoglutarate (aKG), 128–129\nKEYNOTE-012 study , 1209\nKhorana Risk Model, 532\nKidney cancer , 278–279, 280f, 1361–1381\nCT for , 278\nepidemiology of , 1361\nrenal masses in, evaluation of , 278\ntreatment, nonconventional histologic features,  \n1380\nKidneys\nhypercalcemia, impact, 567radical nephrectomy, requirement, 1368\nKinases, activity of , 57\nKinesins, 60Kinetochore\nposition, 60\nscaffold proteins, 67\nKIT, 32–33\nCD117, 1037\nin gastrointestinal stromal tumor (GIST), \n244–245\nin melanoma, 249–250\ngene, 32–33\nusage of , 1044\nKIT TKR gene, in gastrointestinal stromal tumor \n(GIST), 244–245\nKlatskin tumor , 1333\nKnowledge, updating of, Bayesian approach and, 288\nKnudson’s two-hit hypothesis revised, 218f\nKRAS gene\nin colorectal cancer , 1237–1238",
            "•\tAn\tasymptomatic\t abdominal\t mass\tis\t\nfound\tin\tmost\tpatients.\n•\tOther\tcharacteristic\t features\tinclude\t\nabdominal\t pain,\thematuria,\t\nhypertension,\t and\tcongenital\t\nanomalies\t (genitourinary\t\nmalformations,\t aniridia,\tand\t\nhemihypertrophy).\n•\tNeuroblastoma\t is\tthe\tmain\t\nconsideration\t in\tthe\tdifferential\t\ndiagnosis.\n•\tOther\ttumors\tto\tbe\texcluded\t are\t\nrenal\tneoplasms\t (clear\tcell\tsarcoma,\t\nrhabdoid\t tumor,\tcongenital\t\nmesoblastic\t nephroma,\t renal\tcell\t\ncarcinoma).\n•\tBenign\t renal\tprocesses\t (nephrogenic\t\nrests,\tmulticystic\t or\tpolycystic\t\nkidneys,\thydronephrosis,\t renal\t\ncarbuncles,\t hemorrhage)\t also\tshould\t\nbe\truled\tout.\n•\tEvaluation\t begins\twith\tcomplete\t\nhistory\tand\tphysical\texamination,\t\nwith\tcareful\tattention\t to\tblood\t\npressure\t and\tassessment\t for\t\nassociated\t congenital\t anomalies.\n•\tOther\tcomponents\t of\tthe\tstaging\t\nevaluation\t include\tCBC,\tserum\t\nchemistry\t analysis,\t urinalysis,\t\nabdominal\t ultrasonography,\t\nabdominal\t or\tpelvic\tcomputed\t\ntomography\t (CT)\tor\tmagnetic",
            "•\tPregnancy-related\t complications\t in\t\nadulthood\t have\toccurred\t in\tgirls\twho\t\nreceive\tflank\tirradiation.\n•\tA\tsecond\tmalignant\t neoplasm\t also\t\nmay\tdevelop\t(6.7%\tcumulative\t\nincidence\t of\tsolid\tmalignancies\t at\t\nage\t40\tyears).\n•\tWith\t favorable\thistology,\t outcomes\t\ninclude\t85%\t4-year\trelapse-free\t\nsurvival\trate\tand\t90%\t4-year\tOS\t\nrate.\n•\tWith\t anaplastic \thistology,\t outcomes\t\ninclude\t50%\t4-year\trelapse-free\t\nsurvival\trate\tand\t50%\t4-year\tOS\t\nrate.\nRenal Cell Carcinoma\n•\tThe\tincidence\t of\trenal\tcell\tcarcinoma\t\nis\t7\tcases\tper\t10\tmillion\tpopulation\t\nper\tyear\tamong\tchildren\tyounger\t\nthan\t20\tyears\tof\tage.\n•\tMean\tage\tat\tdiagnosis\t in\tpediatric\t\nseries\tis\t9\tyears.\n•\tOther\trenal\ttumors\tof\tchildhood,\t\nprimarily\tWilms\ttumor,\tshould\tbe\t\nruled\tout.\n•\tStaging\t evaluation\t includes\ta\t\ncomplete\t history\tand\tphysical\t\nexamination,\t CBC,\tserum\tchemistry\t\nanalysis,\t and\timaging\tstudies\tof\tthe\t\nabdomen,\t pelvis,\tand\tchest.\n•\tNephrectomy\t of\tthe\tinvolved\tkidney\t\nconstitutes\t definitive\t therapy\tfor"
        ]
    },
    {
        "answer": "Based on the patient's history of multiple spontaneous pneumothoraces, a family history of lung-related issues, and the diagnosis of chromophobe renal cell carcinoma, the most likely gene mutation associated with this patient's condition is the Birt-Hogg-Dube (BHD) syndrome, caused by a mutation in the FLCN gene (BHD) on chromosome 17p11.2. BHD syndrome is characterized by the development of fibrofolliculomas, lung cysts, and an increased risk of renal cancer, particularly chromophobe and hybrid oncocytic tumors.\n\nThe patient's history of spontaneous pneumothoraces and the family history of lung-related issues are key indicators of BHD syndrome. The development of chromophobe renal cell carcinoma further supports this diagnosis. Although the patient is a former smoker, the presence of multiple spontaneous pneumothoraces and the family history of lung-related issues suggest that the lung cysts associated with BHD syndrome, rather than smoking, are the primary cause of the patient's lung issues.\n\nIt is important to note that the patient's colon cancer history is unclear, and there may be genotype-phenotype correlations in BHD syndrome. Therefore, further genetic testing and evaluation may be necessary to confirm the diagnosis and assess the patient's risk for other associated conditions.\n\nIn terms of treatment, the patient has already undergone a right radical nephrectomy for the chromophobe renal cell carcinoma. For BHD syndrome, management typically involves dermatologic care for fibrofolliculomas, imaging and surgical management (nephron-sparing) for renal tumors, and monitoring for lung cysts and potential pneumothoraces. The patient should also consider colon cancer screening due to the unclear history and potential risk associated with BHD syndrome.",
        "sources": [
            "10.\n2Kay, F.U. and Pedrosa, I. (2018). Imaging of solid renal masses. Urol. Clin. North\nAm.45: 311–330.\n3Shuch, B., Vourganti, S., Ricketts, C.J. et al. (2014). Defining early-onset kid-\nney cancer: implications for germline and somatic mutation testing and clinicalmanagement. J. Clin. Oncol. 32 (5): 431–437.\n4Choyke, P.L., Glenn, G.M., Walther, M.M. et al. (2003). Hereditary renal cancers.\nRadiology226 (1): 33–46.\n5Brauch, H., Weirich, G., Hornauer, M.A. et al. (1999). Trichloroethylene exposure\nand specific somatic mutations in patients with renal cell carcinoma. J. Natl.\nCancer Inst. 91 (10): 854–861.\n6Nguyen, K.A., Syed, J.S., Espenschied, C.R. et al. (2017). Advances in the diagno-\nsis of hereditary kidney cancer: initial results of a multigene panel test. Cancer\n123 (22): 4363–4371.\n7Gudbjartsson, T., Jónasdóttir, T.J., Thoroddsen, A. et al. (2002). A population-\nbased familial aggregation analysis indicates genetic contribution in a majority of",
            "1365 Cancer\tof \tthe \tKidney\t•\tCHAPTER\t79\t\nof firm epididymal nodules at physical examination should prompt \nscrotal ultrasonography and with a family history of VHL provides an easy method to confirm the diagnostic suspicion. Endolymphatic sac tumors of the inner ear also may be seen.\nBirt-Hogg-Dube syndrome is a disorder of autosomal dominant \ninheritance. Signs and symptoms usually manifest in the fifth decade of life and include renal tumors and cysts, benign skin tumors (fibrofol -\nliculomas) and pulmonary cysts, which can lead to spontaneous pneumothorax. The renal neoplasms may be multifocal and bilateral tumors and most often have pure chromophobe histologic features \nor a “hybrid” mixture of chromophobe and oncocytoma; infrequently,",
            "35 \nWhereas PTEN has been implicated in a rarer type of hereditary \nchromophobe RCC, its mutation is yet to be identified in the sporadic disease.\n36\nTFE3-Fusion Renal Cell Carcinoma\nAlso known as Xp11 translocation kidney cancer, TFE3-fusion RCC represents less than 1% of all sporadic renal cell cancers. It is the most recently designated histologic subtype of RCC by the WHO. chromophobe RCC, hereditary cancer syndromes, multilocular cystic RCC, collecting duct carcinoma, medullary carcinoma, mucinous tubular and spindle cell carcinoma, neuroblastoma-associated RCC, Xp11.2 translocation–TFE3 carcinoma, and unclassified lesions.\n20,21 \nThe 2016 WHO update to the RCC classification added several other subtypes: hereditary leiomyomatosis and RCC syndrome–associated RCC, succinate dehydrogenase–deficient RCC, tubulocystic RCC, \nacquired cystic disease–associated RCC, and clear cell papillary RCC \n(previously called renal angioadenomatous tumors).\n22 Clear cell",
            "ventional clear cell renal carcinomas,\n386,387 thus demonstrating the \nphenotypic heterogeneity of renal cancer that is unique to this syndrome compared with other hereditary renal cancer predispositions. Chro -\nmophobe and hybrid oncocytic tumors comprise 23% and 67% of \nBHD renal tumors, respectively; clear cell tumors comprise 7% and \noncocytomas comprise 3%, whereas papillary renal cell carcinomas are rarely noted.\n386 Persons with BHD syndrome are at markedly \nincreased risk of spontaneous pneumothoraces. About a third, 64 of 198 (32%), of BHD-affected individuals had a history of a spontaneous pneumothorax.\n388 The syndrome is also associated with a progressive \nflecked chorioretinopathy with constricted visual fields.389 There is an \nassociation with colorectal neoplasia in some families with BHD,390 \nas well as colorectal polyps in up to half of patients with BHD.390,391",
            "233\n9\nKidney Cancer\n9.1 Introduction\nThekidneysareapairoforganslocatedintheabdominalcavity,witheachkidney\nbeingaboutthesizeofaperson’sfist.Thepartoftheurinarytract,thekidneyshelpthebodyprocesswasteasurineandfilterbloodbeforesendingitbacktotheheart.\nThekidneyshavemanycrucialfunctions:\n●Maintainingoverallfluidbalance.\n●Removingextrawaterfromtheblood.\n●Regulatingandfilteringmineralsfromtheblood.\n●Filteringwastematerialsfromfood,medications,andtoxicsubstances.\n●Creatinghormonesthathelpproduceredbloodcells,promotebonehealth,and\nregulatebloodpressure.\n9.2 Genes Associated with Kidney Cancer\nCancer begins when there is a mutation of certain genes within the cells of thisorgan,resultinginanuncontrolledproliferationofcancercells(Figure9.1)thatformatumorinsidethekidney[1–45].Thetwomostcommontypesofkidneycancerare\nrenal cell carcinoma (RCC) and transitional cell carcinoma (TCC), also known as",
            "deficiency—metabolic disorder, profound developmental delay, seizures, fumaric aciduria\nFLCN\n398,477–480\nTumor suppressorDominant inheritanceBirt-Hogg-Dube (BHD) syndrome\nHigh Cutaneous (fibrofolliculomas, trichodiscomas/ angiofibromas, perifollicular fibromas, acrochordons)Pulmonary cystsRenal tumors (oncocytoma, chromophobe, oncocytic hybrid tumors)No consensus at this timeDermatologic careImaging for and surgical management (nephron-sparing) of renal tumorsFibrofolliculomas are specific to BHDLung cysts are multiple and bilateralSpontaneous pneumothoraxRenal tumors are multifocal, bilateral, slow growingOther features: Parotid lesions, oral papules, thyroid lesionsUnclear data regarding colon cancerPossible genotype-phenotype correlations\nKIT (C-Kit)406,481–484\nOncogene",
            "Hereditary leiomyoma RCC 1q42–43 (FH) Type 2 papillary RCC Cutaneous and uterine leiomyomas\nBirt-Hogg-Dube syndrome 17p11.2 (BHD) Chromophobe RCC, oncocytoma, hybrid tumorsSkin lesions, lung cysts\nModified from Prasad SR, Humphrey PA, Catena JR, et  al. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. \nRadiographics. 2006;26:1795–1806."
        ]
    },
    {
        "answer": "Based on the information provided, the patient's disease has progressed despite the current treatment regimen of continuous leuprolide, zoledronic acid, and abiraterone + prednisone. The appearance of new liver lesions on imaging and the rise in PSA level suggest that the patient's cancer has developed resistance to the current therapy.\n\nOne appropriate next therapy for this patient could be enzalutamide, a second-generation androgen receptor inhibitor that has been shown to improve overall survival in men with metastatic castration-resistant prostate cancer (mCRPC). The recommended dose of enzalutamide is 160 mg orally once daily.\n\nAnother option could be radium-223 dichloride (223Ra), a radiopharmaceutical that targets bone metastases and has been shown to improve overall survival in men with mCRPC and bone metastases. The recommended dose of 223Ra is 50 kBq/kg intravenously every 4 weeks for a total of six injections.\n\nIt is important to note that the patient's bone pain has improved with the current therapy, and it is important to continue to manage his bone health. Zoledronic acid can continue to be used for bone health management.\n\nIt is also important to consider that the patient's liver function should be closely monitored during any new therapy, as liver metastases may affect the patient's ability to tolerate certain medications.\n\nIn summary, enzalutamide or radium-223 dichloride could be appropriate next therapies for this patient's progressive disease. Close monitoring of liver function and bone health is also necessary.",
        "sources": [
            "380. James ND, Sydes MR, Clarke NW, et al. Addition \nof docetaxel, zoledronic acid, or both to first-line \nlong-term hormone therapy in prostate cancer \n(STAMPEDE): survival results from an adap -\ntive, multiarm, multistage, platform randomised \ncontrolled trial. Lancet . 2016;387:1163–1177.\n387. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-\nT immunotherapy for castration-resistant prostate \ncancer. N Engl J Med . 2010;363:411–422.\n389. Saad F , Gleason DM, Murray R, et al. Long-term \nefficacy of zoledronic acid for the prevention of \nskeletal complications in patients with metastatic \nhormone-refractory prostate cancer. J Natl Cancer \nInst. 2004;96:879–882.\n390. Fizazi K, Carducci M, Smith M, et al. Denosumab \nversus zoledronic acid for treatment of bone \nmetastases in men with castration-resistant prostate \ncancer: a randomised, double-blind study. Lancet . \n2011;377:813–822.\n393. Smith MR, Egerdie B, Hernandez Toriz N, et al. \nDenosumab in men receiving androgen-deprivation",
            "223Ra was subjected to a randomized, placebo-\ncontrolled, phase III trial (ALSYMPCA).397 This study enrolled \nmen with symptomatic bone-mCRPC who had previously received docetaxel or were considered unfit for docetaxel; participants received treatment with \n223Ra (50  kBq/kg) or placebo giv en in six injections \nat 4-week intervals. Overall survival was superior for the 223Ra treat-\nment arm; grade 3 and 4 adverse events were common (62%), but  \nmanageable.398\nMore recent data for 223Ra comes from a trial ( N = 696) in a \npopulation similar to that accrued in the ALSYMPCA study.399 \nInteresting to note, asymptomatic men were included, as were men receiving concurrent abiraterone, enzalutamide, or denosumab. Findings included acceptable safety and an overall survival of 16 months, similar \nto that seen in ALSYMPCA. Survival was higher in men with normal \nbaseline alkaline phosphatase levels, hemoglobin levels above 10  g/",
            "dronate. Patients treated with zoledronic acid had a better chance of survival, with an improvement in median overall survival period of \n5.5 months compared with patients treated with clodronate ( P = .04).\nProstate cancer\nBisphosphonates have been shown to reduce biochemical markers of \nbone resorption in patients with osteoblastic bone lesions that are associated with advanced prostate cancer. Additionally, several phase 2 studies have assessed bone pain and analgesic use with some benefit \nin these acute end points\n90 However, early, randomized, placebo-\ncontrolled trials of bisphosphonates had failed to demonstrate a sig -\nnificant reduction in skeletal complications from bone metastases in \npatients with advanced prostate cancer.100,101 Despite these somewhat \ndisappointing results with other bisphosphonates, zoledronic acid was investigated in patients with CRPC and bone metastases and showed that the increased potency of this compound translated into improved",
            "358. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone \nin metastatic prostate cancer without previous \nchemotherapy. N Engl J Med . 2013;368:138–  \n148.\n359. de Bono JS, Logothetis CJ, Molina A, et al. Abi -\nraterone and increased survival in metastatic prostate \ncancer. N Engl J Med . 2011;364:1995–2005.\n360. Saad F , Fizazi K, Jinga V, et al. Orteronel plus \nprednisone in patients with chemotherapy-naive \nmetastatic castration-resistant prostate cancer \n(ELM-PC 4): a double-blind, multicentre, phase \n3, randomised, placebo-controlled trial. Lancet Oncol . \n2015;16:338–348.\n361. Fizazi K, Jones R, Oudard S, et al. Phase III, \nrandomized, double-blind, multicenter trial \ncomparing orteronel (TAK-700) plus prednisone \nwith placebo plus prednisone in patients with \nmetastatic castration-resistant prostate cancer that has \nprogressed during or after docetaxel-based therapy: \nELM-PC 5. J Clin Oncol . 2015;33:723–731.\n362. Byar DP , Corle DK. Hormone therapy for prostate",
            "the major systemic treatment target for advanced prostate cancer, with \nnew agents introduced to restrain ongoing androgen receptor activation in castration-resistant disease. Men with CRPC and DNA repair gene defects may benefit from new agents targeting PARP .\nThe complete reference list is available online at  \nExpertConsult.com.For men with prostate cancer bone metastases, a second phase III \ntrial was undertaken, comparing denosumab, given as 120  mg sub -\ncutaneously every 4 weeks, with zoledronic acid, given as 4  mg \nintravenously every 4 weeks.390 The primary end point of the trial \nwas time to first SRE, including pathologic fracture, need for radiation therapy or surgery, and spinal cord compression. At the time of the efficacy analysis, an improvement in time to first SRE for denosumab \nwas evident. There were no differences in overall survival or in",
            "to that seen in ALSYMPCA. Survival was higher in men with normal \nbaseline alkaline phosphatase levels, hemoglobin levels above 10  g/\ndL, good performance status, and an absence of baseline bone pain. \nIn an exploratory analysis, survival was also greater in men receiving concurrent abiraterone or enzalutamide, and in those concurrently receiving denosumab. However, whether the addition of abiraterone",
            "cancer treatment.\nDenosumab, given as 60  mg subcutaneously ev ery 6 months, was \ninitially studied in men receiving ADT for nonmetastatic prostate \ncancer in a randomized, placebo-controlled, phase III trial.393 Deno-\nsumab therapy was associated with increased bone mineralization at all sites, with an increase in the bone mineral density of the lumbar spine of 5.6%, as compared with a loss of 1.0% for placebo treatment. \nMen receiving denosumab along with ADT also had a decreased \nincidence of new vertebral fractures at 36 months (1.5% versus 3.9% with placebo).metastatic (but not nonmetastatic) hormone-sensitive prostate cancer. Chemohormonal therapy may be particularly appropriate for men with high-volume metastatic prostate cancer as defined in the  \nCHAARTED study.\nAR-V7 as a Treatment-Selection Biomarker in \nCastration-Resistant Prostate Cancer\nDeveloping biomarkers to enable selection of optimal therapy (e.g.,"
        ]
    },
    {
        "answer": "Based on the information provided, the patient has metastatic castration-sensitive prostate cancer. The treatment options for metastatic prostate cancer include androgen deprivation therapy (ADT), chemotherapy, and radiation therapy.\n\nGiven the extensive bone metastases, radiation therapy to the sites of bone pain can be considered for palliation. However, this would not be sufficient to control the disease.\n\nADT is the standard of care for metastatic prostate cancer. It can be achieved through surgical castration or medical castration with luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. Bicalutamide, which the patient has already been prescribed, is an anti-androgen that can be used in combination with ADT.\n\nIn addition to ADT, chemotherapy can be considered in patients with metastatic prostate cancer. Docetaxel is the standard first-line chemotherapy in this setting. A phase III clinical trial (CALGB 90401) showed that adding bevacizumab to docetaxel and prednisone did not improve overall survival in men with metastatic castration-resistant prostate cancer.\n\nTherefore, the recommended treatment plan for this patient would be to start ADT with an LHRH agonist or antagonist, continue bicalutamide, and consider adding docetaxel chemotherapy. The dosage and timeline for ADT and chemotherapy should be discussed with the patient and tailored to his individual needs and preferences. Close monitoring of PSA levels and symptoms is necessary to assess treatment response and make any necessary adjustments.",
        "sources": [
            "380. James ND, Sydes MR, Clarke NW, et al. Addition \nof docetaxel, zoledronic acid, or both to first-line \nlong-term hormone therapy in prostate cancer \n(STAMPEDE): survival results from an adap -\ntive, multiarm, multistage, platform randomised \ncontrolled trial. Lancet . 2016;387:1163–1177.\n387. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-\nT immunotherapy for castration-resistant prostate \ncancer. N Engl J Med . 2010;363:411–422.\n389. Saad F , Gleason DM, Murray R, et al. Long-term \nefficacy of zoledronic acid for the prevention of \nskeletal complications in patients with metastatic \nhormone-refractory prostate cancer. J Natl Cancer \nInst. 2004;96:879–882.\n390. Fizazi K, Carducci M, Smith M, et al. Denosumab \nversus zoledronic acid for treatment of bone \nmetastases in men with castration-resistant prostate \ncancer: a randomised, double-blind study. Lancet . \n2011;377:813–822.\n393. Smith MR, Egerdie B, Hernandez Toriz N, et al. \nDenosumab in men receiving androgen-deprivation",
            "Part\tIII:\tSpecific \tMalignancies 1422Part\tIII:\tSpecific \tMalignancies\ncancer and positive surgical margins after prostatectomy treated with \nadjuvant radiation therapy, especially for men younger than 70 years.305 \nIn a second study targeting the same patient population conducted by the Southwest Oncology Group (SWOG), men with prostate cancer who received adjuvant radiation not only had better biochemical and \nlocal control, but also had a better metastasis-free survival and overall \nsurvival.\n306 A trial tested the value of antiandrogen therapy, bicalutamide \nfor 24 months, given along with adjuvant radiation therapy. The findings were reduced prostate cancer metastasis and prostate cancer death attributable to antiandrogen treatment, accompanied by sig -\nnificant gynecomastia.\n307\nUnfortunately, although the available evidence provides a convincing \ncase for adjuvant radiation treatment after prostatectomy, it also clearly shows that not all men benefit from such treatment.",
            "were randomized equally to one of three arms: cabazitaxel 25  mg/\nm2, cabazitaxel 20  mg/m2, or docetaxel 75  mg/m2. The trial failed to \nmeet its primary end point; neither of the cabazitaxel arms produced superior survival to the docetaxel arm (the median overall survival was 24–25 months in all arms). The only secondary end point \nthat favored cabazitaxel was the objective response rate, which was \nsuperior for cabazitaxel 25  mg/m2 compared with docetaxel (42% \nversus 31%). Febrile neutropenia, diarrhea, and hematuria were more \nfrequent in the cabazitaxel 25  mg/m2 arm; peripheral neuropathy, \nankle edema, alopecia, and nail dystrophy were more frequent in \nthe docetaxel 75  mg/m2 arm. Based on this pivotal trial, cabazitaxel \nshould generally not be used as first-line chemotherapy in men with \nmCRPC, and docetaxel remains the chemotherapy standard of choice in  \nthis setting.\nChemohormonal Therapy for Metastatic \nHormone-Sensitive Prostate Cancer",
            "Index 1996\nErectile dysfunction\nmanagement of , 672\nin radical prostatectomy , 666\nEribulin, 1599\nfor metastatic soft tissue sarcoma, 1683\nEribulin mesylate (Halaven), 419.e1t–419.e44t\nErlotinib (Tarceva), 30, 419.e1t–419.e44t, 886\nas approved molecularly targeted agents, 421t–423t\nfor colorectal cancer , 1276–1277\nfor head and neck cancers, 353\nphase III trials, 1147t\nERPs. see Enhanced recovery programs\nERSPC. see European Randomized Study of Screening \nfor Prostate Cancer\nErwinia L-asparaginase, as approved molecularly \ntargeted agents, 421t–423t\nErythema multiforme, 632\ndose reductions in, 632prevention of , 632–633\nprognosis of , 634\nreactive/symptomatic treatment of , 634\nErythematous plaque formation, adult T-cell leukemia/\nlymphoma (ATLL), 1969\nErythrocyte velocity, in vessel diameter , 111–112, 115f\nErythrocytosis (control), interferon-alfa (usage) of , \n1825\nErythrodermic CTCL, classification, 1951tErythroid “snowman”, in myelodysplastic syndromes, \n1806f",
            "Part\tIII:\tSpecific \tMalignancies 1414Part\tIII:\tSpecific \tMalignancies\nbone scan for evaluation of bony metastases are recommended for \nmen with unfavorable intermediate- to high-risk prostate cancer.\nThere is a need for improved imaging of patients with distant \ndisease not detected with conventional imaging techniques, both for \ninitial staging and in the setting of recurrent disease after initial therapy. \nCarbon-11 (11C)–choline PET-CT and various PSMA tracers are being \nevaluated for this purpose.207,208\n“Molecular” Assays for Prognosis\nTissue-based expression assays have been developed to aid in decision making for men with lower-risk prostate cancer in whom active surveil -\nlance versus immediate intervention is being considered, and for risk stratification to guide the need for adjuvant therapy and salvage therapy \nafter initial treatment.\n209,210 There is a need for further stratification \nof risk of disease progression, metastatic disease, and prostate cancer",
            "level above 10  ng/mL.266,267 In this study, men with stage T1 to T3 \nprostate cancer received either radiation therapy to a total dose of \n70 G y administered with conventional radiotherapeutic techniques, or \nto 78  G y with a 3D-CRT approach. Results revealed rates of freedom \nfrom PSA relapse of 64% and 70% at 6 years for the 70-Gy and \n78-Gy groups, respectively. Men with a pretreatment serum PSA level \nabove 10  n g/mL were found to have the most significant benefit from \nradiation dose escalation, with rates of freedom from PSA relapse of 62% for the 78-Gy arm and 43% for the 70-Gy arm. Overall survival was not significantly different between the two radiation doses, but a trend toward an improved rate of freedom from distant metastasis \nwas evident in men treated in the 78-Gy arm, 98% versus 88%  \nat 6 years.\nBrachytherapy\nProstate brachytherapy involves the implantation of radioactive sources",
            "114Jurincic, C.D., Horlbeck, R., and Klippel, K.F. (1991). Combined treatment\n(goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced\nprostate cancer: a randomized study. Semin. Oncol. 18 (suppl 6): 21–25.\n115Crawford, E.D., Eisenberger, M.A., DG, M.L. et al. (1989). A controlled trial of\nleuprolide with and without flutamide in prostatic carcinoma. N .E n g l .J .M e d .\n321: 419–424. Erratum in: N Engl J Med 1989 Nov 16;321(20):1420.\n116Kelly, W.K., Halabi, S., Carducci, M. et al. (2012). Randomized, double-blind,\nplacebo-controlled phase III trial comparing Docetaxel and Prednisone withor without Bevacizumab in men with metastatic castration-resistant prostate\ncancer: CALGB 90401. J. Clin. Oncol. 30: 1534–1540.\n117Skarlos, D.V., Samantas, E., Briassoulis, E. et al. (2001). Randomized compari-\nson of early versus late hyperfractionated thoracic irradiation concurrently with\nchemotherapy in limited disease small-cell lung cancer: a randomized phase II"
        ]
    },
    {
        "answer": "Given the patient's history of metastatic prostate cancer to the bone, his castration-resistant status, and the absence of visceral disease, several treatment options could be considered.\n\n1. Radium-223 dichloride: This alpha-emitting radionuclide selectively targets bone metastases and has been shown to improve overall survival, delay symptomatic skeletal events, and reduce the need for external beam radiation therapy in patients with castration-resistant prostate cancer and bone metastases. The recommended dose is 50 kBq/kg intravenously every 4 weeks for six cycles.\n2. Enzalutamide or apalutamide: These androgen receptor inhibitors have demonstrated improved overall survival and radiographic progression-free survival in patients with castration-resistant prostate cancer. The recommended dose for enzalutamide is 160 mg orally once daily, while apalutamide is given at 240 mg orally once daily.\n3. Chemotherapy with docetaxel: Docetaxel remains the standard of care for first-line chemotherapy in men with metastatic castration-resistant prostate cancer. The recommended dose is 75 mg/m2 intravenously every 3 weeks for six cycles.\n4. Immunotherapy with sipuleucel-T: This autologous cellular immunotherapy is approved for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is given as three intravenous infusions, typically on days 0, 14, and 28.\n5. Participation in a clinical trial: Given the patient's asymptomatic status, he may be a candidate for a clinical trial evaluating novel therapies or combinations of therapies for castration-resistant prostate cancer.\n\nIt is essential to consider the patient's preferences, potential side effects, and the overall goals of care when selecting the most appropriate treatment option. Regular monitoring of PSA levels, imaging studies, and the patient's symptoms will be necessary to assess the response to treatment and make adjustments as needed.",
        "sources": [
            "cancer treatment.\nDenosumab, given as 60  mg subcutaneously ev ery 6 months, was \ninitially studied in men receiving ADT for nonmetastatic prostate \ncancer in a randomized, placebo-controlled, phase III trial.393 Deno-\nsumab therapy was associated with increased bone mineralization at all sites, with an increase in the bone mineral density of the lumbar spine of 5.6%, as compared with a loss of 1.0% for placebo treatment. \nMen receiving denosumab along with ADT also had a decreased \nincidence of new vertebral fractures at 36 months (1.5% versus 3.9% with placebo).metastatic (but not nonmetastatic) hormone-sensitive prostate cancer. Chemohormonal therapy may be particularly appropriate for men with high-volume metastatic prostate cancer as defined in the  \nCHAARTED study.\nAR-V7 as a Treatment-Selection Biomarker in \nCastration-Resistant Prostate Cancer\nDeveloping biomarkers to enable selection of optimal therapy (e.g.,",
            "149 Prostate cancer is the second leading cause of \ncancer-related death in men. Many men with prostate cancer are at risk of osteoporosis, largely because of the ADT they receive for their cancer.\n132 ADT is very widely used, is being introduced earlier in the \ncourse of the disease, and is being given for longer. As a result, men often experience many years of androgen suppression. ADT results in substantially reduced serum concentrations of testosterone (to <5% \nof normal level) and estrogen (to < 20% of normal level) with con -\nsequent adverse effects on bone turnover. Moreover, newer treatments for advanced prostate cancer that are effective in extending life also result in testosterone depletion.\nAndrogen deprivation therapy leads to accelerated bone loss and \nan increase in fracture rate, as evidenced by large retrospective epide -\nmiologic studies.\n150 In addition, ADT affects muscle mass, making",
            "326 The aim of this phase III trial was to evaluate the \nrole of long-term adjuvant androgen suppression in men with high-risk prostate cancer. Men enrolled in the trial had clinical stage T3 ( >\n25 cm2) \nprostate cancer, or T1 or T2 disease and radiographic or histologic evidence of lymph node involvement. Men were eligible after pros -\ntatectomy if positive surgical margins or seminal vesicle invasion was \nfound. ADT featured goserelin acetate alone; radiotherapy was given \nat a dose of 44 to 46  G y to the whole pelvis, with a 20- to 25-Gy \nboost to the prostate or postoperative prostatic fossa for a total dose \nof 65 to 70  G y. At 10 years after treatment, the addition of androgen \ndeprivation to radiation therapy had improved local disease control, \nfreedom from distant metastases, disease-free survival, and overall survival.\n326\nThe EORTC 22863 trial also tested the contribution of adjuvant",
            "a range of cell types in the bone microenvironment regulated by complex interactions among hormones, paracrine growth factors, and  \ncytokines.\n22factors for a longer survival after first relapse in bone are low histologic grade, positive estrogen receptor (ER) status, long postoperative disease-free interval, and lack of development of extraosseous disease.\n2\nThe skeleton is by far the most common site of metastatic disease \nin persons with prostatic cancer. Unlike breast cancer, in which the lesions frequently show a mix of osteoblastic and osteolytic appearances radiologically, osteosclerotic disease predominates in prostate cancer. \nNevertheless, computed tomography (CT) often identifies lytic areas \nwithin these ostensibly sclerotic lesions. Histologic and biochemical studies also have demonstrated increased bone resorption in meta -\nstatic prostate cancer.\n3 As in breast cancer, metastatic bone disease in",
            "Part\tIII:\tSpecific \tMalignancies 1414Part\tIII:\tSpecific \tMalignancies\nbone scan for evaluation of bony metastases are recommended for \nmen with unfavorable intermediate- to high-risk prostate cancer.\nThere is a need for improved imaging of patients with distant \ndisease not detected with conventional imaging techniques, both for \ninitial staging and in the setting of recurrent disease after initial therapy. \nCarbon-11 (11C)–choline PET-CT and various PSMA tracers are being \nevaluated for this purpose.207,208\n“Molecular” Assays for Prognosis\nTissue-based expression assays have been developed to aid in decision making for men with lower-risk prostate cancer in whom active surveil -\nlance versus immediate intervention is being considered, and for risk stratification to guide the need for adjuvant therapy and salvage therapy \nafter initial treatment.\n209,210 There is a need for further stratification \nof risk of disease progression, metastatic disease, and prostate cancer",
            "were randomized equally to one of three arms: cabazitaxel 25  mg/\nm2, cabazitaxel 20  mg/m2, or docetaxel 75  mg/m2. The trial failed to \nmeet its primary end point; neither of the cabazitaxel arms produced superior survival to the docetaxel arm (the median overall survival was 24–25 months in all arms). The only secondary end point \nthat favored cabazitaxel was the objective response rate, which was \nsuperior for cabazitaxel 25  mg/m2 compared with docetaxel (42% \nversus 31%). Febrile neutropenia, diarrhea, and hematuria were more \nfrequent in the cabazitaxel 25  mg/m2 arm; peripheral neuropathy, \nankle edema, alopecia, and nail dystrophy were more frequent in \nthe docetaxel 75  mg/m2 arm. Based on this pivotal trial, cabazitaxel \nshould generally not be used as first-line chemotherapy in men with \nmCRPC, and docetaxel remains the chemotherapy standard of choice in  \nthis setting.\nChemohormonal Therapy for Metastatic \nHormone-Sensitive Prostate Cancer",
            "therapy for prostate cancer. N Engl J Med . 2009;361:  \n745–755.\n394. Goyal J, Antonarakis ES. Bone-targeting radiophar -\nmaceuticals for the treatment of prostate cancer with \nbone metastases. Cancer Lett . 2012;323:135–146.\n395. Nilsson S, Larsen RH, Fossa SD, et al. First clinical \nexperience with alpha-emitting radium-223 in the \ntreatment of skeletal metastases. Clin Cancer Res . \n2005;11:4451–4459.\n396. Bruland OS, Nilsson S, Fisher DR, Larsen RH. \nHigh-linear energy transfer irradiation targeted to \nskeletal metastases by the alpha-emitter 223Ra: \nadjuvant or alternative to conventional modalities? \nClin Cancer Res . 2006;12:6250s–6257s.\n397. Nilsson S, Franzen L, Parker C, et al. Bone-\ntargeted radium-223 in symptomatic, hormone-\nrefractory prostate cancer: a randomised, multicentre, \nplacebo-controlled phase II study. Lancet Oncol . \n2007;8:587–594.\n398. Hoskin P , Sartor O, O’Sullivan JM, et al. Efficacy \nand safety of radium-223 dichloride in patients with"
        ]
    }
]